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Abstract 
The molecular pathways mediating motor neuron degeneration in Amyotrophic 
lateral sclerosis and axonal regeneration following peripheral nerve injury 
remain elusive.  
The transcription factor c-Jun, an important orchestrator of axonal regeneration, 
has been found upregulated in the spinal cord of ALS cases and the 
SOD1G93A mouse model of the disease. However the functional role of c-Jun 
in ALS degeneration has not been defined. The current thesis demonstrates 
that genetic deletion of c-Jun from neurons and neuroglia prolonged the lifespan 
of SOD1G93A mice. Associated with this effect on survival, motor neuron loss, 
axonal loss and neuroinflammation were attenuated in c-Jun deficient 
SOD1G93A mice. Interestingly, in addition to the neurodegenerative changes, 
motor neuron pools affected by ALS disease in SOD1G93A mice demonstrated 
a disease-mediated axotomy response, which was characterised by the 
expression of regeneration associated proteins and was dependent on the 
expression of c-Jun. 
Since the expression of regeneration-associated proteins changes in ALS, it 
was next investigated whether the expression of ALS-associated proteins 
changes during axonal regeneration. This thesis demonstrates that the pattern 
of expression of ALS associated proteins; TDP-43, FUS and alsin, does indeed 
change within motor neurons following facial nerve axotomy, in wild type mice. 
In addition, it describes for the first time that alsin protein may localise to the 
cellular nucleus in uninjured motor neurons. Interestingly, axotomy resulted in a 
transient clearing of the normal nuclear immunoreactivity for all three studied 
proteins. The size of this effect was dependent on the severity of nerve injury for 
TDP-43 and alsin. 
Finally, to begin to investigate the functional role of ALS associated genes in 
axonal regeneration the A315T TDP-43 model of ALS was assessed following 
facial nerve transection. Genetic overexpression of ALS associated A315T 
mutant TDP-43 resulted in delayed motor function recovery following facial 
nerve axotomy in mice. This effect was associated with increased perineuronal 
inflammation and increased motor neuron expression of the adhesion molecule 
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CD44 but reduced perineuronal sprouting. However, overexpression of A315T 
mutant TDP-43 did not affect anatomical target reinnervation, motor neurons 
loss or the pattern of expression of other regeneration associate proteins. 
Thus, this thesis demonstrates that the molecular changes in ALS-associated 
motor neurodegeneration and peripheral nerve injury-associated regeneration 
overlap, and it suggests that insights obtained from studying one of these 
processes may be applied to further understand the other. 
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Chapter 1: Introduction 
ALS 
Clinical features 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects 
motor neurons in the spinal cord, brainstem and brain. The combined 
degeneration of lower and upper motor neurons results in progressive muscle 
atrophy, weakness, fasciculations and spasticity (Swinnen and Robberecht, 
2014). ALS has an incidence of around 2 per 100, 000 per year and a 
prevalence of around 5 per 100, 000 (Chio et al., 2013). Although highly 
variable, the onset of ALS clinical symptoms and signs occurs typically after the 
fifth decade of life. However, juvenile ALS can also occur with an onset age 
below 25 years, but this is rare (Sabatelli et al., 2008). Patients suffering from 
ALS generally die around 3 to 4 years from diagnosis. However, the 
progression of the disease is variable, with some patients living longer than 10 
years and others dying within 12 months (Pupillo et al., 2014). Survival can be 
prolonged by riluzole, the only approved medication for the treatment of ALS. 
However, its effects are modest, prolonging lifespan by around two months 
(Miller et al., 2007). 
Neuropathology 
Post mortem examination demonstrates that ALS is characterised by 
degenerative changes in all levels of the neuromuscular unit. There is motor 
neuron cell body atrophy and loss, and the presence of intracellular 
proteinaceous inclusion bodies. Axonal degeneration can be observed in motor 
nerves and the corticospinal tract. In addition, neuromuscular junction 
denervation and associated muscle atrophy are also features of the disease 
(Swinnen and Robberecht, 2014). All of these degenerative changes are 
associated with surrounding neuroinflammation (Philips and Robberecht, 2011). 
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Genetics 
Most cases (90-95%) of adult onset ALS occur sporadically without an apparent 
cause (SALS). Putative risk factors have been identified and include age, 
smoking, contact with pesticides and insecticides, soldering and welding work, 
high-fat/low fibre diet, slimness and athleticism, and living in urban areas. 
However, evidence for any of these risk factors is not conclusive (Longo et al., 
2012). Aside from the sporadic  form, it is estimated that around 5% of ALS 
cases are familial (FALS), with a genetic cause driving the disease (Byrne et al., 
2011). A large, and growing, number of genes associated with FALS have been 
identified. The genes responsible for the majority of FALS cases are C9orf72 
(causing around 40% of FALS), SOD1 (12%), TARDBP (4%) and FUS (4%) 
(Renton et al., 2014). Other implicated genes are each associated with only a 
few cases of FALS; these include VAPB, FIG4, CHMP2B, OPTN, DAO, VCP, 
UBQLN2, SQSTM1 and PFN1. In addition, the rare juvenile form of ALS is 
linked with mutations in several others genes including, ALS2, SETX, Spatacsin 
and SIGMAR1 (Byrne et al., 2011). Table 1 lists the different genes associated 
ALS, their chromosomal locus, inheritance pattern and putative cellular function. 
Animal models of ALS 
The elusive nature of the aetiology of ALS has driven the production of genetic 
animal models which express mutated genes associated with ALS. These 
encapsulate most of the clinical and neuropathological features of the disease. 
The use of these has led to the increasing understanding of the molecular and 
cellular processes driving ALS, and has provided a means of pre-clinical testing 
of desperately needed new therapies (Islam et al., 2014). Table 2 shows the 
different animal models of ALS, the genes, species used and type of genetic 
modifications. 
Table 1. Genes implicated in the pathogenesis of ALS. AD, autosomal 
dominant; AR, autosomal recessive; XD, X-linked dominant; DENN, 
differentially expressed in normal and neoplasia. Modified from (Renton et al., 
2014). 
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Gene Location Inheritance Putative protein function 
TARDBP 1p36 AD RNA metabolism 
SQSTM1 5q35 AD Ubiquitination; autophagy 
C9ORF72 9p21 AD DENN protein 
VCP 9p13 AD 
Proteasome; vesicle 
trafficking 
OPTN 10p13 AR and AD Vesicle trafficking 
FUS 16p11 AD and AR RNA metabolism 
PFN1 17p13 AD Cytoskeletal dynamics 
SOD1 21q22 AD and AR Superoxide metabolism 
UBQLN2 Xp11 XD Proteasome 
DCTN1 2p13 AD Axonal transport 
ALS2 2q33 AR Vesicle trafficking 
CHMP2B 3p11 AD Vesicle trafficking 
FIG4 6q21 AD and AR Vesicle trafficking 
HNRNPA2B1 7p15 AD RNA metabolism 
ELP3 8p21 Undefined RNA metabolism 
SETX 9q34 AD RNA metabolism 
HNRNPA1 12q13 AD RNA metabolism 
ATXN2 12q24 Undefined Endocytosis; RNA translation 
ANG 14q11 AD Angiogenesis 
SPG11 15q14 AR DNA damage repair 
VAPB 20q13 AD Vesicle trafficking 
NEFH 22q12 AD Axonal transport 
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Table 2. Animal models of ALS. Genetic modification of ALS associated genes: 
KD, knock down; KI, knock in of ALS associated mutation into mouse gene; KO, 
knock out; MO, morpholino oligo inhibition of gene expression; Tg, transgenic 
for human gene with ALS associated mutation. Table modified from (Islam et 
al., 2014). 
 
ALS Gene Animal 
Genetic 
modification 
SOD1 
Mouse KO, Tg 
Swine Tg 
Zebrafish Tg 
Drosophila Tg, KO 
C. elegans Tg 
TDP-43 
Mouse Tg 
Zebrafish MO, RI 
Drosophila Tg, KD 
C. elegans Tg 
FUS 
Mouse Tg 
Zebrafish RI 
Drosophila Tg 
ALS2 
Mouse KO 
Zebrafish MO 
VAPB(P56S) 
Mouse KI 
Drosophila Tg 
DCTN1/p150
glued
 
Mouse KI, Tg 
Drosophila Tg 
DCTN2/p50 Mouse Tg 
VCP Mouse KI 
FIG4 Mouse KO 
 
  
23 
 
Mechanisms of degeneration 
Motor neuron death 
Morphological changes of the motor neuron is ALS 
Post-mortem histological assessment of ALS cases demonstrates that motor 
neurons undergo three morphologically distinct stages of degeneration (Martin, 
1999). The chromatolytic stage is characterised by cell body swelling, 
dispersion of the Nissl substance (rough endoplasmic reticulum), displacement 
of the normally central nucleus to the cellular periphery, and the presence of 
cytoplasmic inclusion bodies. In the somatodendritic attrition stage, the cell 
body atrophies and takes a blurred multipolar shape, while the nucleus and 
cytoplasm take on a condensed homogenous appearance. In the apoptotic 
stage, the motor neuron takes a fusiform or round shape devoid of any 
processes, its diameter decreases to a fifth of its normal size and its cytoplasm 
and nucleus become extremely condensed (Martin, 1999). Interestingly, 
histopathological examination of human ALS cases analysis fail to demonstrate 
evidence of cytoplasmic vacuoles or nuclear and chromatin condensation which 
are normally associated with apoptosis (Martin, 1999). 
Similar to changes in human cases, motor neurons in the widely used SOD1 
mouse model of ALS demonstrate morphological evidence of chromatolysis 
(Sasaki et al., 2002) and atrophy. In addition, cytoplasmic vacuoles are found, 
which correspond to both intracellular organelle dilation (Dalcanto and Gurney, 
1995) and the process of  autophagy (Chen et al., 2012, Fidzianska et al., 
2006). However, unlike ALS human tissue, changes which resemble apoptosis 
can be observed in the SOD1 mouse model. These changes include 
cytoplasmic and nuclear condensation, compaction of nuclear chromatin and 
cellular fragmentation of motor neurons. Nonetheless, morphological features of 
apoptosis are only observed infrequently (Przedborski, 2004). 
Expression and role of death related proteins 
Immunohistochemical studies have demonstrated that motor neurons in human 
ALS cases and mutant SOD1 mice can express a number of apoptosis related 
markers including the carbohydrate antigen LeY (Yoshiyama et al., 1994), Par-4 
protein (Pedersen et al., 2000) and fractin (Vukosavic et al., 2000). DNA 
fragmentation, indicative of apoptosis, has also been detected in small 
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subpopulations of motor neurons of ALS cases and ALS-linked mutant SOD1 
mice (Martin, 1999, Hetz et al., 2007). However, this has not been replicated by 
other groups (Migheli et al., 1994, He and Strong, 2000) and has not been 
observed in the SOD1 mouse model of ALS (Migheli et al., 1999). 
As described above there is evidence that a type of programmed cell death 
(PCD) may be involved in the loss of motor neurons in ALS (Przedborski, 2004). 
PCD involves a cascade of molecular signals which may be initiated 
extrinsically, through death receptors, or intrinsically through the activation of 
cell death proteins through the mitochondrial apoptotic pathway (McIlwain et al., 
2013). 
There is evidence that ALS degeneration may be mediated, at least in part, via 
activation of death receptors on the surface of motor neurons. The TNF, Fas, 
DR6 and p75 death receptors, as well as their ligands, are all upregulated in 
ALS-linked mutant SOD1transgenic mice (Veglianese et al., 2006, Raoul et al., 
2006, Huang et al., 2013, Kiaei et al., 2007, Bryson et al., 2012, Turner et al., 
2003, Copray et al., 2003). In addition, DR6 and p75 receptors, and the 
cytokine TNF-alpha (TNF receptor ligand) are upregulated in the spinal cords of 
ALS patients (Huang et al., 2013, Moreau et al., 2005, Seeburger et al., 1993). 
Functionally, knocking down Fas or p75 receptors using an antisense peptide 
nucleic acids delayed disease and reduced motor neuron cell loss in ALS SOD1 
transgenic mice (Turner et al., 2003, Locatelli et al., 2007). Similarly, 
pharmacological inhibition of DR6 in mutant SOD1 mice reduced pathology in 
mutant SOD1 mice (Huang et al., 2013). However, deletion of the TNF-alpha 
gene did not affect motor neuron disease in ALS SOD1 transgenic mice 
(Gowing et al., 2006). 
Changes in expression and activation of members of Bcl-2 family of cell death 
proteins have been associated with ALS disease. On the one hand, the pro-
apoptotic proteins Puma, Bim, Bid, Bad and Bax have all been found 
upregulated or activated in mutant SOD1 mice (Kieran et al., 2007, Hetz et al., 
2007, Guegan et al., 2002, Vukosavic et al., 1999, Guegan et al., 2001). In 
addition, Harakiri, Puma, Bak and Bax have are also upregulated or activated in 
ALS cases (Shinoe et al., 2001, Kieran et al., 2007, Martin, 1999, Mu et al., 
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1996). On the other hand, the anti-apoptotic proteins Bcl-2 and Bcl-xL are 
down-regulated but Bcl-2a1 is upregulated in mutant SOD1 mice (Vukosavic et 
al., 1999, de Aguilar et al., 2000, Crosio et al., 2006). In post mortem ALS 
cases, Bcl-2 is also reduced but Bcl-XL expression is unchanged (Mu et al., 
1996, Martin, 1999). Interestingly, mutant SOD1 protein has been found to 
interact directly with Bcl-2 protein and it has been suggested that it interferes 
with the anti-apoptotic function of Bcl-2 in both ALS cases and mutant SOD1 
mice (Pasinelli et al., 2004, Pedrini et al., 2010). Functionally, genetic deletion 
of pro-apoptotic genes Puma or Bim slows down disease and reduces motor 
neuron loss in ALS mutant SOD1 mice (Kieran et al., 2007, Hetz et al., 2007). 
Furthermore, genetic deletion of Bax abolishes motor neuron loss and 
increases survival in ALS SOD1 mutant mice (Gould et al., 2006). Functionally, 
overexpression of anti-apoptotic genes Bcl-2 or Bcl-xL mitigates 
neurodegeneration and prolongs survival of ALS SOD1 mice (Kostic et al., 
1997, Vukosavic et al., 2000, Yamashita et al., 2003, Azzouz et al., 2000, 
Garrity-Moses et al., 2005). 
The pattern of expression of mitochondrial proteins involved in apoptosis is also 
changed in ALS. Cytoplasmic translocation of the pro-apoptotic protein 
cytochrome C has been found in ALS cases and mutant SOD1 mice (Martin, 
1999, Guegan et al., 2001). In contrast, the anti-apoptotic XIAP protein is 
cleaved and its expression down regulated in mutant SOD1 mice (Guegan et 
al., 2001, Wootz et al., 2006). Functionally, overexpression of XIAP attenuated 
disease progression and reduced motor neuron loss in SOD1G93A mice (Inoue 
et al., 2003, Wootz et al., 2006). 
There is evidence that caspases may play a role in motor neuron degeneration 
in ALS. The inflammatory caspases-1, 11 and 12 (Pasinelli et al., 2000, Kang et 
al., 2003, Wootz et al., 2004), the initiator caspases-8 and 9 (Guegan et al., 
2001, Wootz et al., 2004) and the executioner caspases-3 and 7 have all been 
found activated in the spinal cord of mutant SOD1 transgenic mice (Pasinelli et 
al., 2000, Vukosavic et al., 2000, Wootz et al., 2004). In addition, caspase-9 and 
caspase-3 have also been found activated in the spinal cord of ALS cases 
(Wootz et al., 2004, Inoue et al., 2003, Martin, 1999). However, the functional 
roles of most caspases in ALS have not yet been determined (Inoue et al., 
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2003, Kang et al., 2003). Nonetheless, irreversible broad-caspase inhibitor 
attenuates cell death in SOD1 mice (Li et al., 2000a). In addition, using 
transgenic mice the role for caspases-1, 2 and 11 have been specifically 
investigated. On the one hand, inhibition of caspase-1 via transgenic expression 
of dominant negative caspase-1 significantly slowed the progression of ALS 
disease in mutant SOD1 mice (Friedlander et al., 1997). On the other hand, 
genetic deletion of caspase-2 or -11 did not affect disease in mutant SOD1 mice 
(Kang et al., 2003, Bergeron et al., 1998). 
The Glial and Inflammatory Response in ALS 
In ALS pathology, a glial and inflammatory reaction can be observed around 
degenerating neuronal cell bodies and axons. This process involves microglia, 
astrocytes and T-cells (Philips and Robberecht, 2011). 
Histopathological changes in ALS 
Humans 
Microglia, the resident macrophages of the nervous system, are constantly 
monitoring the extracellular environment, and are the first line of defence 
against infection and injury (Raivich et al., 1999). In the intact central nervous 
system microglia have a ramified morphology (resting). However, following 
neuronal injury, the cell body of microglia enlarges, and the processes shorten 
and thicken (activated). In the presence of cell death, microglia acquire a round 
amoeboid shape, characteristic of microglia being involved in the process of 
phagocytosis (phagocytic),  (Del Rio-Hortega, 1932). These morphological 
changes coincide with the upregulation of immunologically related proteins in 
the cell surface of microglia. 
In post-mortem tissue of patients with ALS, the grey matter and white matter of 
the precentral gyrus, as well as the lateral funiculus and the anterior horn of the 
spinal cord contained microglia that have a round/amoeboid morphology. These 
microglia are strongly immunoreactive for the pan-leukocyte marker CD45, 
immunoglobulin receptor FcγR1, integrin αMβ2, and MHC class II glycoproteins 
(Kawamata et al., 1992). Others have found that in the corticospinal tract and 
the spinal ventral horns of ALS patients, phagocytic microglia highly express 
IgG in the cell surface and the MHC class II cell surface receptor HLA-DR  
(Engelhardt and Appel, 1990), In addition, phagocytic cells that express the 
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glycoprotein CD68, which is found in the cell surface of antigen presenting cells, 
are evident in the ventral horn, Clarke’s column, and mid-dorsal horn (Rexed 
laminae III–V), as well as the nerve roots of the fifth and seventh nerves. 
Furthermore, moderate levels of CD68-immunoreactivity are found in the motor 
nuclei of the trigeminal, facial and hypoglossal nerves (Ince et al., 1996). 
Astrocyte activation has also been reported in CNS regions undergoing ALS-
associated degeneration. Astrocytes have many functions in the nervous 
system including, the regulation of extracellular neurotransmitter concentrations 
and providing trophic support to surrounding neurons (Sofroniew and Vinters, 
2010). In the normal brain, fibrillary astrocytes can be found in the white matter. 
They have long processes that are positive for the cytoskeletal protein glial 
fibrillary acid protein (GFAP). In the grey matter, astrocytes have numerous 
short and highly ramified processes that are GFAP-negative. However, the cell 
body and a few proximal branches can be identified by staining for S100b 
(Didier et al., 1986).  
In the post-mortem brain of humans with ALS, the motor, frontal, temporal, 
inferior parietal, cingulate, and occipital cortices have intensely stained GFAP-
positive astrocyte clusters (Nagy et al., 1994). In addition, in the subcortical 
white matter of the ALS frontal cortex, GFAP-positive stellate astrocytes with 
long extended processes can be observed (Kushner et al., 1991). In 
comparison to the human tissue without the disease, ALS patients 
demonstrated intense GFAP immunoreativity in the precentral gyrus and spinal 
cord (Kawamata et al., 1992).  
T-cells are recruited to areas of CNS damage (Raivich et al., 1999). T-cell 
recruitment has been observed in areas affected by ALS. CD4-positive T-cells 
are observed in close proximity of degenerating corticospinal tracts of ALS 
patients, while CD4-positive and CD8-positive T-cells are found in the vicinity of 
motor neurons of the ventral horns (Engelhardt et al., 1993). In addition, there 
are more CD4- or CD8-positive T-cells in precentral gyrus, the lateral funiculus 
and the anterior horn of patients with ALS, than those without the disease 
(Kawamata et al., 1992). 
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Additional inflammatory processes in ALS include, the increased presence of 
monocytes/macrophages, dendritic cells and cytokine/chemokine expression in 
the central nervous system and cerebrospinal fluid of ALS patients (Kuhle et al., 
2009, Mitchell et al., 2009, Rentzos et al., 2007, Nagata et al., 2007, Tanaka et 
al., 2006, Baron et al., 2005, Henkel et al., 2004, Wilms et al., 2003, Lippa et al., 
1995). 
Mice 
, The neuroinflammatory response observed in the mutant SOD1 mouse model 
of ALS is similar to that found in human cases with ALS (Alexianu et al., 2001). 
At 80 days of age, when SOD1 transgenic mice do not show any clinical 
symptoms but only minimal motor neuron cell death, the ventral horn and 
proximal part of the anterior roots contained numerous αMβ2-positive microglia 
with round cell bodies and thickened short ramified processes. Microglia 
activation is predominantly found in the grey matter of the spinal cord, at day 
80. However, during the phase of active clinical disease progression, activated 
microglia are seen in both the grey and white matter of both the ventral and 
dorsal horn (Alexianu et al., 2001). An increase in microglial density is also 
found in the spinal cord of SOD1 transgenic mice at 100 days of life compared 
to non-transgenic controls (Hall et al., 1998b). In addition, large microglial 
clusters are evident in the spinal cord proximal to large neuronal cell bodies 
(Alexianu et al., 2001). These activated microglia are highly immunoreactive for 
IgG throughout the sacral, lumbar, thoracic, and cervical spinal cord. In addition, 
immunostaining for FcγR1 is significantly increased in mutant SOD1-mice at 
day 80 and to a greater extend at day 120 (Alexianu et al., 2001). Furthermore, 
stronger expression of the adhesion molecule ICAM1 is found in the grey matter 
of the ventral horn of day 80 mutant SOD1-mice, compared to wild type mice. At 
later time points, ICAM1 staining is widespread, present in microglia of the 
anterior and posterior horns of the spinal cord (Alexianu et al., 2001). Recently, 
it has been shown that CD44 is also expressed by some microglia in the spinal 
cord of mutant SOD1 mice (Matsumoto et al., 2012). 
Unlike microglial activation, astrocyte activation is seen at the later time points 
in ALS transgenic mice. GFAP-immunorectivity is robust in the grey matter of 
the spinal cord at end stage (Almer et al., 1999). GFAP-positive astrocytes in 
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the grey matter of the spinal cord have darkly stained cell bodies with elongated 
processes (Alexianu et al., 2001). However, at early time points, minimal 
astrocyte activation is seen in the grey and white matter of the spinal cord of 
mutant SOD1 mice (Almer et al., 1999). At the late stage of the disease, GFAP 
positive astrocytes strongly express CD44 in the lumbar spinal cord of mutant 
SOD1 mice (Matsumoto et al., 2012). Finally, at the end stage of the disease T-
cells infiltrate the spinal cord. T-cells that are positive for CD3, a pan marker of 
T-cells, are found to preferentially enter the grey matter of the ventral horn at 
the late stages the disease  (Alexianu et al., 2001).  
The role of inflammation in ALS 
Motor paralysis associated with ALS is dependent on the progressive 
degeneration and death of motor neurons. It has become apparent that motor 
neuron degeneration is not only due to changes within the motor neuron, but 
also in other cells types such as glia. Mice that selectively express ALS 
associated mutant SOD1 in neurons do not show any motor neuron loss (Lino 
et al., 2002, Pramatarova et al., 2001) and developed only mild abnormalities 
(Jaarsma et al., 2008). In the same way, mice that express mutant SOD1 
specifically in microglia (Beers et al., 2006) or astrocytes (Gong et al., 2000) do 
not show any motor neuron degeneration. However, motor neuron degeneration 
is evident in mice that ubiquitously express mutant SOD1 (Dalcanto and 
Gurney, 1994). The notion that motor neuron death is non-cell autonomous is 
further supported by work on chimeric mice. Chimeric mice have been 
composed from mixtures of cells carrying wild-type (WT) SOD1 and cells that 
express human mutant SOD1 (Clement et al., 2003). Using this technique it 
was demonstrated that motor neurons carrying mutant SOD1 failed to 
degenerate in an environment of cells carrying WT SOD1 (Clement et al., 
2003). This suggests that neighbouring non-neuronal cells carrying mutant 
SOD1 promote degeneration of motor neurons (Clement et al., 2003).  
The specific roles of neuronal and non-neuronal cell types on SOD1 mediated 
motor neuron damage was shown by cell specific excision of the floxed mutant 
SOD1 gene using the cre-lox system in mice (Boillee et al., 2006b). In mice, 
specific neuronal deletion of mutant SOD1 extends survival by delaying onset of 
disease (Boillee et al., 2006b). Alternatively, the deletion of mutant SOD1 
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specifically from microglia/macrophages, using the CD11b promoter, extends 
survival by 99 days by sharply slowing disease progression (Boillee et al., 
2006b). The role of microglia/macrophages on survival was further 
demonstrated in SOD1 mutant mice unable to produce myeloid cells that are 
known to differentiate into macrophages, dendritic cells, granulocytes, T cells, 
or B cells (Beers et al., 2006). Myeloid deficient SOD1 mutant mice that 
underwent transplantation of myeloid cells that express human mutant 
SOD1G93A at birth, survived up to similar ages as myeloid competent 
SOD1G93A mutants. However, transplantation of wild type cells of microglial, 
monocyte, and macrophage lineage into myeloid deficient SOD1 mutant mice 
slowed down disease progression after onset (Beers et al., 2006). Thus it 
appears that mutant SOD1 within the motor neurons is a primary determinant of 
onset of disease, while mutant SOD1 within macrophages/microglial cells 
determines disease progression.  
Microglia may cause neurotoxic effects through the release of reactive oxygen 
species (ROS) and pro-inflammatory factors. Microglia can induce neuronal 
injury through the expression of proinflammatory cytokines TNF-α and IL-1β 
and the ROS superoxide and nitric oxide, and by reducing the expression and 
release of trophic factors (Michelucci et al., 2009, Ebert et al., 2008, Komohara 
et al., 2008, Town et al., 2005). 
As disease progresses in mutant SOD1 mice, there is an increase in the 
expression of peroxynitrite and proinflammatory cytokines TNF-α and IL-1β 
(Beers et al., 2008, Henkel et al., 2006, Hensley et al., 2002, Alexianu et al., 
2001, Almer et al., 1999, Hall et al., 1998a). In vivo, the expression of ALS 
associated mutant SOD1 gene in microglia enhances microglial activation and 
increases neurotoxicity (Beers et al., 2006, Boillee et al., 2006b). A pathway 
through which SOD1 may be amplifying microglial mediated neurotoxicity, 
involves ALS mutant SOD1 binding to Rac1, a member of the Rho familily of 
GTPases, which subsequently overstimulates NADPH oxidase, which leads to 
the production of superoxide, which may react with NO to form the toxic 
compound peroxynitrite (Harraz et al., 2008). 
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Lymphocytes have been shown to prolong survival of ALS mice (Beers et al., 
2008). ALS mutant SOD1 mice that lack functional T- and B- cells have shorter 
life spans than mutant SOD1 mice with normal T- and B-cells. In addition, 
mutant SOD1 mice without functional T-and B-cells that receive a bone marrow 
transplant from normal mutant SOD1 or wild type mice, show longer survival 
than those which do not (Beers et al., 2008). In the SOD1 mice that lack T and 
B cells, following bone marrow transplant, CD4-positive T-cells can be found in 
the spinal cord from the time of disease onset up to end stage, while CD8-
posiitve T-cells are only observed at end stage (Beers et al., 2008). There is no 
consistent evidence for the presence of B cells in the spinal cord at any time 
point in disease progression, suggesting that T-cells may be driving 
neuroprotection (Beers et al., 2008). Evidence confirming that T-cells are 
responsible for prolonging disease duration comes from CD4 deficient mice 
which lack CD4-positive cells, but have unaltered myeloid-, CD8-postive T-cells 
and B cells. Mutant SOD1 mice lacking CD4-positve cells have shorter survival 
times than mutant SOD1 mice that have CD4-positive cells (Beers et al., 2008). 
T-cells may prolong survival by altering microglial activation in mutant SOD1 
mice (Beers et al., 2008). SOD1 mice without functional T- and B-cells show 
less microglial activation than those that have T- and B-cells. SOD1 mice 
lacking CD4-positive T-cells have a reduced expression of microglial markers 
CD11b and CD68 in the spinal cord, when compared to mutant SOD1 mice that 
have CD4-positive cells. However, bone marrow transplants from SOD1 mutant 
or wild type mice to gamma-irradiated SOD1 mice lacking functional T- and B-
cells, restores the CD11b, CD68, CD11c, CD40, and MHC II microglial 
immunoreactivities, as well as CD68 mRNA expression in the spinal cord 
(Beers et al., 2008).  In addition, in the spinal cords of mutant SOD1 mice that 
lack lymphocytes, the mRNA levels for neurotrophic factors IGF-1 and GDNF, 
and glutamate transporters that affect neuronal viability are all reduced, as well 
as those for anti-inflammatory cytokines IL-4 and TGF-β (Beers et al., 2008). 
However, pro-inflammatory factors, such as TNF-α and peroxynitrite are 
increased (Beers et al., 2008). This data suggests that T-cells have an 
important anti-inflammatory and neuroprotective function in mutant SOD1 mice. 
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Astrocytes also contribute to ALS pathology. In vitro, astrocytes derived from 
neural progenitor cells of ALS post-mortem spinal cord are toxic to mouse motor 
neurons in co-culture. By 96 hours, motor neurons atrophy and shorten their 
neurites, and by 120 hours motor neuron number is reduced to 50% (Haidet-
Phillips et al., 2011). This coincides with the production of numerous 
proinflammatory cytokines and chemokines, known to be toxic to neurons 
(Haidet-Phillips et al., 2011). It has been found that mutant SOD1 promotes a 
toxic phenotype in astrocytes. More motor neurons survive after co-culturing 
with ALS astrocytes that have had the mutant SOD1 knocked down, compared 
to those which have not (Haidet-Phillips et al., 2011). Interestingly, 
transplantation of wild type astrocytes precursor cells into the cervical spinal 
cord, near respiratory motor neuron pools of mutant SOD1 rats, increases 
motor neuron viability, extends survival, and slows down functional decline 
(Lepore et al., 2008). It has been suggested that the neuroprotection observed 
in this model is mediated by enhanced glutamate uptake, performed by glial 
precursor cells (Lepore et al., 2008). 
 
Figure 1. Schematic of the evolution of Motor Neuron Degeneration and glial 
activation during the course of SOD1 Mutant-Initiated ALS Disease. Four stages 
are defined (normal, early phase, symptomatic, and end stage). Toxicity is non-
cell-autonomous, produced by a combination of damage incurred directly within 
motor neurons that is central to disease initiation and damage within non-
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neuronal neighbours, including astroctyes and microglia, whose actions amplify 
the initial damage and drive disease progression and spread (Boillee et al., 
2006a). 
Excitotoxicity 
There is evidence that excitotoxicity may play a role in the ALS disease process 
(Van den Bosch et al., 2006). Glutamate levels are found decreased in the 
spinal cord parenchyma (Malessa et al., 1991, Tsai et al., 1991, Rothstein et al., 
1990, Plaitakis et al., 1988) but increased in the CSF of patients with ALS 
(Rothstein et al., 1990, Shaw et al., 1995b). In addition, there is evidence of 
increased expression of NAALADase, an enzyme involved in the synthesis of 
glutamate (Rothstein et al., 1990). In addition, there is evidence of decreased 
synaptic removal of glutamate in the spinal cords of ALS patients (Shaw et al., 
1994). This reduction appears to be secondary to the selective loss of 
EAAT2/GLT1 glutamate transporter from astroglia in the spinal cord of ALS 
patients (Rothstein et al., 1995, Sasaki et al., 2000a, Fray et al., 1998). In 
addition, a loss in EAAT2 transporter has also been observed in the ventral 
horn of mutant SOD1 mice (Bendotti et al., 2001b, Bruijn et al., 1997). Genetic 
overexpression of EAAT2 resulted in delayed disease onset in mutant SOD1 
mice (Guo et al., 2003). In addition, pharmacological stimulators of EAAT2 
expression significantly increased lifespan and prevented motor neuron death in 
mutant SOD1 mice (Rothstein et al., 2005). Furthermore, there is evidence of a 
change in glutamate-AMPA receptors on motor neurons in the spinal cord of 
ALS cases and mutant SOD1 mice, which is associated with increased 
vulnerability to excitotoxicity mediated by enhanced calcium permeability 
(Tortarolo et al., 2006, Kawahara et al., 2003, Takuma et al., 1999). 
Functionally, pharmacological inhibition of AMPA receptors is associated with 
increased lifespan of SOD1 mutant mice (Canton et al., 2001, Van Damme et 
al., 2003, Tortarolo et al., 2006). Furthermore, Riluzole, the only therapeutic 
agent for human ALS, is reported to act by preventing the release of glutamate 
and blocking its action on postsynaptic AMPA receptors (Doble, 1999, Gurney 
et al., 1996). Similarly, pharmacological inhibition of glutamate production by 
carboxypeptidase II increases the lifespan of mutant SOD1 mice (Ghadge et al., 
2003). 
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There is evidence of increased levels of intracellular calcium in the motor nerve 
terminals of biopsied human ALS cases and mutant SOD1 mice (Siklos et al., 
1996, Siklos et al., 1998). In addition to overstimulation of excitatory 
neurotransmitter receptors in ALS, it has been suggested that dysregulation in 
calcium homeostasis is the result of mitochondrial dysfunction and endoplasmic 
reticulum stress (Grosskreutz et al., 2010). Associated with the increase in 
intracellular calcium there is also evidence of the activation of calcium 
dependent proteases, calpains, in mutant SOD1 mice (Stifanese et al., 2010, 
Gou-Fabregas et al., 2014, Stifanese et al., 2014). Calpains have important 
regulatory roles in many cellular processes but their prolonged activation has 
been implicated with neurodegeneration (Vosler et al., 2008). Functionally, 
inhibition of calcium entry and calpain activity reduces motor neuron 
degeneration in vitro (Tran et al., 2014, Tradewell and Durham, 2010). 
Mitochondrial dysfunction 
Histopathological studies of ALS cases demonstrate that degenerating motor 
neurons contain dilated and vacuolated mitochondria that have disorganised 
cristae and membranes (Hirano et al., 1984a, Hirano et al., 1984b). Similarly, 
mitochondria with multi-membrane containing vacuoles can be found in mutant 
SOD1 mice in presymptomatic stages before any motor neuron loss can be 
observed (Dalcanto and Gurney, 1994, Higgins et al., 2003, Kong and Xu, 
1998). Interestingly, SOD1 protein, which is normally cytosolic, is found 
enriching mitochondria in both ALS cases and SOD1 mutant mice (Bergemalm 
et al., 2006, Deng et al., 2006, Liu et al., 2004). It has been suggested that this 
might drive the mitochondria changes found in the disease (Liu et al., 2004). It 
is however unclear whether these morphological changes are associated with 
mitochondrial dysfunction. There is evidence that calcium buffering capacity of 
mitochondrial is impaired in mutant SOD1 models (Damiano et al., 2006). In 
addition, some evidence points to motor neuronal energy deficits secondary to 
the effect of mutant SOD1 on the electron transport chain (Mattiazzi et al., 2002, 
Browne et al., 2006). In this vein, elevating presumed energy deficits by 
providing creatine in the diet of mutant SOD1 mice prolonged their survival 
(Klivenyi et al., 1999). However, human clinical trials have failed to show any 
benefit for ALS patients (Groeneveld et al., 2003, Shefner et al., 2004).  
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High levels of oxidative stress markers, protein carbonyl, lipid peroxidation and 
protein glycoxidation have been reported in areas affected by ALS disease in 
human cases and SOD1 mutant mice (Shaw et al., 1995a, Shibata, 2001, 
Shibata et al., 2002, Andrus et al., 1998, Bogdanov et al., 1998, Liu et al., 1998, 
Liu et al., 1999, Liu et al., 2004). A possible role of oxidative stress in the 
pathogenesis of ALS was strongly suggested by the fact that the gene for 
superoxide dismutase-1(SOD1) is found mutated in 20% of familial cases of 
ALS (Boillee et al., 2006a). Superoxide is a natural by-product of respiration 
which can have cytotoxic effects through its interaction with nitric oxide and the 
subsequent formation of peroxinitrite, a potent free radical which oxidises lipids, 
proteins and nucleic acids within cells (Rosen et al., 1993). Since SOD1 
detoxifies the superoxide anion by its dismutation to water and hydrogen 
peroxide, a loss of SOD1 function was the first proposed mechanism of ALS 
pathogenesis (Rosen et al., 1993). However, mice expressing dismutase active 
(Wong et al., 1995, Gurney et al., 1994, Howland et al., 2002) and inactive 
forms (Bruijn et al., 1997, Ripps et al., 1995, Jonsson et al., 2004, Wang et al., 
2003) of ALS associated mutant SOD1 develop similar pathology to that 
observed in ALS patients. In addition, deletion of endogenous SOD1 gene in 
mice does not cause ALS like pathology (Reaume et al., 1996) and expression 
of high dismutase active SOD1 mutants does not attenuate the ALS disease 
process (Bruijn et al., 1998, Deng et al., 2006, Jaarsma et al., 2000). This 
evidence strongly suggests that mutations in SOD1 cause ALS disease via a 
gain of toxic function and not through a loss of its normal dismutase function. In 
this vein, a number of mechanisms for aberrant oxidative chemistry have been 
suggested for mutant SOD1 (Beckman et al., 2001, Carroll et al., 2004). 
However, these putative mechanisms have been refuted by in vivo experiments 
(Subramaniam et al., 2002, Son et al., 2007). Thus, it is likely that oxidative 
stress is not the primary process driving ALS disease but rather a byproduct. 
Pathological inclusions and failure of proteostasis 
Neuropathology of ALS protein inclusions 
Early post-mortem studies of FALS and SALS cases identified three main types 
of proteinaceous inclusions within degenerating motor neurons: 1) Bunina 
bodies (BB) which are found in around 90% of all ALS cases; 2) Lewy body-like 
hyaline inclusions (LBHI), observed in 15% of cases (mostly familial) and 3) 
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Small round basophilic inclusions (BI), identified in 12% of ALS cases (mostly 
sporadic juvenile onset) (Bunina, 1962, Hirano et al., 1967, Chou, 1978, 
Rowland, 2009, Matsumoto et al., 1992, Ince et al., 1998). Two more types of 
ALS inclusion were discovered with the use immunohistochemistry (IHC) for 
ubiquitin, a marker of protein proteosomal degradation, which stained previously 
unrecognised skein-like (SI) and rounded hyaline (RHI) inclusions (Lowe et al., 
1988). In addition, ubiquitin immunoreactivity is also found in the previously 
described LBHIs, but not in BBs or BIs (Matsumoto et al., 1992). Interestingly, 
ubiquitin positive inclusions (UBI) are the most common inclusions found in 
ALS, occurring in over 95% of cases (Piao et al., 2003). 
Electron microscopy reveals that all known ALS inclusions contain at least 
some filamentous (suggestive of neurofilaments) and granular structures 
(suggestive of organelle fragments) (Murayama et al., 1989). 
Immunohistochemical studies confirmed the presence of phosphorylated 
neurofilament in ubiquitin positive LBHIs (Murayama et al., 1989). The highly 
granular BBs are not immunoreactive for ubiquitin or neurofilament but instead 
contain Cystatin C, a vesicular protein involved in the inhibition of cysteine 
proteases (Okamoto et al., 1993). In addition, the discovery of the association 
between superoxide dismutase 1 (SOD1) gene mutations and familial ALS 
(Rosen et al., 1993) led to the identification of SOD1 in the LBHIs of SOD1 
associated FALS cases (Shibata et al., 1996). Thus some of the constituent 
proteins of BBs and LBHIs have been identified for many years now. However, 
the proteins making up the ubiquitin positive SIs and RHIs and the ubiquitin 
negative BIs were not discovered until quite recently. 
The relationship between ALS and frontotemporal dementia shed light on the 
composition of SIs, RHIs and BIs. SALS can be associated with frontotemporal 
dementia (ALS-FTD) (Giordana et al., 2011). In addition, some forms of non-
SOD1 FALS, present with a family history of FTD, ALS-FTD, or both (Giordana 
et al., 2011). Post-mortem studies of cases of ALS with cognitive impairment 
(ALSCi) demonstrate marked frontal lobe atrophy, accompanied by the 
presence of ubiquitin positive inclusions or Tau positive, ubiquitin negative 
neurofilamentous inclusions (Ferrari et al., 2011). These observations have 
resulted in FTD being divided into two major subtypes; FTD with tau-positive 
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inclusions (FTD-tau), and FTD with ubiquitin-positive (FTD-U) but tau-negative 
inclusions (Ferrari et al., 2011). Interestingly, some of the ubiquitin positive 
inclusions found in FTD-U are identical to those observed in ALS (SI/RHIs and 
LBHIs) and ALS-FTD, but just as for ALS, the identity of their constituent 
proteins were unknown until recently (Ferrari et al., 2011). The group led by 
Virginia Lee and John Trojanowski created novel monoclonal antibodies (mAbs) 
against FTD-U protein inclusions and with the use of mass spectrometry 
identified transactivating DNA binding protein-43 (TDP-43), a protein involved in 
gene transcription and translation, as a constituent of those inclusions 
(Neumann et al., 2006). Immunolabelling with antibodies specific for TDP-43 
demonstrated that all ubiquitin-positive inclusions in FTD-U were found to be 
immunoreactive for TDP-43 (Neumann et al., 2006). Similarly, 
immunohistochemical analysis revealed that the ubiquitin-positive inclusions 
(SI, RHI and LBHIs) in ALS which had no constituents previously identified, 
were also all immunoreactive for TDP-43 (Neumann et al., 2006). Importantly, 
mutations in the TDP-43 gene were then associated with ALS and FTD 
(Sreedharan et al., 2008, Borroni et al., 2009). 
Recently, studies have gone on to demonstrate, that TDP-43 positive inclusions 
are found in more than 90% of ALS (Tan et al., 2007, Mackenzie et al., 2007) 
and around 60% of FTD cases (Seilhean et al., 2011). Interestingly, however, 
TDP-43 immunoreactivity is not found in SOD1-positive LBHIs, Cystatin-positive 
BBs or in BIs (Tan et al., 2007, Mackenzie et al., 2007). Researchers were 
guided to the identification of the constituent proteins of BIs by the discovery 
that mutations in the FUS gene are associated with ALS (Kwiatkowski et al., 
2009, Vance et al., 2009). FUS is another protein which has function in RNA 
regulation at both the transcription and translation level (Kwiatkowski et al., 
2009, Vance et al., 2009). FUS immunoreactivity was found in the ubiquitin- and 
TDP-43-negative BIs characteristic of juvenile ALS cases (Kwiatkowski et al., 
2009, Vance et al., 2009) and in the majority of cases of tau- and TDP-43-
negative frontotemporal lobar degeneration (Neumann et al., 2009). 
Interestingly, recent studies have gone on to demonstrate that FUS protein is 
found in the skein-like inclusions of a large proportion of non-SOD1 ALS cases 
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and that it can often colocalise with TDP-43 in such inclusions (Deng et al., 
2010). 
Dysregulation of translation in ALS 
The identification of the involvement of the RNA binding proteins TDP-43 and 
FUS in ALS has suggested that the disease may represent a failure in RNA 
processing within motor neurons (Droppelmann et al., 2014). In support with 
this hypothesis, other genes involved in RNA metabolism have recently been 
discovered to associate with ALS (Droppelmann et al., 2014). These include:  
ARHGEF28 (encoding Rho Guanine Nucleotide Exchange Factor; RGNEF), 
HNRNPA1 (encoding Heterogeneous Nuclear Ribonucleoprotein A1), TAF15 
(encoding TATA-binding protein-associated factor 2N) and EWS (encoding 
Ewing Sarcoma) (Droppelmann et al., 2014). In addition, many proteins 
involved in RNA metabolism are detected in the pathological inclusions of 
postmortem tissues from individuals with ALS (Bentmann et al., 2013, Dormann 
et al., 2010, Kim et al., 2013, Liu-Yesucevitz et al., 2010, Collins et al., 2012, 
Keller et al., 2012). Furthermore, a hexanucleotide GGGGCC repeat expansion 
in the noncoding region of the C9ORF72 gene has been recently found to be 
the most common genetic abnormality in ALS, being found in around 40% of all 
cases of FALS and 8% of SALS (DeJesus-Hernandez et al., 2011, Majounie et 
al., 2012, Renton et al., 2011). The hexanucleotide repeats in C9ORF72 have 
been shown to generate RNA foci which give rise to aberrant translation that 
generates protein species which sequester proteins, including those involved in 
RNA regulation, (Donnelly et al., 2013, Lee et al., 2013b), and thus may provide 
a basis for the formation of protein inclusions. 
Dysregulation of proteostasis 
The presence of intracellular protein inclusions in ALS indicates that there is a 
failure in proteostasis in the disease (Robberecht and Philips, 2013). Normally, 
the unfolded protein response, ubiquitin proteasome system, and autophagy-
lysosome system function to monitor protein quality and protect cells from 
dysfunctional, misfolded or denatured proteins (Blokhuis et al., 2013).There is 
evidence that failure in these systems may be driven by the aberrant 
aggregation of mutant proteins and that this process is at the centre of the 
pathogenesis of ALS (Saxena and Caroni, 2011, Bendotti et al., 2012). 
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Endoplasmic reticulum stress 
The ER is the first cellular compartment where proteins are synthesized and 
folded. For this process, a large and efficient network of chaperones, foldases, 
and co-factors are expressed at the ER to promote folding and prevent 
abnormal aggregation of proteins. When the function of this organelle is 
affected and abnormal oxidative protein folding occurs at the ER lumen “ER 
stress” occurs (Matus et al., 2013b). ER stress activates the unfolded protein 
response (UPR), a signalling pathway that increases the protein folding capacity 
and quality control mechanisms of the ER to promote proteostasis (Matus et al., 
2013b). However, chronic ER stress can result in cell death by a number of  
mechanisms (Matus et al., 2013b). 
The protein folding chaperone machinery, which includes heat-shock proteins 
(HSPs), assists protein folding under physiological circumstances, and prevent 
protein misfolding and aggregation during cellular stress (Blokhuis et al., 2013). 
Heat shock proteins are found upregulated in the motor neurons of the spinal 
cord of ALS cases (Anagnostou et al., 2010) and within protein inclusions 
(Basso et al., 2009, Watanabe et al., 2001). However, it has been reported that 
there is an overall decrease in chaperone activity in mutant SOD1 mice 
(Tummala et al., 2005), which may be due to the preferential binding and 
inhibition of heat shock proteins by mutant SOD1 protein (Okado-Matsumoto 
and Fridovich, 2002). Functionally, pharmacological activation of HSPs 
increases the lifespan in mutant SOD1 mice (Kieran et al., 2004). Similarly, 
upregulation of HSPs in vivo and in vitro increases solubility of and reduces 
toxicity of mutant SOD1 (Crippa et al., 2010), FUS (Miguel et al., 2012), TDP-43 
(Crippa et al., 2010, Gregory et al., 2012). 
Ultrastructural studies of motor neurons in ALS cases demonstrate evidence of 
endoplasmic reticulum fragmentation (Oyanagi et al., 2008). Post mortem 
immunohistochemical studies have demonstrated the induction of the UPR in 
cases of ALS. There is evidence of enhanced phosphorylation of eIF2α and 
increased levels of XBP1s, ATF4, CHOP, PERK, ATF6, IRE1 and the ER 
foldases PDIA1 and ERp57  (Ilieva et al., 2007, Atkin et al., 2008, Hetz et al., 
2009, Ito et al., 2009). 
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Mutant SOD1 mice demonstrate accumulation of mutant SOD1 protein in the 
endoplasmic reticulum (ER) (Kikuchi et al., 2006, Urushitani et al., 2008, 
Tobisawa et al., 2003) and the presence of ER chaperones such as protein 
disulfide isomerase (PDI) in mutant SOD1 protein inclusions (Atkin et al., 2006). 
In fact PDI is also found in SOD1, TDP-43 and FUS inclusion in human cases of 
ALS (Ilieva et al., 2007, Honjo et al., 2011, Farg et al., 2012). There is evidence 
of endoplasmic reticulum stress in early stages of the disease process in mutant 
SOD1 mice (Saxena et al., 2009). This has been demonstrated by the 
upregulation of genes and proteins involved in the unfolded protein response 
(UPR): PERK, ATF4 and phosphorylated eukaryotic initiation factor 2alpha (Pi-
eIF2 alpha) (Saxena et al., 2009). Importantly, the UPR appears to have a 
functional role in the disease as its pharmacological inhibition, by preventing the 
dephosphorylation of Pi-eIF2 alpha, delays disease and reduces motor neuron 
degeneration in mutant SOD1 mice (Saxena et al., 2009) In this vein, 
haploinsufficiency of the PKR-like ER kinase (perk), the enzyme responsible for 
the phosphorylation of Pi-eIF2 alpha, exacerbates neurodegeneration in mutant 
SOD1 mice (Wang et al., 2011). In addition, reducing the expression of 
GADD34, which normally dephosphorylates p-eIF2 and allows recovery from 
the global suppression of protein synthesis, markedly ameliorates disease in 
SOD1 mice (Wang et al., 2014). 
Ubiquitin-proteasome system 
The ubiquitin-proteasomal system (UPS) is essential for the clearance of 
aberrant proteins in the cellular environment (Finley, 2009). The degradation of 
a protein via the UPS involves two steps: 1) the tagging of the target protein 
with multiple ubiquitin molecules and 2) degradation of the tagged protein by the 
26S proteasome (Finley, 2009). 
In addition to the presence of ubiquitin positive inclusion, changes in the 
expression of UPS-related proteins have been found in the motor neurons of 
ALS cases and in animal models of the disease (Cheroni et al., 2005, Urushitani 
et al., 2004, Urushitani et al., 2002). Furthermore, some of the mutations 
associated with ALS affect genes of proteins which either directly interact with 
the UPS or which are targets of degradation by it (Bendotti et al., 2012). 
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Mutant SOD1 protein misfolds and forms insoluble aggregates in SOD1 FALS 
cases and mutant SOD1 mice (Basso et al., 2006). In addition, Wild-type SOD1 
protein when oxidised also misfolds, is aggregation prone and has neurotoxic 
effects (Ezzi et al., 2007, Bosco et al., 2010, Rakhit et al., 2002). Interestingly, 
immunolabelling using an antibody specific for the oxidised form of SOD1 has 
recently demonstrated the presence of SOD1 protein inclusions in a subset of 
sporadic ALS patients (Bosco et al., 2010). Protein inclusions in SOD1 ALS 
cases and mutant SOD1 mice are immunoreactive for proteins that are 
members of the UPS, including dorfin, CHIP, Gp78, NEDL1, SUMO, UCHL1 
and MITOL (Bendotti et al., 2012). Interestingly, although some of the mutant 
SOD1 protein in the inclusions found in SOD1 mice is ubiquitinated, the majority 
is not (Basso et al., 2006). This suggests that there may be an underlying failure 
of the UPS driving the formation of SOD1 protein inclusion within neurons 
(Basso et al., 2006). In vivo, the expression of proteasome subunits decreases 
as the intracellular accumulation of SOD1 protein increases in the motor 
neurons of SOD1 mutant mice (Cheroni et al., 2005, Kabashi et al., 2008, 
Urushitani et al., 2002, Cheroni et al., 2009). Failure of the UPS has been 
demonstrated in SOD1 transgenic mice that expressed a fluorescently tagged 
reporter substrate of the UPS (Cheroni et al., 2009). These mice accumulated 
the fluorescent reporter protein within motor neurons suggesting that UPS is 
indeed impaired in SOD1 mutant mice (Cheroni et al., 2009). Functionally, 
activation of UPS in mutant SOD1 mice appears to be neuroprotective, as 
transgenic overexpression of dorfin, a ubiquitin ligase, in these mice decreases 
mutant SOD1 protein and ameliorates neurological deficits (Sone et al., 2010). 
Genetics have also provided evidence that failure in the UPS may drive the 
disease process in ALS. Mutations in the ubiquilin-2 gene (UBQLN2) have been 
associated with X-linked FALS or FALS-FTLD (Deng et al., 2011). UBQLN2 is a 
member of the ubiquitin-like protein family which delivers proteins to the 
proteasomal degradation machinery (Ko et al., 2004). In vitro, cells expressing 
ALS-linked UBQLN2 mutants demonstrate an impairment of the UPS (Deng et 
al., 2011). In addition, UBQLN2 has been found in the SIs, which also contain 
TDP-43, in the spinal cord of humans with ALS (Deng et al., 2011). 
Furthermore, it has been found in inclusions of SALS and FTLD cases (in the 
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absence of disease-linked UBQLN2 mutations) (Deng et al., 2011) and of 
patients with FUS mutations (Robberecht and Philips, 2013). 
Autophagy 
Autophagy is a process by which cellular contents are degraded in a controlled 
fashion through the formation of intracellular vesicles (autophagosomes) and 
fusion with lysosomes (Mizushima, 2007). The UPS is involved in the 
degradation of short lived proteins while autophagy is responsible for the 
degradation of long-lived proteins and intact organelles or proteins complexes 
(Mizushima, 2007). Autophagy depends on microtubule transport and proteins 
associated in this process, including dynein, histone deacetylase 6 (HDAC6) 
and p62 (Lee et al., 2010, Pankiv et al., 2007). Importantly, dysregulation of 
autophagy can result in an specific type of cell death, termed autophagy cell 
death (type II cell death), which is characterised by the accumulation of 
autophagosomes and the lack of nuclear condensation (Scarlatti et al., 2009). 
Neuropathological studies demonstrate increased number of autophagosomes 
in the spinal cords of ALS patients and SOD1 mutant mice (Sasaki, 2011, 
Morimoto et al., 2007, Li et al., 2008). However, it is not clear whether the 
increase in autophagosome number indicate autophagy induction or autophagy 
flux impairment in ALS (Chen et al., 2012). On the one hand, in vitro induction 
of autophagy by rapamycin treatment decreases mutant SOD1 protein 
aggregates and associated toxicity (Kabuta et al., 2006). On the other hand, 
activation of autophagy by treatment of SOD1 mutant mice with rapamycin 
augmented motor neuron degeneration (Zhang et al., 2011). SOD1 can be 
degraded by autophagy and the UPS in neuronal cells (Kabuta et al., 2006). It 
has been demonstrated that this process is dependent on the interaction 
between SOD1 and the autophagy related protein p62 (Gal et al., 2009). 
Evidence suggests a similarly relationship between mutant TDP-43 and 
autophagy. TDP-43 inclusion co-localise with the maker of autophagy LC3 and 
the adaptor protein p62 (Wang et al., 2010, Brady et al., 2011). It has been 
demonstrated that TDP-43 protein degradation occurs through both autophagy 
and the UPS (Wang et al., 2010). Activation of autophagy in cellular models of 
mutant TDP-43 pathology results in reduced protein aggregation and 
neurotoxicity (Caccamo et al., 2009). In vivo, treatment of transgenic TDP-43 
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mice with the pharmacological activator of autophagy reduces motor deficits 
and neuronal loss (Wang et al., 2012b). 
Genetics has supported a role of autophagy in ALS further. Mutations in the 
sequestosome 1 gene (SQSTM1; also known as p62), which encodes for a key 
adaptor protein involved in autophagy, has also been associated with ALS 
(Fecto et al., 2011). In addition, its protein has been found in the ubiquitin-/TDP-
43-/FUS-positive inclusions of a large portion of both familial and sporadic ALS 
cases (Deng et al., 2010). In addition, mutations in the gene coding for charged 
multivesicular body protein 2b (CHMP2B) have been found in FTD and ALS 
cases (Parkinson et al., 2006, Cox et al., 2010). CHMP2B protein is a subunit of 
endosomal sorting complexes required for transport-III (ESCRT-III), which is 
necessary for the formation of multivesicular bodies in autophagy (Filimonenko 
et al., 2007). It has been reported that cells depleted of ESCRT subunits or 
expressing ALS associated mutant CHMP2B show inhibited autophagic protein 
degradation, leading to the accumulation of ubiquitinated proteins which include 
TDP-43 and p62 (Filimonenko et al., 2007). Similarly, mutations in the gene 
coding for valosin-containing protein (VCP) have been associated with ALS. 
VCP is a protein that interacts with various ubiquitin-binding partners to regulate 
many ubiquitin-dependent processes including autophagy (Ju et al., 2008). Loss 
of VCP or expression of mutant VCP results in accumulation of 
autophagosomes and in their failure to mature in vitro (Ju et al., 2009, Ju et al., 
2008). Furthermore, mutations in the optineurin (OPTN) gene have been 
associated with ALS (Maruyama et al., 2010). Optineurin protein has been 
found in inclusions containing TDP-43, SOD1 and FUS in ALS cases (Ito et al., 
2011, Maruyama et al., 2010). Optineurin is a ubiquitin-binding protein that is 
involved in autophagy (Wild et al., 2011) and which is a target of the UPS (Shen 
et al., 2011). Functionally, overexpression of wild type or ALS –linked mutant 
optineurin results in the inhibition of UPS and the activation of autophagy in vivo 
and in vitro (Shen et al., 2011). 
Dysregulation of axonal transport 
There is evidence that neuromuscular denervation and axonal degeneration are 
the earliest pathological changes observed in ALS (Fischer et al., 2004). It has 
been suggested that these changes are in part due to changes at the level of 
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the  neuromuscular junction (NMJ) and due to defects in axonal transport 
(Dadon-Nachum et al., 2011). 
Electrophysiological and histological assessment of NMJ function in human ALS 
cases and mutant SOD1 mice has demonstrated evidence of denervation, 
which begins prior to the onset of muscle weakness and which is initially 
compensated by axonal sprouting at the NMJ (Felice, 1997, Hayworth and 
Gonzalez-Lima, 2009, Gordon et al., 2004, Fischer et al., 2004). At the 
molecular level, there is reduced muscle expression of Cdk5, a protein normally 
upregulated in muscle during denervation, in mutant SOD1 mice (Park and 
Vincent, 2008). There is also evidence of increased expression of Sema3A in 
the muscle in mutant SOD1 mice, which has been suggested to repel the 
terminal axon from the NMJ it innervates (Pasterkamp and Giger, 2009). In 
addition, Sema3A has also been found secreted by terminal Schwann cells in 
mutant SOD1 mice (De Winter et al., 2006). The axon guidance protein Nogo-A 
is also found upregulated in muscle of ALS cases and mutant SOD1 mice early 
on the disease (Jokic et al., 2005). In addition, there is evidence of reduced 
expression of trophic factors, such as Glial cell line-derived neurotrophic factor 
(GDNF) and Insulin-like growth factor (IGF-I) in the muscle of ALS cases 
(Yamamoto et al., 1996, Lunetta et al., 2012). Importantly, silencing the 
expression of mutant SOD1 protein in lower motor neurons, by injecting the 
muscle with a lentiviral vector expressing RNAi molecules specifically targeting 
the human SOD1 gene,   ameliorated disease in mutant SOD1 mice (Ralph et 
al., 2005).  
There also changes in Schwann cells in ALS cases and mutant SOD1 mice. 
Histological studies on ALS cases have described myelin alterations along the 
peripheral nerves which are most likely secondary to axonal degeneration in the 
disease (Perrie et al., 1993). Schwann cells in mutant SOD1have been shown 
to play an active role in the ALS disease process (Lobsiger et al., 2009, Wang 
et al., 2012d). They express axon repellent molecules such as semaphorin 3A 
and CD44 (Gorlewicz et al., 2009, De Winter et al., 2006). Importantly, specific 
deletion of mutant SOD1 from Schwann cells in mutant SOD1 mice ameliorates 
disease and extended survival (Wang et al., 2012d). 
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Neuropathological studies demonstrate abnormal accumulation of 
phosphorylated neurofilaments within motor neurons of ALS cases (Hirano et 
al., 1984b, Hirano, 1991) and mutant SOD1 mice (Sasaki and Iwata, 1996, 
Sasaki et al., 2005). In addition, neurofilament binding proteins such as alpha-
internexin, kinesin-associated protein 3 (KAP3), peripherin and tau are also 
found in protein aggregates in ALS post-mortem cases (Page et al., 2011, Gros-
Louis et al., 2004, Corrado et al., 2011, Strong et al., 2006, Tateno et al., 2009). 
Phosphorylation of neurofilament by p38 alpha stress-activated protein kinase is 
involved in the accumulation of neurofilament with motor neurons of ALS cases 
and mutant SOD1 mice (Ackerley et al., 2004, Ackerley et al., 2003). In 
addition, p38MAPK is a component of the intracellular inclusions found in 
human amyotrophic lateral sclerosis and mutant SOD1 Transgenic mice 
(Bendotti et al., 2004). 
Genetic studies have found mutations in the neurofilament heavy (NF-H) gene 
in around 1% of sporadic ALS cases but not in familial cases of ALS (Al-Chalabi 
et al., 1999, Figlewicz et al., 1994, Tomkins et al., 1998). In addition, mutations 
in the gene for the intermediate filament subunit protein, peripherin, are found in 
cases of sporadic ALS (Gros-Louis et al., 2004, Corrado et al., 2011, Leung et 
al., 2004). Interestingly, a variant within the gene of the kinesin-associated 
protein KIFAP3 has been identified to decreased KIFAP3 expression and 
increased length of survival for patients with sporadic ALS, has been identified 
(Landers et al., 2009). Similarly, mutations in the profilin gene, an important 
mediator of actin dynamics, have also been found to account for a small portion 
of inherited ALS cases (Wu et al., 2012). 
There is evidence of delayed anterograde axonal transport in mutant SOD1 
mice, which is present in very early stages of the disease (Williamson and 
Cleveland, 1999, Zhang et al., 1997, Collard et al., 1995, Bilsland et al., 2010, 
Parkhouse et al., 2008).  In vitro, both oxidised (found in sporadic cases of ALS) 
and ALS-associated mutant SOD1 protein have been shown to inhibit both fast 
retrograde and kinesin-based anterograde axonal transport (Bosco et al., 2010, 
De Vos et al., 2007). Similarly, mutant SOD1 protein has been found to interact 
with the dynein complex which is involved in retrograde transport (Zhang et al., 
2007). In  addition, mutant SOD1 protein sequesters kinesin-associated protein 
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3 (KAP3), a protein involved in anterograde axonal transport (Tateno et al., 
2009). 
The effect of neurofilament protein burden on axonal transport also appears to 
be important in neuronal viability.  Mice overexpressing neurofilament proteins 
(NFL-H or NFL-L) develop age dependent motor neuron degeneration (Cote et 
al., 1993, Xu et al., 1993). Similarly, the presence of dominant negative point 
mutation in one of the neurofilament genes (NFL-H) results in fatal progressive 
paralysis in mice characterised by motor neuron degeneration (Lee et al., 
1994). Interestingly, deletion of neurofilament genes NFL-H, NFL-M and NF-L 
prolongs survival in mutant SOD1 mice (Nguyen et al., 2001, Williamson et al., 
1998). It has been suggested that this effect is secondary to a decrease in the 
burden neurofilaments place on the axonal transport machinery (Boillee et al., 
2006a). There is evidence that the largest motor neurons, those which have the 
largest calibre axons and innervations ratios, are the most vulnerable to ALS 
degeneration in human cases and mutant SOD1 mice (Bendotti et al., 2001a, 
Fischer et al., 2004, Feinberg et al., 1999, Hegedus et al., 2007). These motor 
neurons of larger size are likely to have higher demands on axonal transport 
and higher vulnerability to its dysfunction (Pun et al., 2006). Neurofilaments 
slow down axonal transport via protein interactions with the axonal transport 
machinery through their phosphorylated tail domain (Ackerley et al., 2003). 
Thus neurofilament burden on axonal transport may promote motor neuron 
degeneration. In line with this, SOD1 mice expressing neurofilament lacking 
phosphorylated tail domains demonstrate ameliorated neurodegenerative 
disease (Lobsiger et al., 2005). Similarly, in Legs at odd angles (Loa) mice, 
mutations in the motor protein dynein are associated with axonal transport 
defects and motor neuron degeneration (Hafezparast et al., 2003). However, 
mutant SOD1 mice which express one Loa mutated dynein allele demonstrate 
improved axonal transport  and ameliorated disease (Kieran et al., 2005). 
Neurotrophic factors 
Trophic support is essential for neuronal viability in physiological and 
pathological states. There is evidence that the expression of neurotrophic 
factors is dysregulated in ALS and that their delivery may provide a therapeutic 
approach for the disease (Tovar-y-Romo et al., 2014). 
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Brain-derived neurotrophic factor (BDNF) is found in motor neurons at similar 
levels as in controls (Kawamoto et al., 1998) but the expression of its receptor, 
trk B, is increased in the spinal cord of  ALS cases (Mutoh et al., 2000). Levels 
of BDNF in the CSF of ALS patients are similar to controls (Grundstrom et al., 
2000). Functionally, BDNF does not appear to play a role in ALS degeneration 
as clinical trials of subcutaneous BDNF did not alter disease outcome in ALS 
patients (Kasarskis et al., 1999).  
Insulin-like growth factor 1 (IGF-1) expression has been found either unaltered 
or increased in the spinal cord of ALS cases (Dore et al., 1996, Kerkhoff et al., 
1994, Adem et al., 1994b, Adem et al., 1994a). However, the expression of IGF-
1 is impaired in muscle from ALS patients (Lunetta et al., 2012). Functionally, 
IGF-1 was found to be protective in mutant SOD1 mice (Kaspar et al., 2003, 
Dodge et al., 2008). However, clinical trials of subcutaneous IGF-1 have failed 
to demonstrate an effect on ALS patients (Borasio et al., 1998b, Lai et al., 
1997). 
Increased levels of glial cell-line-derived neurotrophic factor (GDNF) have been 
found in the spinal cord, CSF and muscle of ALS patients (Yamamoto et al., 
1996, Grundstrom et al., 2000, Grundstrom et al., 1999). In addition, there is 
evidence of increased expression of the GDNF receptor, RET, in the motor 
neurons of ALS cases (Mitsuma et al., 1999). Functionally, muscular delivery or 
overexpression of GDNF preserves promotes motor neuron function and 
prolongs survival in mutant SOD1 mice (Suzuki et al., 2008, Mohajeri et al., 
1999). 
Leukemia Inhibitory Factor (LIF) and Ciliary Neurotrophic Factor (CNTF) have 
been described as modifier genes in ALS disease (Giess et al., 2000, Giess et 
al., 2002). A mutation in the LIF gene, which affects its ability to bind its 
receptor, has been found in ALS patients (Giess et al., 2000). Similarly, 
mutations in CNTF, which affect its expression have been found in patients with 
ALS and are associated with a more severe form of the disease (Giess et al., 
2002). CNTF and its receptor CNTFR-alpha are found upregulated in the spinal 
cord of ALS cases (Duberley et al., 1995, Schorr et al., 1996). LIF expression 
has not been characterised in the spinal cord but it has been found upregulated 
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in skin biopsies from patients with ALS (Hu et al., 1999). Functionally,  genetic 
deletion of CNTF in mutant SOD1 mice accelerates motor neuron degeneration  
(Giess et al., 2002). In this vein, systemic administration of LIF improved motor 
function in mutant SOD1 mice but failed to protect motor neurodegeneration or 
prolong lifespan (Azari et al., 2003).  However, human clinical trials have 
demonstrated no effect of subcutaneous CNTF on ALS disease (Miller et al., 
1996, Penn et al., 1997).   
Vascular endothelial growth factor (VEGF) levels were shown to be unaltered in 
spinal cord but were found raised in the serum of patients with ALS compared 
to controls (Nygren et al., 2002). People with mutations in the VEGF gene, 
which reduce its expression, are at 1.8 greater risk of developing ALS 
(Lambrechts et al., 2003). Reduced expression of VEGF in mice results in ALS-
like disease in mice (Oosthuyse et al., 2001). In vitro, mutant SOD1 mediated 
neurotoxicity is ameliorated by treatment with VEGF and this neuroprotective 
effect is mediated by the PI3K/AKT pathway (Li et al., 2003, Lunn et al., 2009). 
In vivo, there is a decrease in the expression of VEGF receptors in the spinal 
cord of mutant SOD1 mice (Lunn et al., 2009). In addition, mutant SOD1 mice 
with reduced VEGF expression died earlier and had exacerbated motor neuron 
degeneration (Lambrechts et al., 2003). In contrast, lentiviral mediated 
overexpression of VEGF or its receptor prolongs survival in mutant SOD1 mice 
(Azzouz et al., 2004, Storkebaum et al., 2005), and intracerebroventricular 
delivery of recombinant VEGF results in prolonged survival in mutant SOD1 rats 
(Storkebaum et al., 2005). 
Dysregulation of signalling pathways 
There is evidence of dysregulation in a number of signalling pathways in ALS 
(Hu et al., 2003b, Hu et al., 2003a). 
The non-receptor tyrosine kinase c-Abl, which is activated by Src kinase 
mediated phosphorylation, is found upregulated in human cases of ALS and 
activated in mutant SOD1 mice (Katsumata et al., 2012). Abl is involved in 
cytoskeletal rearrangement and migration (through Rac/Wave1/2/Arp2/3 and 
cortactin), receptor endocytosis (through ERK5, STAT1/3, Rac/JNK), 
proliferation (through Rac/Nox or MK4/7/JNK/Myc) and apoptosis (through 
SAPK/JNK and p38 mitogen activated protein kinase (MAPK)) (Sirvent et al., 
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2008, Sun et al., 2000). Importantly, c-Abl appears to have a role in ALS 
neurodegeneration as pharmacological inhibition of its activation ameliorates 
disease in mutant SOD1 mice (Katsumata et al., 2012). 
GSK-3 has been found upregulated in the spinal cord of ALS cases (Hu et al., 
2003b). GSK-3 affects various intracellular signalling pathways which affect 
neuronal survival including phosphatidylinositol 3-kinase/Akt and Wnt (Goold 
and Gordon-Weeks, 2003, Patel et al., 2004). GSK-3 has been shown to 
directly affect a number of transcription factors involved cell survival including 
the CCAAT/enhancer binding (CEBPB) protein, NFAT, Myc, HSTF-1, the cyclic 
AMP response element binding protein (CREB ), activator protein-1 (AP-1), β-
catenin, NFkB, p53, release of cytochrome c, and caspase-3 (Bijur and Jope, 
2001, Grimes and Jope, 2001, Takadera and Ohyashiki, 2004, Watcharasit et 
al., 2003). In vitro, motor neuron cells expressing mutant SOD1 protein also 
show upregulation of GSK-3, and GSK-3 inhibition reduces cell death (Koh et 
al., 2005a, Jeon et al., 2013). In vivo, pharmacological inhibition of GSK-3 is 
associated with suppressed disease progression in mutant SOD1 mice (Koh et 
al., 2007, Sugai et al., 2004, Ahn et al., 2014, Ahn et al., 2012). 
There is evidence of increased expression and activation of p38 MAPK 
(Mitogen-activated protein kinase) in the spinal cord of ALS patients and in the 
motor neurons of mutant SOD1 mice. It also forms part of intracellular protein 
inclusions found in both ALS cases and SOD1 mice (Hu et al., 2003b, Tortarolo 
et al., 2003, Ackerley et al., 2004, Bendotti et al., 2004). The p38 MAPK is 
implicated in various functions such as phosphorylation of cytoskeletal proteins 
and the synthesis of cytokines and nitric oxide (Mielke and Herdegen, 2000, 
Ono and Han, 2000). This kinase has been implicated in a motor neuron 
specific form of cell death, which involves upstream signalling from the cell 
death receptor Fas and death-associated protein 6 (Daxx) (Raoul et al., 2006). 
In addition, there is in vitro evidence that mutant SOD1 neurodegeneration is 
associated with p38 mediated inhibition of fast anterograde axonal transport 
(Morfini et al., 2013). Interestingly, pharmacological inhibition of activated 
protein kinases (SAPK) p38 and c-Jun-N-terminal kinase (JNK) reduces mutant 
SOD1 induced motor neuron death in vitro and ameliorates neurodegeneration 
in mutant SOD1 mice (Dewil et al., 2007). 
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The mammalian sterile 20 (STE20)-like kinase 1 (MST1) has been found 
upregulated in the motor neurons of ALS cases and mutant SOD1mice (Lee et 
al., 2013a). MST1 is associated with the regulation of cell growth, apoptosis, 
stress response, and senescence (de Souza and Lindsay, 2004, Lehtinen et al., 
2006). Importantly, it has been recently associated to neuronal cell death 
initiated by oxidative stress (Lehtinen et al., 2006, Yuan et al., 2009). Mutant 
SOD1 protein is found to lead to the activation of MST1 by inducing its 
dissociation from Thioredoxin-1 and promoting MST1 homodimerisation (Lee et 
al., 2013a). Functionally, genetic deletion of  the MST1 gene delays disease 
onset and extends survival in mutant SOD1 mice (Lee et al., 2013a). This 
neuroprotective effect was associated with reduced activation of p38 and 
improved autophagy flux (Lee et al., 2013a). 
Post-mortem studies have reported an increase in Pi3K (Phosphoinositide 3-
kinase) activity in the spinal cord of ALS patients (Wagey et al., 1998). In 
contrast, Pi3K immunoreactivity has been reported as decreased or unchanged 
in spinal motor neurons of mutant SOD1 mice (Warita et al., 2001, Peviani et 
al., 2007). The Pi3K and AKT pathway play a major role in the transduction of 
survival signals in neurons and in mediating protection against toxic insult 
(Peviani et al., 2014). In this vein, mutant SOD1 mediated cytotoxicity is 
ameliorated by pharmacological activation of Pi3K or AKT (Koh et al., 2005b, 
Nawa et al., 2008). In addition, genetic over expression of AKT3 within motor 
neurons prevents mutant SOD1 mediated neuronal loss in vitro and in vivo 
(Peviani et al., 2014). This neuroprotective effect was reported to involve the 
inhibition of ASK1 and GSK3 (Peviani et al., 2014). 
Microsatellite analysis has identified PLCD1, the gene encoding for 
phospholipase Cδ1 (PLCδ1), to be associated with human ALS (Simpson et al., 
2009). In addition, the expression of PLCδ1 is found upregulated within motor 
neurons in mutant SOD1 mice (Simpson et al., 2009). PLCδ1 is a protein which 
hydrolyses PIP2 to diacylglycerol (DAG) and IP3 and is involved intracellular 
calcium homeostasis. It is upregulated within neurons in excitotoxic conditions 
(Shimohama et al., 1995) and is involved in the release of calcium from the ER 
via the activation of ER IP3 receptors (Nakamura et al., 2003). Functionally, 
while overexpression of IP3 receptor accelerates disease progression in mutant 
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SOD1 mice (Staats et al., 2012), genetic deletion of PLCδ1 prolongs survival of 
mutant SOD1 mice (Staats et al., 2013). 
Immunohistochemical studies have demonstrated increase expression of Jun-
N-teminal kinase (JNK) in spinal cord astrocytes of ALS cases (Migheli et al., 
1997). In addition, JNK expression has also been found upregulated in the 
spinal cord microglia of mutant SOD1 mice (Veglianese et al., 2006). 
Furthermore, there is evidence of aberrant retrograde axonal transport of 
activated JNK in mutant SOD1 within motor neurons (Perlson et al., 2009). 
JNKs are involved in transducing signals of different forms of cellular stress, 
including excitotoxicity through the phosphorylation of many substrates such as 
the transcription factor c-Jun (Raivich, 2008). In vitro, pharmacological inhibition 
of JNK at the axonal compartment of motor neurons from mutant SOD1 mice is 
associated with reduced activation of c-Jun at cell body and reduced cell death 
(Perlson et al., 2009). Similarly, pharmacological inhibition of activated protein 
kinases (SAPK) p38 and JNK reduces mutant SOD1 induced motor neuron 
death in vitro and ameliorates neurodegeneration in mutant SOD1 mice (Dewil 
et al., 2007). 
The functional role of Janus Kinases in mutant SOD1 mediated disease has 
been investigated because of their involvement in inflammation, oxidative stress 
and apoptosis (Kiu and Nicholson, 2012). Pharmacological inhibition of JAK3 
was found to increase survival of mutant SOD1 mice. However, inhibition of 
JAK2 did not affect motor neuron degeneration in mutant SOD1 mice despite 
having some effect on microglia activation (Tada et al., 2014). 
Changes in gene expression 
There is evidence of differential gene expression in the spinal cord of ALS 
patients and mutant SOD1 mice compared to controls (Heath et al., 2013). 
Gene expression in ALS has been assessed using microarrays on whole spinal 
cord, whole ventral horn, ventral horn grey matter and motor neuron 
homogenates (Heath et al., 2013). 
Microarray analysis of motor neurons from cases with ALS demonstrates that 
the expression of a variety of genes is downregulated when compared to 
controls. These include genes associated with cytoskeleton/axonal transport 
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(such as dynactin and microtubule-associated proteins), transcription (EGR3), 
signalling (c-Abl) and cell surface antigens/receptors (TRK-C). In addition, the 
expression of genes involved in cell death (such as caspases-1, -3, and -9) is 
upregulated. However, there is also increased expression of neurotrophic 
factors (CNTF, GDNF and HGF) and other neuroprotective molecules (NF-κB) 
(Jiang et al., 2005). 
Microarray analysis of the grey matter of the spinal cord of ALS patients 
demonstrates changes in the expression of a variety of genes when compared 
to controls. There are alterations in genes involved in mitochondrial function 
(e.g. downregulation of ATP synthase δ-subunit), oxidative stress 
(downregulation in transferrin and heat shock protein hsp90), inflammation 
(upregulation of HLA class I and cathepsin) excitotoxicity (upregulation of 
glutamate transporter EAAT1), apoptosis (downregulation of inhibitor of 
apoptosis 1 (IAP1)), cytoskeletal architecture (down regulation of dynactin, α-
tubulin, and synaptobrevin), cell adhesion (down regulation in integrin-β3), RNA 
transcription (upregulation of FUS) and translation (down regulation in SMN), 
proteasomal function (upregulation of the E6-AP ubiquitin protein ligase 3A), 
growth (downregulation in fibroblast growth factor 4 (FGF4)) and signalling 
(upregulation in transducin-β2, adenylyl cyclase, and protein kinase C-δ) 
(Dangond et al., 2004). 
Microarray analysis of motor neurons in mutant SOD1 mice demonstrates that 
there is little differential gene expression compared to controls at pre-
symptomatic stages of the disease (Perrin et al., 2005). However, as the 
disease progresses the number of differentially expressed genes in mutant 
SOD1 mice, compared to controls, increases dramatically (Perrin et al., 2005). 
The expression of intermediate filament vimentin was found to consistently 
increase with disease progression in these mice and this was associated with 
the formation of cytoplasmic inclusions containing vimentin protein (Perrin et al., 
2005). In addition, genes associated with neuronal cell growth or maintenance, 
such as the IGF binding protein NOV, matrix metalloproteinase, connexin 43 
and GAP-43, were massively upregulated in mutant SOD1 mice compared to 
controls. 
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Similarly  exon-centric microarray technology has been used to analyse 
changes in gene expression and alternate splicing in the lumbar spinal cord of 
mutant SOD1 mice (Chen et al., 2010). This approach demonstrates that the 
expression of genes involved in immunity and inflammation (e.g. CD68 
upregulation); gliosis (GFAP and S100 upregulation), and lipid metabolism (LPL 
upregulation) is dysregulated in mutant SOD1 mice. In addition, a number of 
genes involved MAPK signalling pathway, T-cell receptor signalling pathway 
and cell adhesion molecules are both differentially expressed and alternatively 
spliced in mutant SOD1 mice compare to wild type control (Chen et al., 2010). 
Changes in transcription factor expression and activation 
There is evidence of dysregulation in the process of gene transcription in ALS 
disease, with aberrant changes in the expression and activation of a number of 
transcription factors. 
Nuclear Erythroid 2-Related Factor 2 (Nrf2) is a transcription factor involved in 
coordinating the upregulation of cellular defences to oxidative stress. It acts on 
the antioxidant response element (ARE) in a number of cytoprotective genes 
including heme oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase 1 
(NQO1), and the catalytic subunit of glutamate cysteine ligase (GCLC) (Chan et 
al., 2001). There is evidence of reduced expression of Nrf2 in the spinal motor 
neurons of ALS cases compared to controls (Sarlette et al., 2008). Functionally, 
global genetic deletion of Nrf2 modestly accelerated the onset of disease but 
did not affect lifespan in mutant SOD1 mice (Guo et al., 2013). However, 
overexpression of Nrf2 specifically by astrocytes significantly delays onset of 
disease and extends the lifespan of mutant SOD1 mice (Vargas et al., 2008). In 
addition, pharmacological activation of Nrf2 enhances motor performance and 
prolongs lifespan of mutant SOD1 mice (Neymotin et al., 2011). 
Activating transcription factor 3 (ATF-3), a basic leucine zipper transcription 
factor, is implicated in the cellular response to a variety of stresses. It has a 
wide variety of targets including genes involved in cell survival, proliferation, and 
death (Hai et al., 1999, Thompson et al., 2009). ATF-3 promotes neuronal 
survival and the regenerative response to axonal injury in vitro and in vivo 
(Seijffers et al., 2006, Seijffers et al., 2007). In addition, ATF-3 prevents 
inflammation and brain injury following transient focal cerebral ischaemia and 
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kainite injections in vivo (Wang et al., 2012c, Francis et al., 2004). ATF-3 
expression has been found upregulated in the spinal motor neurons of mutant 
SOD1 mice and rats (Vlug et al., 2005, Malaspina et al., 2010). Functionally, 
genetic overexpression of ATF-3 delays onset of disease in mutant SOD1 mice 
(Seijffers et al., 2014). This effect was associated with increased neuronal 
survival and neuromuscular junction innervation (Seijffers et al., 2014). 
Activating transcription factor 4 (ATF-4) mediates the upregulation of genes 
involved in the UPR and which function in amino acid and redox metabolism, 
autophagy, protein folding, and apoptosis (Zinszner et al., 1998, Harding et al., 
2000, Harding et al., 2003). In apoptosis, ATF-4 controls the expression of the 
transcription factor CHOP and modulates the levels of multiple pro-apoptotic 
proteins such as BIM and PUMA (Galehdar et al., 2010, Puthalakath et al., 
2007, Tabas and Ron, 2011). ATF-4 expression has been found upregulated in 
the motor neurons of ALS cases and mutant SOD1 mice (Hetz et al., 2009, 
Wang et al., 2011). Functionally, genetic deletion of ATF-4 reduces the rate of 
birth of mutant SOD1 mice. However, ATF-4 deficient SOD1 mice that are born 
have a delayed onset of disease and prolonged life span (Matus et al., 2013a). 
This protective effect is associated with abolished expression of pro-apoptotic 
genes, including BIM and CHOP (Matus et al., 2013a). 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1α) is a transcription co-activator which binds to the nuclear receptor 
peroxisome proliferator-activated receptor gamma (PPAR-γ) to interact with 
multiple transcription factors, including nuclear respiratory factors 1 and 2 and 
mitochondrial transcription factor A (Tfam) (Song et al., 2013). PGC-1α and 
PPAR-γ have roles in protecting cells from oxidative stress (Liang et al., 2007, 
Itoh et al., 2008). There is evidence of decreased expression of PGC-1α and 
the transcription factors it regulates in mutant SOD1 mice (Thau et al., 2012). In 
contrast, there is evidence of increased PPAR-γ activity in the spinal cord of 
SOD1 mice (Benedusi et al., 2012). Functionally, genetic overexpression of 
PGC-1α prolonged survival and decreased motor neuron degeneration in 
mutant SOD1 mice (Liang et al., 2011). 
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The transcription factor nuclear factor interleukin 3-regulated (NFIL3) has roles 
in the development and survival of immune cells and motor neuron (Male et al., 
2012, Junghans et al., 2004). It is trans-activated by elevated intracellular Ca2+ 
concentration and activation of cAMP response element-binding protein 
(MacGillavry et al., 2009, Nishimura and Tanaka, 2001). NFIL3 expression has 
been found upregulated in motor neuron of mutant SOD1 mice (Tamai et al., 
2014). Functionally, genetic overexpression of NFIL3 specifically within neurons 
delays onset of disease and reduces axonal degeneration in mutant SOD1 mice 
(Tamai et al., 2014). 
Mitochondrial transcription factor A (TFAM), originally has important roles in the 
maintenance of mitochondrial DNA and its defence from oxidative damage 
(Larsson et al., 1997, Schonfeld and Reiser, 2006, Xu et al., 2009, Hayashi et 
al., 2008). TFAM has been demonstrated to play a role in neuronal survival 
following ischaemic brain injury (Hokari et al., 2010). Neuronal overexpression 
of a human TFAM transgene resulted in delayed onset of disease and improved 
motor scores in mutant SOD1 mice (Morimoto et al., 2012). This effect was 
associated with reduced motor neuron cell loss and markers of oxidative stress 
and apoptosis (Morimoto et al., 2012). 
In addition to those described above, the expression or activation of other 
transcription factors has been found dysregulated in ALS tissues. However, the 
functional roles of these have not yet been assessed. There is evidence of 
increased expression and activation of c-Jun in the motor neurons of mutant 
SOD1 mice (Vlug et al., 2005, Jaarsma et al., 1996), but this increase is only 
observed in astrocytes in the spinal cord of ALS cases (Migheli et al., 1997). In 
addition, there is evidence of activation of STAT-3 in the spinal cord of ALS 
cases and mutant SOD1 mice (Shibata et al., 2009, Shibata et al., 2010). 
Furthermore, CCAAT/enhancer binding protein beta (C/EBP beta) expression is 
found upregulated in activated microglia in ALS cases and mutant SOD1 mice 
(Valente et al., 2012). Similarly, the expression of CCAAT/enhancer binding 
protein (C/EBP) homologous protein (CHOP) is found upregulated in motor 
neurons of ALS cases and mutant SOD1 mice (Ito et al., 2009, Vlug et al., 
2005). Transcription factor p53 is also upregulated in the ventral horn of the 
spinal cord of patients with ALS and within motor neurons in mutant SOD1 mice 
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(Eve et al., 2007, de Aguilar et al., 2000). The expression of FAC1 is also 
enhanced in motor neurons of ALS cases  (Mu et al., 1997). In contrast, 
expression of nuclear factor kappa B (NF-kappa B) is found down regulated in 
the motor neurons but upregulated in the astrocytes of ALS patients (Sako et 
al., 2012, Migheli et al., 1997). Similarly, heat shock transcription factor 1 
(HSF1) expression is downregulated in the spinal cord mutant SOD1 mice 
(Mimoto et al., 2012). Finally, the levels of HoxB2 expression do not change in 
mutant SOD1 mice but HoxB2 has been shown to bind mutant SOD1 and form 
part of inclusion within motor neurons in those mice (Zhai et al., 2005). 
Evidence of a regenerative effort in ALS 
The degenerative process in ALS is accompanied by morphological and 
molecular changes indicative of a regenerative effort. These changes can be 
observed at all anatomical levels of the neuromuscular motor unit. At the level 
of the cell body, histological analysis of the spinal cord of ALS cases and 
mutant SOD1 mice shows that degenerating motor neurons undergo the 
chromatolytic reaction characteristic of regenerating motor neurons (Martin, 
1999, Manetto et al., 1988, Sobue et al., 1990, Sasaki et al., 2000b, Kusaka et 
al., 1988, Riancho et al., 2014). In addition, the increased expression of a 
number of regeneration associate genes and proteins, including c-Jun, AFT-3, 
Pi3K and GAP-43, can be observed in the motor neurons of ALS cases and 
mutant SOD1 mice (Malaspina et al., 2010, Parhad et al., 1992, Ikemoto et al., 
1999, Wagey et al., 1998, Jaarsma et al., 1996, Lobsiger et al., 2007). At the 
ventral root, there is evidence of regenerating axons (Hanyu et al., 1982, Sobue 
et al., 1981, Fischer et al., 2004), as well as increased neurotrophic signalling 
(Kerkhoff et al., 1991, Lobsiger et al., 2009) in both ALS cases and mutant 
SOD1 mice. At the level of the muscle there is axonal terminal sprouting, 
collateral sprouting and reinnervation of NMJs (Tsujihata et al., 1984, Atsumi, 
1981, Hegedus et al., 2008, Hegedus et al., 2007) and proregenerative gene 
expression by denervated muscle fibres (Gonzalez de Aguilar et al., 2008, Weis 
et al., 1998, Yamamoto et al., 1996, Bjornskov and Norris, 1984, Frey et al., 
2000b).  
These regenerative changes appear to have a functional significance in ALS 
disease as it has been demonstrated that muscle weakness only becomes 
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apparent when NMJ reinnervation fails to compensate the ALS mediated 
denervation (Felice, 1997, Hayworth and Gonzalez-Lima, 2009, Gordon et al., 
2004). In this vein, there is evidence that ALS preferentially affects motor 
neurons depending on their regenerative ability. Axons innervating 
neuromuscular junctions have differential terminal sprouting potential (Frey et 
al., 2000b). Interestingly, it has reported that synapse types that fail to exhibit 
terminal sprouting are selectively vulnerable to ALS disease, whereas synapses 
undergoing robust paralysis-induced sprouting are selectively resistant (Frey et 
al., 2000b). In addition, interventions that enhance this regenerative effort 
ameliorates disease in mutant SOD1 mice. For example genetic overexpression 
of the regeneration associated transcription factor ATF-3 prolongs the survival 
of mutant SOD1 mice by enhancing terminal axonal sprouting and NMJ 
innervation at the muscle (Seijffers et al., 2014). In addition, pharmacological 
inhibition of Rho Kinase, which is associated with enhanced neurite outgrowth 
in vitro, improves motor performance and prolongs survival of mutant SOD1 
mice (Tonges et al., 2014, Gunther et al., 2014). In contrast, deletion genetic 
deletion of miR-206, a microRNA required for efficient regeneration of 
neuromuscular synapses after axotomy, exacerbates disease and shortens 
lifespan of mutant SOD1 mice (Williams et al., 2009). Thus a regenerative effort 
mounted by degenerating motor neurons may modulate ALS disease. 
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Trauma and ALS  
The aetiology of ALS remains elusive with multiple risk factors loosely 
associated with the disease (Longo et al., 2012). A link between ALS and 
trauma to the nervous system has been suggested for over one hundred years 
(Woods, 1911) and a number of retrospective epidemiological studies support 
this (Chen et al., 2007). 
Higher incidence rates of ALS have been found in populations were trauma is 
more prevalent, including military veterans, American-football and soccer and 
players (Coffman et al., 2005, Chio et al., 2005, Abel, 2007, Chio et al., 2009). A 
number of case-control studies and meta-analysis have indicated that trauma to 
head, neck or back are more likely to have occurred to patients with ALS prior 
to their diagnosis than control populations (Kondo and Tsubaki, 1981, Strickland 
et al., 1996, Chen et al., 2007, Binazzi et al., 2009, Schmidt et al., 2010, Pupillo 
et al., 2012).  Although these studies suggest that ALS may result from 
traumatic nervous injury, the majority fail to confirm any radiological or 
neurophysiological evidence of nervous injury in the studied ALS groups prior to 
diagnosis. 
In traumatic brain injury the brain and spinal cord undergo shear deformation 
that produces transient elongation and injury of axons, which are associated 
with subsequent plastic cellular and molecular reactions that resemble those 
following peripheral nerve axotomy (Buki and Povlishock, 2006). Interestingly, a 
case control study demonstrates that ALS patients are more likely to have 
suffered radiologically confirmed myelopathy due to spinal spondylosis prior to 
diagnosis (Setzer et al., 2008). Furthermore,  a number of cases of ALS in 
military personnel have been associated with preceding peripheral nerve injury 
(Riggs, 1993, Riggs, 2001). This suggests that axonal injury may modify the 
ALS pathogenic process in certain individuals. 
It has been suggested that genetic and epigenetic factors may contribute to a 
predisposition to the development of ALS following trauma (Malaspina et al., 
2010, Yip and Malaspina, 2012). This has been supported by evidence that 
spondylotic myelopathy prior to ALS is more common in people carrying the 
ApoE epsilon 4 allele (Setzer et al., 2008). In addition, a FIG4 mutation 
associated with ALS was first described in case were quadriplegia occurred 
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subsequent to trauma to the first affected limb (Chow et al., 2007, Chow et al., 
2009).  
Interestingly, recent molecular analysis of SOD1G93A mice after injury of the 
peripheral or central nervous system demonstrate defects in their normal 
response to such injuries (Malaspina et al., 2010, Yip and Malaspina, 2012, 
Mesnard et al., 2011a, Haulcomb et al., 2014, Mesnard-Hoaglin et al., 2014). 
SOD1G93A mice show increased expression pro-apoptotic and pro-
inflammatory genes and reduced expression of pro-survival genes (Malaspina 
et al., 2010, Yip and Malaspina, 2012, Mesnard et al., 2011a, Haulcomb et al., 
2014, Mesnard-Hoaglin et al., 2014).  Thus, a defect in the response to 
traumatic nervous injury may play a role in ALS pathogenesis. 
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Peripheral Nerve Regeneration 
The neuropathological changes observed in ALS resemble those following 
axotomy, including loss of target innervation at the neuromuscular junctions, 
axonal loss and motoneuron death, as well as reactive neuroinflammatory 
changes (Fischer et al., 2004, Raivich et al., 2004). In addition, there is 
evidence of a regenerative effort mounted by the nervous system in ALS 
disease. Thus, analysis of the physiological response of the nervous system to 
acute axonal injury may shed light on factors which play a role in the 
pathological process observed in ALS. 
Morphological changes 
Cell body response 
Following peripheral nerve injury, the injured neuronal cell body exhibits a 
number of ultrastructural changes. Accumulations of rough endoplasmic 
reticulum, known as Nissl bodies, are found randomly dispersed in the neuronal 
cytoplasm, rather than in the normal linear arrangement (Lieberman, 1971). 
These structures are visible under light microscopy when stained with 
basophilic dyes and their dispersion is termed ‘chromatolysis’ or ‘chormatolytic 
reaction’ (Nissl, 1894). The neuronal cell body swells, the nucleus moves to the 
cellular periphery and synaptic terminals retract (Lieberman, 1971). There is 
also an increase in intracellular organelles, such as mitochondria and 
ribosomes. These changes are consistent with an increase in cellular 
metabolism and protein synthesis, which are necessary for axonal growth and 
repair (Raivich and Makwana, 2007) (Fig.2B). If axotomised neurons fail to 
connect with their peripheral target, the injured neurons may become atrophic, 
remain in the chromatolytic state or even go on to degenerate and die 
(Deumens et al., 2010). 
Axonal response 
Following axotomy, axonal changes are observed proximally and distally to the 
site of injury. 
Distal changes 
The distal nerve segment undergoes anterograde changes termed Wallerian 
degeneration (Perry et al., 1987) (Fig. 2B). Around 24 hours after injury, the 
axons bead and swell. Subsequently, granular disintegration of the cytoskeleton 
occurs, breaking axons into fine debris (George et al., 1995, Sievers et al., 
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2003, Bignami and Ralston, 1969, Trojanowski et al., 1984). In addition, the 
myelin sheath partitions into fatty material (Lassmann et al., 1978). Remaining 
myelin debris contains molecules that are inhibitory to the growing axon 
including myelin-associated glycoprotein (MAG) and oligodendrocyte-myelin 
glycoprotein (OMgp) (Huang et al., 2005). Schwann cells degrade the myelin 
and extracellular debris and are the main phagocytic cell in early time points 
after injury (Perry et al., 1995). Infiltrating macrophages are gradually recruited 
by Schwann cells, through the release of cytokines (Tofaris et al., 2002), and 
they take over the process of phagocytosis from Schwann cells at later time 
points (Tanaka et al., 1992). Schwann cells proliferate within the basal lamina 
tubes, where they align to form bands of Büngner. The create a pathway for the 
regenerating axon to reach its peripheral target and also provide necessary 
substrates and growth factors (Bradley and Asbury, 1970, Stoll et al., 1989). 
Proximal changes 
Following the resealing of the severed axoplasm, the tip of the axon swells and 
is inflated with smooth endoplasmic reticulum, mitochondria, and microtubules 
(Meller, 1987, Vallee and Bloom, 1991). These axonal swellings eventually give 
rise to a sheet-like expansions called a lamellapodia, from which numerous fine 
processes called filopodia extend; these structures form the ‘growth cone’, first 
described by Santiago Ramon y Cajal (1928). Growth cones are highly motile 
structures (Spira et al., 2003), which are steered towards the peripheral target 
by guidance cues and growth promoting signals found in the bands of Büngner 
(Ide, 1996). Once the regenerating axon has crossed the site of injury, its rate of 
elongation is around 1-4mm per day (Bisby and Keen, 1985, Forman and 
Berenberg, 1978, Gutmann et al., 1942) (Fig. 2C &D). 
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Figure 2: Schematic of the main events of degeneration and regeneration after 
peripheral nerve injury. (A) Normal nerve fibre, maintaining synaptic contact 
with target cells. (B) Transection of the fibre results in distal fragmentation of 
axon and myelin sheaths. Macrophages and Schwann cells phagocyte 
degraded materials. Chromatolysis at the neuron soma and dendritic arbour 
retraction occur. (C) Fine sprouts emerge from the proximal axonal end, and 
elongate in association with the proliferated Schwann cells in the distal 
segment, that line up in bands of Büngner. (D) Axonal reconnection with target 
cells and maturation of the nerve fibre. The regenerated axon remains of 
smaller calibre and with shorter internodes than normal. The neuron returns to a 
normal transmitting phenotype. Target cells may suffer atrophy and phenotypic 
changes during denervation (Navarro et al., 2007). 
Axonal sprouting and functional recovery 
Morphologic studies by Ramon y Cajal (1928) demonstrate that injured axons 
produce a number of branches or sprouts, which are tipped by growth cones. 
Sprouting has been observed at the nodes of Ranvier (Cajal, 1928), distal part 
of dendrites (Fenrich et al., 2007) and at the level of the injured neuronal cell 
body after axonal injury (Linda et al., 1985, Makwana et al., 2010). Aberrant 
axonal sprouts are removed or pruned, particularly those that regenerate 
through inappropriate distal pathways and innervate the wrong targets 
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(Brushart, 1993, Brushart et al., 1998). Importantly, functional recovery depends 
on the accuracy of target reinnervation and it is therefore dependent on pruning 
of aberrant sprouting (Brushart, 1993, Brushart et al., 1998). 
In rodents, following a crush injury, axons regenerate, show accurate target 
innervation, and there is good functional recovery (Magill et al., 2007). An 
evaluation of axonal innervation of the motor endplate at the neuromuscular 
junction (NMJ), demonstrate that intact mice have one axon innervating one 
motor endplate (Magill et al., 2007). However, one week after peripheral nerve 
crush all of the motor endplates are denervated, at two weeks they are partially 
innervated, at 3 and 4 weeks they are hyperinnervated or polyinnervated, and 
by six weeks all endplates are singly innervated like intact controls. At six weeks 
after nerve crush, and not prior to that, functional recovery reaches its maximum 
level, suggesting that polyinnervation of motor endplates is not ideal for 
functional recovery (Magill et al., 2007). 
Interestingly, after peripheral nerve transection, target innervation is inadequate 
and has been associated with a less than optimal functional recovery (Angelov 
et al., 2005). Following transection, motor endplates can be incorrectly 
reinnervated by axons that have regenerated through wrong nerve fascicles 
(Angelov et al., 2005). This has been associated with uncoordinated muscle 
activity (Angelov et al., 2005). In addition, poor functional recovery after 
transection has been explained by supernumerary collateral branches 
innervating one muscle fibre (Bendella et al., 2011). Interestingly, reducing the 
amount of axonal branching has been shown to yield better functional recovery 
after axonal injury (Angelov et al., 2005). 
Finally, although axons may regenerate and innervate targets, the diameter of 
the regenerated axons as well as their conduction velocity and excitability has 
been shown to be below normal (Fields and Ellisman, 1986a, Fields and 
Ellisman, 1986b), which may result in incomplete or inadequate recovery of the 
innervated muscle (Fields and Ellisman, 1986a, Fields and Ellisman, 1986b). 
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Inflammatory and glial response to injury 
Microglia 
Following injury, microglial activation is apparent by a change in their 
morphology and the expression of cell adhesion molecules, cytoskeletal 
proteins, and antigen presentation molecules (Table 3). This molecular change 
occurs in a stepwise manner, which can be divided into the following stages; 
resting microglia in the normal brain (stage 0), state of alert (stage 1), homing 
(stage 2), phagocytosis (stage 3a) and bystander activation (3b) (Raivich et al., 
1999). 
In the normal brain (stage 0), microglia with their ramified morphology express 
receptors for complement fragments, and Fcγ receptors that bind to 
immunoglobulins (Peress et al., 1993, Williams et al., 1994). In the state of alert 
(stage 1), microglia increase the expression of immunoglobulin-G, 
thrombospondin and the αMβ2-integrin, a receptor for the complement 3ib 
fragment (Kloss et al., 1999, Moller et al., 1996). The cell surface receptor 
ligand, intracellular adhesion molecule 1(ICAM1), is also expressed. This ligand 
mediates the adhesion of microglia to lymphocytes, granulocytes as well as 
other microglia in the vicinity, by interacting with αMβ2 and αLβ2 integrins, 
which are found in the cell surface of these cells (Hynes, 1996).  
Next, the homing stage (stage 2) is characterized by the homing and adhesion 
of microglia to damaged neurons or degenerating dendrites. This step in 
associated with an increase in the expression of α5β1 and α6β1integrins in 
mice (Hailer et al., 1997, Kloss et al., 1999), as well as cytoskeletal proteins like 
vimentin  (Graeber et al., 1988, Raivich et al., 1993). A reduction in the 
ramification of microglial processes is also evident; this change in morphology 
aids mobility and adhesion properties (Angelov et al., 1995). Microglia are found 
to move into direct contact with injured neuronal cell bodies, where the cells 
displace synaptic input in a process called synaptic stripping (Blinzinger and 
Kreutzberg, 1968). At this stage, a decrease in the alert phase markers such as 
αMβ2 and ICAM1 is accompanied by an increase in the receptors for microglial 
mitogens such as, macrophage colony stimulating factor (M-CSF) and 
granulocyte macrophage colony stimulating factor (GM-CSF) (Raivich et al., 
1998a), which are associated with an increase in the number of local microglia 
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(Raivich et al., 1994). In addition, microglia in stage 2 show a weak expression 
of major histocompatibility complex (MHC) class I molecules  (Raivich et al., 
1993, Streit et al., 1989) and immunoaccessory glycoproteins, like B7.2 
(Bohatschek et al., 1998). Microglia can return to a non-activated state in the 
absence of cell death, by decreasing in density, becoming highly ramified, being 
territorially distributed and having normal levels of complement receptors, Fcγ-
receptors and IgG immunoreactivity  (Raivich et al., 1999).  
In the stage of phagocytosis (stage 3a), neuronal death mediates the 
transformation of microglia into phagocytic cells that remove debris, such as 
axons and myelin in Wallerian degeneration (Moller et al., 1996, Streit and 
Kreutzberg, 1988). When the removal of large debris like degenerating 
pyramidal neurons is required, microglia form clusters or nodules of 3 to 20 
microglia (Moller et al., 1996, Streit and Kreutzberg, 1988). This change is 
associated with a strong upregulation in the expression in α5β1 and α6β 
integrins, MHC1 antigen-presenting complex, as well as the de-novo expression 
of MHC2. In addition, the B7.2, ICAM1 and αXβ2 integrin, which may serve as 
stimuli to activate T-cells in the presence of a specific antigen, are also strongly 
expressed. Finally, bystander activation (stage 3b) is also observed in the 
presence of phagocytosis. Microglia in the vicinity of phagocytic microglia, show 
an increase in MHC1, B7.2, α4β1, αMβ2 and ICAM1 (Bohatschek et al., 1998, 
Kloss et al., 1999, Raivich et al., 1998b). In addition, when lymphocytes infiltrate 
they aggregate in a concentric distribution around microglial nodules (Raivich et 
al., 1998b), which suggests the presence of a soluble cytokine produced by 
phagocytotic microglia.  
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Table 3: Molecular markers of microglial activation. Abbreviations: w: weak, m: 
moderate and s: strong expression as identified using immunoreactivity. Edited 
from Raivich et al.,(1999). 
Grading Type of response Specific markers (mouse) 
stage 0 Normal brain FcγR (w), IgG (w), αMβ2 (w) 
stage 1 State of alert IgG (m), αMβ2 (s), ICAM1 (s) 
stage 2 Homing α5β1 (s), α6β1 (s), M-CSFR (s), MHC1(w), 
B7.2(w) 
stage 3a Phagocytosis MHC1 (s), B7.2 (s), αXβ2 (s), αMβ2 (s), α5β1 
(s), α6β1 (s), ICAM1 (s), IgG (s) 
stage 3b Bystander activation MHC1 (m), B7.2 (m), α4β1(m), αMβ2 (m), 
ICAM1 (m) 
 
During the process of activation, microglial cells secrete pro-inflammatory 
cytokines including tumour necrosis factor-alpha (TNFα), Interferon-γ, and 
interleukin 1β; and upregulate the expression of oxidant molecules such as NO, 
which can all have neurotoxic effects (Welser-Alves and Milner, 2013, 
Kawanokuchi et al., 2006, Eriksson et al., 1998, Schluter et al., 1997, Sheng et 
al., 1997, Zhang et al., 1998, Minghetti and Levi, 1998, Ding et al., 1997) 
However, microglia are also involved in neuronal protection following injury. 
Microglia are well known for producing trophic factors including brain derived 
neurotrophic factor (BDNF), and insulin-like growth factor 1 (IGF1) (Gomes et 
al., 2013, Suh et al., 2013). 
Astrocytes 
In response to neuronal injury, astrocytes rapidly increase the synthesis of 
GFAP (Tetzlaff et al., 1988). This is followed by transformation of protoplasmic 
astrocytes into stellar, fibrillary astrocytes (Graeber and Kreutzberg, 1986). This 
change is controlled by the cytokine transforming growth factor-beta 1 (TGFb1), 
as the absence of this cytokine results in the decrease of GFAP-positive 
fibrillary actrocytes following brain injury in mice (Jones et al., 1998). In the 
severely injured brain, protoplasmic astrocytes express the cell adhesion 
molecule CD44 and demonstrate a velate morphology (Raivich et al., 1999). 
T-cells 
The presence of T-cells is evident following CNS injury (Raivich et al., 1999). 
The extent of T-cells being recruited to the brain depends on the severity of 
injury. After mild or indirect neuronal injury, only a fewer T-cells are seen one 
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day after axotomy (Raivich et al., 1998b). However, the numbers of T-cells 
dramatically increase in the presence of cell death, with 100-fold increase in T-
cell influx in injured tissue compared to the unaffected tissue (Raivich et al., 
1998b). The population of T-cells entering the brain is mixed, with CD3-, CD4- 
as well as CD8-positive T-cells being present. T-cells in the brain aggregate 
around phagocytic microglia that express MHC1, B7.2 and αXβ2, which are 
important molecules involved in antigen presentation (Raivich et al., 1999).  
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Molecular changes 
Following peripheral nerve injury, stress signals induces the expression of 
transcription factors, adhesion molecules, growth associated proteins and 
structural components within axotomised neurons (Raivich and Makwana, 
2007). 
Injury cues to axotomised neurons 
There are three main cues that inform the neuron of injury (Patodia and Raivich, 
2012b): 1) the deprivation of neurons from neurotrophic factors following axonal 
injury leads to the disinhibition of regeneration processes within 12 -24 hours 
following injury (Raivich et al., 1991); 2) Proteins from the extracellular 
environment and neighbouring cells enter through the tip of the axon and are 
carried retrogradely to the neuronal cell body (Schmied et al., 1993, Hanz et al., 
2003); 3) There is rapid influx of extracellular ions such as calcium and sodium 
through the transiently opened axonal membrane (Yoo et al., 2003), 
subsequently followed by an increase in injury-mediated action potentials that 
cause an elevation of intracellular calcium and cAMP, which can activate 
various downstream pathways (Berdan et al., 1993) (Berdan et al., 1993). 
Signalling cascades  
Injury signals are propagated within the neuron via signalling cascades, which 
use a network of interacting proteins to influence cellular processes (Raivich 
and Makwana, 2007). One such signalling pathway, collectively known as the 
Mitogen-activated protein (MAP) kinase cascade, uses signals from growth 
factor receptors to sequentially stimulate protein kinases (Raivich and 
Makwana, 2007). This phosphorylation cascade activates regulatory molecules 
in the cytoplasm and cell nucleus to initiate, within the injured neuron, 
processes that may lead to neuronal regeneration (Raivich and Makwana, 
2007). In vivo, the kinases ras, raf, the mitogen-associated protein kinase 
kinase (MEK) and the group of extracellular signal-regulated kinases 1 and 2 
(erk1, erk2), are up-regulated after axonal injury (Kiryu et al., 1995). In vitro, 
neurite outgrowth and local protein synthesis is dependent on the kinases Erk1 
and 2, p38 and caspase-3 (Campbell and Holt, 2003, Verma et al., 2005), as 
well as cAMP, and the cAMP-dependent protein kinase A (PKA) (Chierzi et al., 
2005). Additionally, the ras, raf, mitogen-associated protein kinase kinase 
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(MEK) and the group of Erk 1 and 2 molecules, have been shown to promote 
survival and neurite growth of cultured embryonic neurons (Borasio et al., 1989, 
Ihara et al., 1997). Furthermore, neurite outgrowth of cultured adult neurons is 
dependent on the translocation of Erk from the axon to the cell body (Perlson et 
al., 2005). 
The phosphatidylinositol-3 kinase-Akt (PI3K-Akt) pathway is also involved in 
axonal regeneration following injury. Expression of the PI3K gene (Ito et al., 
1996) and the subsequent activation of protein kinase B or Akt are observed 
following axotomy (Owada et al., 1997, Murashov et al., 2001). Mice with 
altered PI3K catalytic ability have reduced signalling through Akt, dampened 
axonal regeneration and impaired functional recovery after injury (Eickholt et al., 
2007). Additionally, in neonates, Akt overexpression promotes neuronal survival 
following hypoglossal nerve injury (Namikawa et al., 2000). In adults, Akt 
overexpression promotes accelerated axonal regeneration following axotomy 
(Namikawa et al., 2000). 
Jun-N-terminal kinases (JNK) also participate in the neuronal response to 
axotomy. An increase in activated JNK is found in the rat dorsal root ganglion 
following peripheral nerve injury (Kenney and Kocsis, 1998). JNKs carry out the 
N-terminal phosphorylation of the transcription factor c-Jun (Waetzig et al., 
2006). After peripheral nerve injury there is an increase in JNK activation, as 
well as phosphorylated c-Jun (Waetzig et al., 2006). Inhibition of JNKs blocks 
neurite outgrowth in cultured adult neurons (Lindwall et al., 2004). In addition, 
neuron specific genetic deletion of JNK1 and JNK2 delays functional recovery 
after facial nerve injury in mice (Ruff et al., 2012). 
Transcription factors 
Transcriptional factors contribute to the changes in neuronal gene expression 
after injury. The activation of signalling pathways in injured neurons leads to the 
increased expression and nuclear translocation of some transcription factors 
such as, c-Jun, Jun D, ATF3 (cyclic AMP-dependent transcription factor), 
STAT3, P311, p53, CREB (cAMP response element-binding), Sox11 (sex-
determining region Y box-containing 11) and C/EBP (CCAAT/enhancer binding 
protein) β, δ. (Schwaiger et al., 2000, Raivich et al., 2004, Nadeau et al., 2005, 
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Di Giovanni et al., 2006, Jankowski et al., 2009, Moore and Goldberg, 2011, 
Ruff et al., 2012, Patodia and Raivich, 2012b). In contrast, the expression of 
other transcription factors such as islet-1, Fra-2, ATF2, and TDP-43, is 
downregulated (Doyle and Hunt, 1997, Herdegen et al., 1997, Hol et al., 1999, 
Moisse et al., 2009b, Sato et al., 2009). These transcription factors bind to 
complementary DNA promoter regions and increase or repress the expression 
of target genes (Patodia and Raivich, 2012b).  
Regeneration associated genes 
Changes in transcriptional regulation are subsequently followed with altered 
expression of a number of regeneration associated genes after injury, which 
can be grouped into the following categories; adhesion molecules, guidance 
molecules, neuropeptides and cytoskeletal adaptors (Patodia and Raivich, 
2012a). 
Adhesion molecules 
Adhesion molecules on the surface of the axonal growth cone, guides the axon 
along the bands of Büngner towards its target (Grumet, 1991, Shapiro et al., 
2007). Following injury, axons express integrins such as α7β1, as well as 
receptors for laminin, fibronectin and paxillin, which are molecules found on the 
surface of Schwann cells and the inner lining of the neural tube basal 
membrane (Kloss et al., 1999, Werner et al., 2000, Vogelezang et al., 2001, 
Vogelezang et al., 2007, Ekstrom et al., 2003, Wallquist et al., 2004, Gardiner et 
al., 2005).The expression of the receptor CD44, which binds to hyaluronic acid 
(Jones et al., 2000), and galectin-1, a receptor for galactoside residues (Horie 
and Kadoya, 2000, Akazawa et al., 2004), are also upregulated.  In addition, 
axons express molecules involved in homophilic binding such as ninjurin (Araki 
and Milbrandt, 2000) and gicerin/CD146 (Hiroi et al., 2003). Furthermore, 
enzymes such as urokinase and plasminogen activator (PA), 
metalloproteinases (MMP) 2, 3 and 9 (Demestre et al., 2004, Shubayev and 
Myers, 2004), and damage-induced neuronal endopeptidase (DINE) (Kiryu-Seo 
et al., 2000) are also expressed by the regenerating axons. 
Thus far, the adhesion molecules that have been functionally characterised in 
vivo include α7β1, and the β2-microglobulin (β2-MG). A moderate reduction in 
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axonal regeneration was found in mice deficient of β2-MG (Oliveira et al., 2004). 
A decrease in the speed of axonal regeneration and reinnervation of the 
peripheral tissue was observed in mice deficient of α7β1 (Werner et al., 2000). 
Although the function of CD44 in regeneration has not yet been investigated in 
vivo, it has been demonstrated that antibody inhibition of CD44 affects the 
routing of retinal axons in brain slice preparations (Lin and Chan, 2003). 
Neuropeptides 
Specific neuronal populations express neuropeptides after axonal injury and 
these neuropeptides can be found in the most distal part of the growing axon 
known as the growth cone (Raivich and Makwana, 2007). Following injury, 
subpopulations of spinal and motor neurons can upregulate the neuropeptides 
calcitonin gene-related peptide (CGRP), galanin, and pituitary adenylate 
cyclase activating peptide (PACAP) (Moore, 1989, Raivich et al., 1995). 
Functionally, when the PACAP gene is deleted the promotion of the initial 
axonal growth that is seen within 24 hours after injury and reinnervation of the 
peripheral target is delayed (Armstrong et al., 2008). The deletion of galanin or 
its receptor results in a reduction in speed of regeneration after sciatic nerve 
crush (Holmes et al., 2000). Reducing the production of intra-axonal CGRP with 
short interfering RNA (siRNA) decreases axonal growth across a conduit 
between the proximal and distal nerve stumps (Toth et al., 2009). In addition, 
blocking the receptor for CGRP in Schwann cells with siRNA, results in 
decreased axonal growth, which suggests that axon interaction with Schwann 
cells, is important for neurite growth (Raivich et al., 1992, Toth et al., 2009). 
Guidance molecules 
Guidance molecules allow elongating axons to navigate to the correct 
destination by inducing axonal attraction or repulsion signals. Many guidance 
molecules that promote growth have been identified, for example, Bex1, an 
intracellular adaptor molecule that interacts with p75NTR, and neuropilin-2, a 
transmembrane receptor protein that binds to semaphorins, are strongly up 
regulated after axonal injury (Lindholm et al., 2004). Mice deficient of Bex1 
(Khazaei et al., 2010) or neuropilin-2 (Bannerman et al., 2008) showed 
significantly slower functional recovery than controls. However, deleting their 
complementary receptors does not have such a strong effect. The deletion of 
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the Bex1 receptor, p75NTR, fails to alter neuronal survival or speed of 
functional recover (Khazaei et al., 2010). In addition, deleting the semophorin 
recpetors 3B, 3C and 3F, which bind to neuropilin-2, has no effect on functional 
recovery, but reduces the density of the light neurofilament-positive axons in the 
distal nerve (Bannerman et al., 2008). 
Molecules that inhibit growth are also involved in axonal regeneration, for 
example, the G-protein RhoA and the Rho-associated kinase (Hiraga et al., 
2006, Madura et al., 2007, Cheng et al., 2008). After injury, the G-protein RhoA 
and the Rho-associated kinase are strongly expressed (Hiraga et al., 2006, 
Madura et al., 2007, Cheng et al., 2008). Inhibition of RhoA GTPase signalling 
through RhoA-associated kinase (ROCK) accelerated functional recovery and 
increased the density of both myelinated and unmyelinated axons after 
peripheral nerve injury (Hiraga et al., 2006, Madura et al., 2007). 
Cytoskeletal adaptors 
The growth cone is a motile structure at the distal tip of the elongating axon, 
which interacts with the surrounding cells and the extracellular substrate to find 
its target. This process as well as being dependent on adhesion molecules, 
guidance molecules, and neuropeptides, is also dependent on the adaptor 
molecules within the growth cone (Baas and Ahmad, 2001, Ellezam et al., 2002, 
Zhang et al., 2003, Madura et al., 2004, Bouquet et al., 2004). The major 
adaptor proteins expressed in the growth cone are the GAP43/neuromodulin 
and cytoskeleton-associated protein 23 (CAP23) (Goslin and Banker, 1990, 
Bomze et al., 2001). These molecules are important in cytoskeletal remodelling 
of the growth cone. Depleting cultured neurons of GAP-43, resulted in abnormal 
growth cone adherence andmobility, failure to express f-actin, reduced axonal 
branching and enhanced sensitivity to inhibitory stimuli (Aigner and Caroni, 
1995). In vivo, GAP-43 is important in path-finding, as the axons of mice 
deficient of GAP-43 enter inappropriate tracts during development (Strittmatter 
et al., 1995). Mice lacking CAP23 fail to produce sprouting at the neuromuscular 
junction following a muscular injection of botulinum toxin A (Frey et al., 2000a). 
Alternatively, the over expression of GAP43 or CAP23 promotes excessive 
neuromuscular sprouting (Caroni, 1997). Neuronal deletion of the CAP23 gene 
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dramatically reduces the level of innervation of the mouse whisker pad, 
following transection of the facial nerve (Werner et al., 2000).  
Cell death signals 
The cell surface molecules that mediate neuronal cell death following axotomy 
include Fas, TNFR 1 and 2 (Terrado et al., 2000b, Raivich et al., 2002, Ugolini 
et al., 2003), and even p75NTR (Ferri et al., 1998, Terrado et al., 2000a, 
Gschwendtner et al., 2003). Apart from TNF-2, these receptors exert their 
proapoptotic effects through FADD (Fas-Associated protein with Death 
Domain). Animals lacking FADD demonstrated enhanced neuronal protection to 
axotomy induced cell death signal due to Fas or TNFR (Ugolini et al., 2003). 
Tumor suppressor p53 and its downstream cascade also influence neuronal cell 
death (Kiryu-Seo et al., 2005). Mice that are deficient for p53 show a strongly 
elevated amount of neuronal survival after hypoglossal nerve transection in 
mice. This is associated with a reduced expression of Bcl-2 homology domain 3 
(BH3)-only protein Noxa, the actin-binding protein Coronin 1b and the GTPase 
Rab13, all of which regulate neurite outgrowth. Deficiency of p53 decreases 
neurite outgrowth and axonal regeneration (Di Giovanni et al., 2006). 
Furthermore, in neonates, axotomy induced cell death has been ameliorated by 
deletion of bax and by inhibiting caspase 3 or the whole family of caspases 
(Sun and Oppenheim, 2003, Chan et al., 2003). 
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Proteins studied in this thesis 
In this thesis three ALS associated proteins, namely TDP-43, FUS and alsin, 
and the regeneration associated transcription factor c-Jun were studied in the 
context of motor neuron degeneration and regeneration. 
TDP-43 
Autosomal dominant mutations in TARDBP, the gene coding for TAR DNA-
binding protein 43 (TDP-43), have been found in around 3% of familial and 
1.5% of sporadic cases of ALS (Lagier-Tourenne and Cleveland, 2009). In 
addition, TDP-43 is a major constituent of the intracellular protein inclusions 
found in ALS cases at post-mortem (Tan et al., 2007, Mackenzie et al., 2007). 
TDP-43 is a 414 amino acid protein, member of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family. It contains five functional domains: two RNA 
recognition motifs (RRM1 and RRM2), a nuclear export signal (NES), a nuclear 
localization signal (NLS) and a glycine-rich sequence at the C-terminal. Each of 
the RRM domains has two highly conserved hexameric ribonucleoprotein 2 
(RNP2), and octameric ribonucleoprotein (RNP1) regions, which are involved in 
DNA and RNA binding; the NES and NLS enable TDP-43 to shuttle between 
the nucleus and the cytoplasm; and glycine-rich C-terminal mediate 
protein::protein interactions (Lagier-Tourenne and Cleveland, 2009). Most of the 
ALS associated mutations identified so far are localized in the C-terminal region  
(Lagier-Tourenne and Cleveland, 2009). TDP-43 is ubiquitously expressed 
across different cell types and normally localised to nucleus of cells (Ou et al., 
1995). However, in the presence of cellular stress, TDP-43 translocates to the 
cytoplasm (Ayala et al., 2008b). This is particularly apparent in the neurons and 
glia of ALS cases, where TDP-43 is absent from the nucleus and instead found 
in cytoplasmic inclusions (Neumann et al., 2006, Dickson et al., 2007). In ALS, 
TDP-43 undergoes aberrant post-translational modifications; it is ubiquinated, 
hyperphosphorylated and cleaved producing C-terminal fragments (CTFs) of 
around 25 kDa (Neumann et al., 2006, Arai et al., 2006). 
TDP-43, as a member of the hnRNP family, has roles in multiple levels of RNA 
processing including transcription, splicing, transport and translation (Buratti 
and Baralle, 2008). Within the nucleus TDP-43 has been found to localise to 
sites of transcription and cotranscriptional splicing (Casafont et al., 2009).TDP-
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43 has been described to repress transcription by binding to: TAR DNA 
sequence of human immunodeficiency virus type-1 (HIV-1) (Ou et al., 1995), 
the mouse SP-10 gene promoter and GT repeats in the target gene sequence 
of cyclin-dependent kinase 6 (Cdk6) (Abhyankar et al., 2007, Lalmansingh et 
al., 2011, Ayala et al., 2008a). In addition, TDP-43 plays an important role in the 
regulation of mRNA splicing (Buratti et al., 2001). TDP-43 associates with a 
number of proteins involved in splicing through its glycine rich C-terminal 
domain (Buratti et al., 2005, Freibaum et al., 2010). Recent work using cross-
linking and immunoprecipitation coupled with high-throughput sequencing has 
identified TDP-43 binding sites in the RNA of 6,304 genes in the mouse brain 
(Polymenidou et al., 2011). In addition, massively parallel sequencing and 
splicing-sensitive junction arrays have revealed that levels of 601 mRNAs are 
changed and 965 altered splicing events occur after depletion of TDP-43 from 
mouse adult brain using antisense oligonucleotides (Polymenidou et al., 2011). 
The mRNAs affected by TDP-43 depletion included those from genes involved 
in neurodegeneration such as FUS, progranulin and the progranulin receptor 
sortilin (Polymenidou et al., 2011). Furthermore, TDP-43 is also involved in 
micro-RNA (miRNA) processing (Buratti et al., 2010). It is found in 
perichromatin fibres (Casafont et al., 2009) a nuclear region specifically 
associated with miRNA biogenesis (Lin et al., 2006) and within the 
microprocessor protein complexes involved in mRNA biogenesis and 
maturation (Gregory et al., 2004, Kawahara and Mieda-Sato, 2012). 
Functionally, experiments where TDP-43 expression is knocked down have 
demonstrated that the expression of a number of miRNAs is under the control of 
TDP-43 (Buratti et al., 2010, Kawahara and Mieda-Sato, 2012). Importantly, 
these miRNAs are involved in neuronal function, differentiation and synapse 
formation (Li et al., 2013b, Kawahara and Mieda-Sato, 2012). 
TDP-43 binds a number of RNA targets in the cytoplasm through their three-
prime untranslated region (3′UTR) (Tollervey et al., 2011). It interacts with 
proteins involved in RNA transport (Freibaum et al., 2010), is trafficked in 
neurons (Fallini et al., 2012, Wang et al., 2008a) and can be detected in 
presynaptic membrane of axon terminals and dendrite terminals (Narayanan et 
al., 2013). Functionally, mutations in TDP-43 impair mRNA transport in vivo and 
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in vitro (Alami et al., 2014). In addition, TDP-43 is a component of RNA stress 
granules, microscopically visible cytoplasmic bodies consisting of mRNA and 
RNP complexes, which stall translation under conditions of cellular stress 
(Freibaum et al., 2010, Anderson and Kedersha, 2008, Anderson and 
Kedersha, 2009). Functionally, TDP-43 binds to other protein within SGs and it 
contributes to the formation and maintenance of SGs (McDonald et al., 2011). 
It is unclear whether mutations in TDP-43 cause toxicity via a loss of normal 
function or a toxic gain of aberrant function (Lagier-Tourenne et al., 2010). 
Genetic deletion of both TDP-43 alleles is embryonically lethal in mice (Wu et 
al., 2010, Sephton et al., 2010, Kraemer et al., 2010). However, mice with a 
single TDP-43 allele knocked out have been reported to be developmentally 
indistinguishable from control littermates (Wu et al., 2010, Sephton et al., 2010, 
Kraemer et al., 2010). Nonetheless, aged heterozygous TDP-43 knockout mice 
develop motor dysfunction in the absence of detectable neurodegeneration 
(Kraemer et al., 2010). In line with an essential role in cellular viability, 
knockdown of TDP-43 induces cell death in cultured tumour cells and 
differentiated neurons (Ayala et al., 2008a, Iguchi et al., 2009). However, wild-
type TDP-43 overexpression also results in neurotoxicity in vitro associated with 
increased cytoplasmic localisation of TDP-43 protein (Barmada et al., 2010). 
Cytoplasmic accumulation and toxicity is worsened by disrupting the NLS motif 
and by ALS associated mutations in TDP-43 (Barmada et al., 2010), suggesting 
that cytoplasmic translocation of TDP-43 may mediate toxicity. However, TDP-
43 transiently moves from the nucleus to the cytoplasm as a normal 
physiological response to axonal injury (Moisse et al., 2009b, Sato et al., 2009). 
In ALS, TDP-43 is aberrantly cleaved by caspase-3, resulting in 25 kDa CTFs 
being present in the brain and spinal cord of cases with the disease (Zhang et 
al., 2009). These CTFs accumulate in protein inclusion found in ALS cases 
(Neumann et al., 2006, Arai et al., 2006). Whole TDP-43 and CTFs in ALS 
protein inclusion are hyperphosphorylated and polyubiquitinated (Neumann et 
al., 2006, Arai et al., 2006). Interestingly, expression of 25 kDa CTFs in cells 
results in cytotoxicity associated with the CTFs being accumulated 
cytoplasmically, forming insoluble aggregates and being subject to 
hyperphosphorylation and polyubiquitination (Igaz et al., 2009, Zhang et al., 
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2009). In vivo, mice overexpressing human wild-type or ALS associated mutant 
TDP-43 develop a spastic paralysis reminiscent of ALS (Wils et al., 2010, 
Wegorzewska et al., 2009). As in humans, these mice also demonstrate the 
presence of 25 kDa CTFs (Wils et al., 2010, Wegorzewska et al., 2009). 
However, CTFs in mice do not accumulate in the cytoplasm but in the nucleus 
where they form inclusions (Wils et al., 2010). 
FUS 
Mutations in the gene encoding fused in sarcoma/translocated in liposarcoma 
(FUS/TLS or FUS) account for ∼3% to 5% of familial ALS (Rademakers et al., 
2012). In addition, FUS protein is a component of the protein inclusion found in 
ALS cases at post mortem (Kwiatkowski et al., 2009, Vance et al., 2009, Deng 
et al., 2010). FUS is a member of the FET family of proteins, which includes 
TATA box-binding protein-associated factor 68 kDa (TAF15) and Ewing 
sarcoma (EWS), and is involved in all stages of gene expression from 
transcription to protein translation (Law et al., 2006, Tan and Manley, 2009).  
FUS contains seven functional domains: glutamine-glycine-serine-tyrosine-rich 
or prion-like domain (QGSY-rich), RNA recognition motif (RRM), glycine-rich 
(Gly-rich) two arginine-glycine-glycine-rich motifs (RGG1 and 2), zinc finger 
domain (ZFD), and a nuclear localisation signal (NLS). The QGSY and Gly-rich 
domains are involved in proteinːːprotein interactions, the RRM, ZFD and RGG 
domains are involved in RNA/DNA binding, and the NLS is involved in 
nucleocytoplasm shuttling (Andersson et al., 2008). Most of the ALS associated 
mutations identified are localized in the Gly-rich region and NLS (Lagier-
Tourenne et al., 2010). FUS is ubiquitously expressed in most tissues and is 
predominantly localized subcellularly to the nucleus (Andersson et al., 2008) but 
can engage in nucleocytoplasmic shuttling (Zinszner et al., 1997) particularly 
under cellular stress (Sama et al., 2013). Although some nuclear clearing of 
FUS immunoreactivity does occur in FUS inclusion-bearing motor neurons in 
ALS this is less obvious than the TDP-43 nuclear clearing seen in TDP-43 
inclusion-bearing motor neurons (Vance et al., 2009, Tateishi et al., 2010). 
FUS directly binds to single and double stranded DNA (Baechtold et al., 1999, 
Liu et al., 2013), RNAPII promoters (Tan et al., 2012) and telomeres (Dejardin 
and Kingston, 2009, Takahama et al., 2013). FUS is involved in DNA repair in 
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neurons (Mastrocola et al., 2013, Wang et al., 2013); it also regulates 
transcription by interacting with transcription factors (Sanchez-Ramos et al., 
2011, Du et al., 2011, Hallier et al., 1998, Kim et al., 2010, Sato et al., 2005, 
Uranishi et al., 2001), binding to gene promoters (Wang et al., 2008b), and by 
regulating RNA Polymerase II and III (Schwartz et al., 2012, Tan and Manley, 
2009). ChIP and promoter microarrays have demonstrated that there are over 
1000 genes with promoters to which FUS binds (Tan et al., 2012). These genes 
are involved in various cellular processes, including gene expression, cell cycle, 
and neuronal functions (Tan et al., 2012). However, FUS depletion caused a 
modest upregulation of only 275 genes and downregulation of 335 genes in 
mice (Lagier-Tourenne et al., 2012). 
Like TDP-43, FUS is also a hnRNP, and thus has roles in RNA processing 
(Calvio et al., 1995). FUS binds to GGUG motifs (Lerga et al., 2001) and 
structural  AU-rich stem loops in target RNAs (Hoell et al., 2011). Consistent 
with a role in splicing, FUS binds to introns within prespliced RNAs (Lagier-
Tourenne et al., 2012)s. In addition, FUS associates with components of the 
spliceosome (Kameoka et al., 2004, Meissner et al., 2003, Yang et al., 1998). 
Identified FUS targets include RNAs of genes involved in actin dynamics and 
the cytoskeleton (Fujii et al., 2005, Ishigaki et al., 2012, Lagier-Tourenne et al., 
2012, Orozco et al., 2012, Rogelj et al., 2012). In addition, recent genome-wide 
approaches have identified transcripts bound and potentially regulated by WT 
and mutant FUS (Ling et al., 2013). These have demonstrated that ALS-
associated mutant FUS preferentially binds to a number of cytoplasmic RNAs 
involved in the UPR and ER stress (Hoell et al., 2011, Colombrita et al., 2012). 
Functionally, depletion of FUS results in around 3,000 exons being altered, 
many of which are associated with genes that have neuronal functions or are 
linked to neurodegeneration (Ishigaki et al., 2012). Interestingly, depletion of 
FUS results in the inclusion of exon 10 in MAPT mRNA, a molecular species 
associated with FTD and Parkinsonism (Orozco et al., 2012). 
FUS is involved in the transport of RNA from the nucleus to cytoplasmic and 
throughout the cell (Zinszner et al., 1997, Fujii and Takumi, 2005). The NLS 
domain in FUS interacts with the nuclear import receptor Transportin (Dormann 
et al., 2010). The interaction with Transportin and nuclear export is controlled by 
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methylation of arginine residues in the NLS motif of FUS (Dormann et al., 
2012). In addition, FUS interacts with several motor proteins including Myo5A, 6 
and KIF5B (Yoshimura et al., 2006, Takarada et al., 2009, Kanai et al., 2004). In 
response to synaptic activation FUS translocates into dendritic spines (Fujii and 
Takumi, 2005) and in response to hypertonic stress it moves out of nucleus to 
the cytoplasm (Sama et al., 2013). Finally, like TDP-43, FUS is also involved in 
the SG formation (Bentmann et al., 2013). Interestingly, ALS-linked FUS mutant 
species, which locate to the cytoplasm, preferentially incorporate into SGs 
under conditions of cellular stress (Bentmann et al., 2012, Bosco et al., 2010, 
Dormann et al., 2010, Kino et al., 2011). 
To date, it is not clear whether ALS-linked mutations cause a loss of normal 
FUS function or induce the protein to gain an aberrant toxic function. Genetic 
deletion of FUS in inbred mice results in chromosomal instability and perinatal 
death (Hicks et al., 2000) but only male sterility and enhanced sensitivity to 
radiation in outbred mice (Kuroda et al., 2000). Neither of these mouse lines 
demonstrates motor dysfunction or evidence of neurodegeneration (Hicks et al., 
2000, Kuroda et al., 2000). Transgenic rats overexpressing ALS-associated 
mutant FUS develop progressive paralysis associated with motor axon 
degeneration and substantial loss of cortical and hippocampal neurons (Huang 
et al., 2011). Interestingly, overexpression of wild-type (WT) human FUS is 
enough to cause age dependent cognitive deficits associated with cortical and 
hippocampal neuronal loss in rats (Huang et al., 2011). Recently, mice 
overexpressing WT human FUS have been described to develop progressive 
limb weakness and subsequent fatal paralysis, associated with motor neuron 
loss and neuropathological changes reminiscent of ALS (Mitchell et al., 2013). 
Alsin 
ALS2, the gene encoding for alsin, is mutated in an autosomal recessive form of 
juvenile ALS (Yang et al., 2001, Hadano et al., 2001). Alsin is a 1657 amino 
acid protein with three guanine-nucleotide-exchange factor (GEF)-like domains 
(Yang et al., 2001). The amino-terminal regulator of chromatin condensation like 
domain (RLD) resembles the GEF for Ran GTPase. The middle Dbl homology 
(DH)- and pleckstrin homology (PH)-like domains are similar to the GEF of Rho 
GTPase. The carboxyl-terminal vacuolar protein sorting 9 (VPS9)-like domain is 
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homologous to the GEF of Rab GTPase (Yang et al., 2001). Most mutations in 
the ALS2 gene associated with ALS lead to premature stop codons resulting in 
carboxyl-terminal truncated proteins that are unstable compared with the wild-
type alsin (Yamanaka et al., 2003). However, missense mutations in the RLD 
domain of alsin have also been identified (Eymard-Pierre et al., 2006, Panzeri et 
al., 2006). 
Genetic deletion of ALS2 in mice produces only subtle neuropathological 
changes characterised by smaller motor neuron cell bodies and smaller calibre 
peripheral motor axons (Devon et al., 2006). In addition, there is evidence of 
axonal degeneration in the corticospinal tract and peripheral motor nerve of 
alsin deficient mice (Yamanaka et al., 2006, Gros-Louis et al., 2008). Clinically, 
ALS2 deficient mice have no motor deficits but are significantly less active than 
wild type controls (Devon et al., 2006, Yamanaka et al., 2006). However, there 
is also evidence that genetic deletion of ALS2 results in age-dependent deficits 
in motor coordination and motor learning, as well as a heightened anxiety 
responses in mice (Cai et al., 2005). In comparison to this mild clinical effects, 
knocking down ALS2 expression, with morpholinos in zebrafish, results in 
severe developmental abnormalities, swimming deficits and motor neuron 
degeneration (Gros-Louis et al., 2008). Interestingly, ALS2 mRNA splicing 
variants have been found in ALS2 knock out mice, and treatment with these 
rescue the abnormalities seen in alsin knock down zebrafish (Gros-Louis et al., 
2008). 
Alsin has been described as an activator of Rac1 and Rab5 small GTPases 
(Topp et al., 2004, Otomo et al., 2003, Kanekura et al., 2005). Rab5 is a protein 
involved in endocytic trafficking of neurotransmitters and neurotrophic receptors 
in motor neurons (Wucherpfennig et al., 2003, Brown et al., 2005, Topp et al., 
2004). ALS2 deficiency has been shown to reduce trkB and IGF-1 receptor 
trafficking in vitro and in vivo (Devon et al., 2006). Rac1 and its downstream 
effectors p21-activated kinase (PAK) family kinases are involved in neurite 
outgrowth by regulating actin dynamics within growth cones (Etienne-
Manneville and Hall, 2002, Nikolic, 2002, Li et al., 2000b). Alsin has been 
reported to colocalise and activate Rac1 and PAK1 within growth cones (Tudor 
et al., 2005), and promote neurite outgrowth (Tudor et al., 2005, Jacquier et al., 
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2006, Otomo et al., 2008). In addition, alsin has been reported to interact with 
glutamate receptor interacting protein 1 (GRIP1) both in vitro and in vivo, and to 
colocalise with GRIP1 in neurons. GRIP1 transports AMPA-type glutamate 
receptor subunit 2 (GluR2) to dendrites and anchors them in both postsynaptic 
membrane and intracellular compartments (Setou et al., 2002, Song and 
Huganir, 2002). Cells deficient of alsin, show disrupted subcellular distribution of 
GRIP1 and reduced GluR2 at the synaptic/cell surface (Lai et al., 2006). This 
reduction in GluR2-containing AMPA receptors renders alsin deficient neurons 
more susceptible to glutamate receptor mediated toxicity in vitro (Lai et al., 
2006).  
Furthermore, alsin has been reported to interact with mutant SOD1 protein, 
through its  RhoGEF domain and to suppress mutant SOD1 cytotoxicity in vitro 
(Kanekura et al., 2004). In a glia cell and motor neuron co-cultures, alsin inhibits 
mutant SOD1 mediated reactive oxygen species (ROS) production, Rac1 
activation, secretion of TNF alpha, and activation of NF kappa B in glial cells, 
leading to increased motor neuron survival in co-culture (Li et al., 2011). 
Interestingly however, overexpression of alsin by itself in glial cells in co-culture 
with motor neurons promotes the production of ROS by glia and consequent 
motor neuron death (Li et al., 2011). In vivo, deletion of alsin exacerbates 
disease in one of the mutant SOD1 mouse strains (Hadano et al., 2010). 
Interestingly, this effect was associated with enhanced accumulation of 
autophagosome-like vesicles and protein aggregates containing SOD1, 
ubiquitin and autophagy markers (Hadano et al., 2010). 
The AP-1 transcription factor c-Jun  
c-Jun is a member of the activator protein -1 (AP-1) family of transcription 
factors. AP-1 transcription factors are characterised by the presence of a basic 
leucine zipper (BLZ) domain in their structure and are divided into Jun, Fos and 
ATF subfamilies (Angel and Karin, 1991). These proteins only display regulatory 
activity on transcription when they dimerize through their BLZ motifs (Whitmarsh 
and Davis, 2000). Fuctional dimers can be formed through hetero- and homo-
dimerisation and the particular subunit composition of each dimer determines its 
regulatory properties (Whitmarsh and Davis, 2000). Jun transcription factors are 
able to homodimerise (Angel and Karin, 1991, Jochum et al., 2001) and 
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heterodimerise with members of the Fos and ATF family (Hai and Hartman, 
2001), as well as other transcription factors that contain a BLZ, such as CBP, 
MyoD, NFat or c-rel (Herdegen and Leah, 1998). 
The c-Jun protein has 6 functional domains: a Jun-N-terminal kinase (JNK) 
binding domain, transactivation domain, hinge region, basic region, and the 
leucine zipper domain (Raivich, 2008). The function of c-Jun is regulated by 
three chemical modifications: phosphorylation at the N-terminal transactivation 
domain (Smeal et al., 1991, Morton et al., 2003), dephosphorylation at the hinge 
region (Morton et al., 2003), and acetylation at the basic region (Vries et al., 
2001). JNKs mediate the phosphorylation of the transactivation domain, this 
process has been implicated in stress mediated neuronal cell death (Yang et 
al., 1997, Behrens et al., 1999). The F-box&WD domain repeated 7 (FBW7) 
ubiquitin ligase mediates the degradation of c-Jun by interacting with its hinge 
region when the latter is phosphorylated (Wei et al., 2005). Interestingly, 
phosphorylation of the hinge region is in part mediated by glycogen synthase 
kinase-3 (GSK3), and therefore c-Jun degradation depends partly on this kinase 
(Morton et al., 2003). Finally, the acetylase p300 mediates the acetylation of the 
basic region in c-Jun and promotes its transcriptional activity (Vries et al., 2001, 
Wang et al., 2006). These modifications are themselves controlled by different 
upstream signalling enzymes such as MKK4 or MKK7, PI3-Kinase and ERK1&2 
(Raivich, 2008). 
c-Jun expression is localised in the nucleus of cells and its upregulation is 
associated with neuronal trauma (Herdegen et al., 1991, Jenkins and Hunt, 
1991, Raivich et al., 2004), ischaemia (Kindy et al., 1991, Wessel et al., 1991), 
hyperexcitation (Morgan and Curran, 1988, Gall et al., 1990, Gass et al., 1993),  
and apoptotic cell death (Sun et al., 2005). In addition, c-Jun is also found 
upregulated or activated in neurodegerative disorders such as Alzheimer’s 
disease (Pearson et al., 2006), Parkinson’s disease (Oo et al., 1999, Saporito et 
al., 2000) and ALS (Vlug et al., 2005, Jaarsma et al., 1996, Migheli et al., 1997). 
Functionally, deletion c-Jun or expression of a dominant negative form of c-Jun 
prevents neuronal cell death following neurotrophic factor withdrawal in vitro 
(Ham et al., 1995, Palmada et al., 2002). This neuroprotective effect is 
associated with a reduction in the expression of the pro-apoptotic protein Bim 
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(Whitfield et al., 2001). Importantly, JNK is involved in this type of cell death, as 
genetic inhibition of the ability of JNK to bind and activate c-Jun prevents 
neuronal cell death following neurotrophic factor withdrawal (Eilers et al., 2001, 
Harding et al., 2001). Interestingly, general inhibition of JNK function results in 
neuroprotective effects of a greater magnitude in this model than those 
observed following specific inhibition of its c-Jun activator function (Borasio et 
al., 1998a, Maroney et al., 1999, Besirli et al., 2005). In vivo, JNK mediated 
activation of c-Jun plays a role in excitoxic neuronal cell death, as deletion of 
JNK3 or the genetic modification of c-Jun (junAA), which renders it unable to be 
activated by JNKs, results in reduced neuronal cell death following kainate 
stimuli in mice (Behrens et al., 1999, Yang et al., 1997). However, the effects of 
JNK and c-Jun are not always linked. While inhibition of JNK reduces tissue 
loss secondary to medial cerebral artery occlusion (MCAO) in mice, genetic 
deletion of c-Jun or junAA modification does not have such an effect (Vogel et 
al., 2007, Brecht et al., 2005). Similarly, while deletion of neuronal c-Jun 
abrogates neuronal cell death following axotomy (Raivich et al., 2004, Ruff et 
al., 2012), deletion of JNK or junAA modification do not have such an effect 
(Ruff et al., 2012). Thus, there appears to be three different sets of signalling 
effects via the JNK/c-Jun pathway: 1) JNK-independent effects of c-Jun 2) c-
Jun-independent effects of JNKs; 3) effects of JNK activated c-Jun(Raivich, 
2008). 
The JNK/c-Jun pathway is also involved in the response of glial and 
inflammatory cells to neuronal injury. Upregulation of c-Jun expression is 
observed mainly in astrocytes in conditions, such as Alzheimer’s disease 
(Anderson et al., 1994) and ALS (Migheli et al., 1997), as well as in models of 
cerebral ischemia (Kato et al., 1995), neuropathic pain (Zhuang et al., 2006), 
and toxin-induced degeneration of cholinergic (Rossner et al., 1997) and 
dopaminergic (Nakagawa and Schwartz, 2004) neurons. Functionally, JNKs 
have been shown to regulate the synthesis and release of neurotrophins, 
cytokines, ROS and matrix degrading enzymes by astrocytes, microglia and 
oligodendroglia, following a variety of stressful stimuli in vitro (Hidding et al., 
2002, Waetzig et al., 2005, Kim et al., 2008, Tanaka et al., 2008). Studies report 
that JNK mediates some of these effects in glia through the activation of glial c-
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Jun (Hidding et al., 2002, Zhuang et al., 2006, Kim et al., 2008). The role of c-
Jun in astrocytes, microglia or oligodendrocytes has not been characterised in 
vivo. However, neuronal deletion of c-Jun results in reduced perineuronal 
inflammation following axotomy in mice, with reduced microglia and astrocyte 
activation, as well as diminished T-cell infiltration around axotomised neurons 
(Ruff et al., 2012, Raivich et al., 2004). Similarly, genetic deletion of c-Jun from 
Schwann cells is associated with a failure in demyelination and macrophage 
recruitment in injured nerves following peripheral nerve transection in mice 
(Arthur-Farraj et al., 2012). 
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Animal models used in this thesis 
In this thesis three mouse models were used to analyse the involvement of 
TDP-43, FUS, alsin and c-Jun in motor neuron degeneration or regeneration. 
Animal models of Amyotrophic lateral sclerosis 
SOD1G93A mice 
The most commonly used model of ALS disease is the transgenic SOD1G93A 
mouse (Fig. 3) (Turner and Talbot, 2008). This mouse model was generated 
and first described by Gurney et al. (1994). The transgene design was based on 
the G93A human SOD1 mutation associated with familial ALS, where a single 
amino acid is substituted from glycine to alanine at codon 93 in the SOD1 gene 
(Rosen et al., 1993). The transgene expression in these mutant mice is under 
the control of the ubiquitous expressor endogenous human SOD1 promoter 
(Gurney et al., 1994). The cloned transgenes were injected to B6/SJL fertilised 
eggs and founder mice were crossed with B6 mice for subsequent analysis 
(Gurney et al., 1994). Transgenesis resulted in a high transgene-copy line 
named B6SJL-TgN(SOD1-G93A) 1Gur (carries 18-25 transgene copies). This 
line is the most widely used model of ALS (Turner and Talbot, 2008) and is 
commonly maintained by crossing SOD1G93A heterozygous transgenics with 
B6/SJL wild type hybrids (Turner and Talbot, 2008). 
Phenotypically, as SOD1G93A mice age they develop features typical of ALS 
neurodegeneration, including motor functional deficits and pathological 
changes. Analysis of these mice can be divided into the presymptomatic phase, 
ranging from birth to around 75 days of age; and the symptomatic phase, which 
begins from around 75 days and lasts until death. Analysis of locomotion 
demonstrated that at three to four months of age mice show signs of hind limb 
weakness, tremor, hyper-reflexia and weight loss (Turner and Talbot, 2008). 
Ultimately these mice die prematurely, commonly at around 4 months (Gurney 
et al., 1994, Turner and Talbot, 2008). 
Pathological features can be seen at the level of the muscle, nerve and 
neuronal soma in these mice. Neuromuscular degeneration begins at 25 (Gould 
et al., 2006) to 47 days of age (Fischer et al., 2004, Pun et al., 2006). 
Retrograde axonal degeneration is evident at 80 days and coincides with motor 
impairment. At 100 days a strong reduction in lower motor neuron number is 
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observed (Fischer et al., 2004). Ultrastructurally, motor neurons demonstrate 
mitochondrial vacuolisation (Dalcanto and Gurney, 1995), Golgi apparatus 
fragmentation (Mourelatos et al., 1996), neurofilament-positive inclusions (Tu et 
al., 1996) and cytoplasmic SOD1-immunoreactive aggregates (Johnston et al., 
2000). A non-neuronal reaction characterised by microglial and astrocyte 
activation is also evident around the neuronal soma in the spinal cord at around 
the onset of disease (Hall et al., 1998b). Similar pathological features can be 
seen in cranial nuclei including that of the trigeminal, facial and hypoglossal 
nerve (Niessen et al., 2006). 
 
 
 
Figure 3. The phenotype of SOD1G93A mutant mice. Mice carrying the mutant 
form of the human SOD1G93A gene develop functional and pathological features 
of ALS. Among these features, SODG93A mice (G93A) appear to be thin along 
the flanks compareed to wild type mice (WT), which suggests muscle wasting. 
Photograph obtained from Turner and Talbot (2008).  
The onset and progression of disease in SOD1G93A mice can be clinically 
established and monitored through different measures, including: weight, 
neurological scores, rotarod performance, grip strength wire hanging, gait 
analysis and wheel distance (Scott et al., 2008, Ludolph et al., 2010). To 
prevent unnecessary suffering, length of survival is measured using number of 
humane artificial clinical end points. These include: loss of self-righting ability 
within 10 to 30 seconds of being placed on the back, weight loss of 30% for 72 
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hours and onset of bilateral hind limb paralysis (Scott et al., 2008, Solomon et 
al., 2011). 
The clinical and pathological progression of disease in SOD1G93A mice depends 
on the number of transgene copies expressed in the transgenic mice (Gurney et 
al., 1994, Gurney, 1997, DalCanto and Gurney, 1997). Although the number of 
transgene copies carried in the high copy SOD1G93A line is stable (18 to 25 
copies), sporadic drops in copy number have been described due to intra locus 
recombination events during meiosis (Gurney, 1997). Such an event resulted in 
a SOD1G93A transgenic mouse line with a reduced number of copies from the 
original high copy transgenic mice (Gurney, 1997). This mouse line carries only 
8 SOD1G93A transgene copies and has been designated B6SJL-TgN(SOD1-
G93A)dl1Gur. The low transgene copy number SOD1G93A (dl1Gur) mouse line 
demonstrates delayed onset of disease and an increase in lifespan compared to 
high copy number (1Gur) carriers (Gurney, 1997, Alexander et al., 2004, 
DalCanto and Gurney, 1997, Chiu et al., 1995). 
Although widely used, the major weakness associated with the SOD1G93A 
mouse model of ALS has been its poor predictive value in terms of potential 
therapies (Scott et al., 2008). However, the differences in efficacy of treatments 
form mice to humans may be due to the inherent differences in experimental 
design and control of confounding variables (Scott et al., 2008). Nonetheless, it 
remains to be demonstrated whether the findings in these mice are applicable 
to other animal models or humans and forms of familial or sporadic ALS 
(Robberecht and Philips, 2013). 
TDP-43 mice 
Transgenic mice over-expressing human TDP-43 transgene containing the ALS 
associated A315T mutation were used in this project (Wegorzewska et al., 
2009). These mice were generated by pronuclear microinjection of a transgene 
construct comprising full length human TDP-43 A315T cDNA under the control 
of the mouse prion protein promoter (Wegorzewska et al., 2009). The 
phenotype in these mice consists of abnormalities associated with cortical and 
lower motor neuron degeneration (Wegorzewska et al., 2009). At 3-4 months of 
age mice lose weight, and develop gait abnormalities (Wegorzewska et al., 
2009). On average mice survive around 154 days but some are found to die 
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spontaneously (Wegorzewska et al., 2009). This spontaneous death is due to 
bowel obstruction secondary reduced gut motility, which results from  
degeneration of the myenteric nervous system (Herdewyn et al., 2013). 
Assessments using electromyography demonstrates changes associated with 
the loss of muscle fibre innervation. This coincides with pathological changes in 
the muscle that are characteristic of muscle deinnervation, such as the 
scattered and grouped atrophic muscle fibres (Wegorzewska et al., 2009). 
Degeneration of descending motor axons of the spinal cord lateral columns is 
also evident (Wegorzewska et al., 2009). Furthermore, degenerating motor 
neurons in the ventral horn of the spinal cord show increased ubiquitin staining. 
In addition to the changes associated with ALS, pathological abnormalities that 
are similar to that found in frontotemporal lobar degeneration are also evident in 
these mice (Wegorzewska et al., 2009). Increased cytoplasminc ubiquitin 
staining in cortical neurons, which appears either diffuse, punctate with multiple 
small aggregates, or in the form of large organized cytoplasmic aggregates is 
observed. In addition, astrogilosis and microgliosis are observed around cortical 
neurons (Wegorzewska et al., 2009). 
Neural specific c-jun knock-out mouse 
Mice carrying both alleles of the c-jun gene flanked by lox-P sites were originally 
created and described by Behrens et al. (2002) to study the role of c-Jun in the 
liver. Mice with floxed c-jun alleles are fertile and do not show any phenotypical 
or histological abnormalities (Behrens et al., 2002).  
Transgenic mice expressing Cre recombinase under the control of the 
neuroepithelial specific Nestin promoter and enhancer [intron II; (Zimmerman et 
al., 1994)] were generated and first described by Tronche et al. (1999). This 
Nestin Cre recombinase transgene allows the specific removal of floxed genes 
from neuroepithelial cells including those that will develop into motor neurons ; 
(Zimmerman et al., 1994). Nestin Cre mice are fertile and do not show any 
phenotypical or histological abnormalities (Tronche et al., 1999).  
Raivich et al. (2004) created a mouse line that did not express c-jun in cells 
from the nervous system. To do this, male mice carrying two floxed c-jun alleles 
(c-jun f/f) were crossed with heterozygous female Nestin Cre mice (NesCre).  
This produced Nestin Cre transgenic mice carrying one floxed c-jun allele and a 
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wild type one (NesCre c-jun f/+). Female NesCre c-jun f/+ mice were crossed 
again with male c-jun f/f mice to produce Nestin Cre transgenic mice carrying 
two floxed c-jun alleles [NesCre c-jun f/f or c-jun ΔN(Raivich et al., 2004)]. 
These mice are born with Mendelian frequency, are viable and fertile, and have 
normal motor, learning and fear behaviour (Raivich et al., 2004). The c-jun ΔN 
mice have overall normal brain architecture and histology apart from a 19% 
increase in number of motor neurons in the facial nucleus compared to their c-
jun competent littermates (c-jun f/f; (Raivich et al., 2004). In addition, as 
described earlier, neural c-jun deficient mice show a major defect in peripheral 
nerve regeneration and central axonal sprouting response after peripheral nerve 
injury (Raivich et al., 2004, Makwana et al., 2010). 
The facial nerve injury model 
The rodent facial nerve axotomy model is widely used to study the regeneration 
and degeneration of the peripheral nervous system in vivo (Moran and Graeber, 
2004). Motor neurons of the facial motor nucleus send axons around the 
abducens nucleus that then exit through the bony part of the skull (Fig.4A) to 
innervate the muscles that control the movements of the whiskers, lips and eyes 
(Fig.4B) (Semba and Egger, 1986). There are a number of benefits associated 
with this model. Firstly, the surgical procedure of injuring the nerve is simple 
(Figure 4B). Different injury severities can be tested, from the mild form of 
injury, nerve crush lesion, to a more severe one such as nerve cut. Secondly, 
injury to the facial nerve at the level of the stylomastoid foramen, keeps the 
CNS intact, causes no disruption of the blood-brain barrier, and reduces the 
chance of the nerve nucleus becoming contaminated by blood-borne elements 
(Streit and Kreutzberg, 1988). Thirdly, functional analysis can be easily carried 
out. Whisker function on the intact/uninjured side can be used to compare the 
extent of functional recovery on the injured side. Fourthly, an internal control 
nucleus located on the other side of the brainstem abolishes any effects that 
may be associated with inter-animal variations. For the above reasons the 
model is an effective tool when the quantification of the motor neuron and non-
neuronal responses to axonal injury is required.  
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Figure 4. The facial nerve injury model. A) Diagram shows the trajectory of the 
facial nerve from the facial motor nucleus (hatched area), to the abducens 
nucleus (balck cicle: arrow), and finally exiting the skull (large arrow). Edited 
from Moran and Graeber, (2004).  B) Sketch showing the primary branching of 
the facial nerve distal to the stylomastoid foramen innervating the eye lips and 
whisker pad. At the stylomastoid foramen a nerve injury can be performed. 
Edited from  Angelov et al., (2011). 
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Aims 
The expression of c-Jun is found upregulated in astrocytes in ALS cases and 
within motor neurons in mutant SOD1 mice (Migheli et al., 1997, Jaarsma et al., 
1996). However, it is unclear whether c-Jun plays a functional role in the 
disease. The previously described central role of c-Jun in motor neuron death 
and perineuronal neuroinflammation following peripheral nerve injury strongly 
suggests a possible functional role in ALS motor neuron degeneration (Raivich 
et al., 2004). This thesis aims to determine the functional role of c-Jun in the 
neurodegenerative changes observed in the SOD1G93A mouse model of ALS.  
In addition, as there is previous evidence of a regenerative effort mounted 
within the ALS disease process (Tsujihata et al., 1984, Atsumi, 1981, Hegedus 
et al., 2008, Hegedus et al., 2007), and c-Jun plays a central role in axonal 
regeneration (Raivich et al., 2004), this thesis aims to characterise further the 
ALS associated regenerative response in degenerating motor neuron pools of 
SOD1 G93A mice. 
Furthermore, because the morphological and molecular changes observed in 
ALS and following peripheral nerve injury resemble each other (Raivich et al., 
2004, Fischer et al., 2004), and a number of ALS associated protein and genes 
have function relevant to axonal regeneration (Narayanan et al., 2013, Tudor et 
al., 2005, Wang et al., 2008a), another aim of this thesis is to determine 
whether the pattern of expression of ALS associated proteins TDP-43, FUS and 
alsin changes within axotomised motor neurons after facial nerve injury. 
Finally, since peripheral nerve injury results in changes in the pattern of 
expression of TDP-43 (Moisse et al., 2009a) and ALS associated mutations 
affect its normal function (Alami et al., 2014), this thesis aims to determine 
whether the overexpression of ALS mutated A315T TDP-43 in mice can affect 
the normal physiological process of axonal regeneration following facial nerve 
transection. 
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Chapter 2: Materials and Methods 
Animals 
All experimental procedures were carried out in accordance with the UK 
Animals (Scientific Procedures) Act, 1986, and were approved by the UK Home 
Office and the University College London local ethics committee. Animals were 
housed with a 12 hour light-dark cycle, at 21-23ºC, an average humidity of 60%, 
and had access to food pellets and water at libitum.  
Wild Type Mice 
This study used C57/BL6 mice (Charles Rivers) at 4-15 weeks of age.  
Genetically Modified Mice 
The transgenic animals used for experimentation included, junf/f & junΔN (Axel 
Brehens, Cancer Research, UK), SOD1G93A (Axel Brehens, Cancer Research, 
UK) and A315T mutant TDP-43 (Christopher Shaw, King’s College London).  
The role of c-Jun in SOD1 G93A mediated motor neuron disease 
Genetically modified mice were used to investigate the role of the transcription 
factor c-Jun in SOD1G93A mediated motor neuron disease.  Three mutant mouse 
lines were used to generate a mouse model of SOD1G93A ALS where the c-jun 
gene may be deleted from cells in the nervous system. The three genetically 
modified mouse lines used in this study were: high copy SOD1G93A transgenic 
mouse model of ALS (Gurney et al., 1994),  mice carrying floxed c-jun alleles 
(Behrens et al., 2002) and mice expressing cre-recombinase under the control 
of neuroepithelial specific nestin promoter and enhancer (Tronche et al., 1999). 
Interbreeding of these three mouse lines allowed for the identification changes 
in SOD1G93A mediated motor neuron disease that are dependent on neural c-
jun. 
SOD1G93A mouse model of ALS 
High copy SOD1G93A transgenic mice in a B6JLF background 
[B6SJLTgN(SOD1-G93A)1Gur] were obtained from Jackson Laboratory and 
maintained by breeding hemizygous male carriers to B6/SJLF hybrids in CRUK. 
SOD1G93A mice were originally generated and described by Gurney et al. (1994) 
and are the first and most commonly used model of ALS.  These mice are 
hemizygous carriers of 18 to 25 copies of a human mutant SOD1 transgene 
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containing a single amino acid substitution of glycine to alanine at codon 93 
(Gurney et al., 1994). This transgene was designed to replicate the SOD1G93A 
mutation found in human cases of ALS and its expression in the SOD1G93A mice 
is driven by the human SOD1 promoter (Gurney et al., 1994). 
SOD1G93A mice are fertile, develop progressive limb paralysis and die 
prematurely in adulthood. In addition, they demonstrate progressive 
pathological changes including the degeneration and death of motor neurons 
and activation glial and inflammatory cells in the nervous system (Gurney et al., 
1994). 
The floxed c-jun mouse 
Mice carrying both alleles of the c-jun gene flanked by lox-P sites were originally 
described by Behrens et al. (2002).  These mice are fertile and do not show any 
phenotypical or histological abnormalities (Behrens et al., 2002). They were 
originally in a mixed 129/B6/FBV background (Behrens et al., 2002) but were 
subsequently bread with B6 mice for at least 5 generations to establish the 
colony in CRUK. 
Nestin Cre-Recombinase mouse 
Transgenic mice expressing Cre recombinase under the control of the 
neuroepithelial specific Nestin promoter and enhancer [intron II; (Zimmerman et 
al., 1994)] were generated and first described by Tronche et al. (1999). This 
Nestin Cre recombinase transgene allows the specific removal of floxed genes 
from neuroepithelial cells including those that will develop into motor neurons. 
Nestin Cre mice are fertile and do not show any phenotypical or histological 
abnormalities (Tronche et al., 1999). This transgenic mouse line was 
maintained by breeding hemizygous female carriers to B6 mice in CRUK. 
Nestin Cre mediated c-jun knock out 
To create a neural specific c-jun knock out animal, male mice carrying two 
floxed c-jun alleles (c-jun f/f) were crossed with heterozygous female Nestin Cre 
mice (NesCre).  This produced Nestin Cre transgenic mice carrying one floxed 
c-jun allele and a wild type one (NesCre c-jun f/+). Female NesCre c-jun f/+ 
mice were crossed again with male c-jun f/f mice to produce Nestin Cre 
transgenic mice carrying two floxed c-jun alleles (NesCre c-jun f/f or c-jun ΔN). 
These mice were born with Mendelian frequency, were viable and fertile, and 
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had normal motor, learning and fear behaviour (Raivich et al., 2004). The c-jun 
ΔN mice had overall normal brain architecture and histology apart from a 19% 
increase in number of motor neurons in the facial nucleus compared to their c-
jun competent littermates (c-jun f/f; (Raivich et al., 2004). 
SOD1G93A c-jun knock out 
To determine the role of c-jun in SOD1G93A mediated disease a two-step 
breeding strategy was used. First, mice carrying two floxed c-jun alleles (c-jun 
f/f) were crossed with heterozygous transgenic SOD1G93A mice. This produced 
SOD1G93A transgenic mice carrying one floxed c-jun allele and a wild type one 
(SOD1G93A c-jun f/+). These SOD1G93A c-jun f/+ mice were then crossed again 
with c-jun f/f mice to produce SOD1G93A transgenic mice carrying two floxed c-
jun alleles (SOD1G93A c-jun f/f). Second, SOD1G93A c-jun f/f male mice were 
crossed with female NesCre c-jun f/f (c-jun ΔN) mice. This breeding strategy 
resulted in littermates that were all homozygous for floxed c-jun and in a 
Mendelian frequency expressed the SOD1G93A and Nestin Cre transgenes. 
Thus, the effects of neural specific deletion of c-jun on SOD1G93A mediated 
disease and SOD1G93A independent effects of c-jun deletion could be 
determined between littermates. 
Peripheral nerve regeneration in TDP-43 A315T model of ALS 
To study the effect of overexpression of ALS associated mutant TDP-43 protein 
on peripheral nerve regeneration in mice, the TDP-43 A315T transgenic mouse 
model of ALS was employed (Wegorzewska et al., 2009). 
TDP-43 A315T transgenic mice were obtained from Jackson Laboratory in a 
B6/SJLF background but hemizygous male carries were bread with B6 mice for 
at least 5 generations to establish a colony at Kings College London. 
TDP-43 mutant mice were originally generated and described by Wegorzewska 
et al. (2009) and are the first TDP-43 mouse model of ALS. These mice are 
hemizygous carriers of multiple copies of a human mutant TDP-43 transgene 
containing a single amino acid substitution of alanine to threonine at codon 315 
(Wegorzewska et al., 2009). This transgene was designed to replicate the TDP-
43 mutation found in human cases of ALS and its expression in TDP-43 A315T 
mice is driven by the mouse prion protein promoter (Wegorzewska et al., 2009).  
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Genotyping  
Polymerase chain reaction (PCR) was carried out, using chloroform extracted 
DNA from mice tails, in order to recognize the genotypic identity of the mice 
used in this study. 
SOD1G93A jun f/f and SOD1G93A jun ΔN 
The primers used for SOD1 G93A PCR were: CATCAGCCCTAATCCATCTGA 
forward and CGCGACTAACAATCAAAGTGA reverse. Those used for floxed c-
jun were: CTCATACCAGTTCGCACAGGCGGC forward and 
CCGCTAGCACTCACG TTGGTAGGC reverse. For the nestin CRE the primers 
were: CGGTCGATGCAACGAGTGATGAGG forward and 
CCAGAGACGGAAATCCATCGCTCG reverse. All PCRs were carried out under 
the same following conditions: 3 minutes at 94ºC then 40secs at 94ºC, 40secs 
at 57ºC and 60 secs at 72ºC for 35 cycles ending with 10minutes at 72ºC. A 1% 
ethidium bromide agarose gel, ran in a 10X TAE buffer, was used to resolve 
and visualise the products of the PCRs. 
A315T mutant TDP-43 
Genotyping for these mice was carried out in Kings College London, by the 
Shaw group. Genomic DNA was extracted and PCR amplified. PCR primers 
used are listed as follows: human TDP-43, 5′-GGATGAGCTGCGGGAGTTCT-
3′ and 5′-TGCCCATCATACCCCAACTG-3′ (400 bp); Internal positive control, 5′-
CAAATGTTGCTTGTCTGGTG-3′ and 5′-GTCAGTCGAGTGCACAGTTT-3′ (200 
bp). 
Surgical procedures  
Animals were anaesthetised with a mixture of 5% Isoflurane and oxygen 
(Merial, UK) and then maintained with 3% Isoflurane and oxygen. Before 
surgery animals were checked for the depth of anaesthesia by using the paw 
withdrawal reflex. 
Facial Nerve Axotomy 
Mice received a 1 mm cut posterior to the right ear, at the level of the mastoid 
process. Muscles were bluntly dissected to reveal the facial nerve. For the facial 
nerve axotomy experiments the main branch as well as the retro-auricular branch 
were transected at the stylomastoid foramen, using microscissors (Fig. 1). For 
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facial nerve crush experiments, only the main branch of the facial nerve was 
crushed. Blunt forceps were used to grip the nerve approximately 1mm away 
from the stylomastoid foramen. The nerve was crushed for 10 seconds before 
releasing it. For both nerve cut and crush, the skin was closed using wound 
clips (Autoclip, USA). The animal was allowed to recover in a heat chamber for 
(32°C) ten minutes. Animals that had successful facial nerve transections or 
crush were identified by the lack of whisker function ipsilateral to the injury.  
If retrograde labelling was required, to identify successfully reinnervating 
neurons, animals under anaesthesia had a piece of Gelfoam, (Johnson and 
Johnson, Skipton, UK) soaked with 30μl of Fluorogold (Fluorochrome, Denver, 
USA) diluted from stock to 2% with distilled water, inserted under the left and 
right whisker pads two days prior to sacrifice. Animals were sacrificed at 30 
days (Fig. 1). 
 
Figure 1. Simplified diagram demonstrating the right facial nerve in mice as it 
exits from the stylomastoid foramen. The facial nerve is drawn in grey. The 
main branch as well as the retro-auricular branch are transected in facial nerve 
axotomy experiments (red dashed lines), while in nerve crush experiments only 
the main branch is manipulated. For retrograde labelling of reinnervated 
neurons, fluorogold pads can be inserted into the whisker pads (yellow 
rectangle). Edited from Wang et al, (2012a).  
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Perfusion Fixation and Tissue Collection 
Mice were terminally anaesthetised with an overdose of 2,2,2-tri-bromoethano 
(Avertin) (Sigma-Aldrich, Germany). This was carried out by means of an 
intraperitoneal injection of Avertin at 16.6 μl/g of body weight. The paw 
withdrawal reflex was used as an indication of deep anaesthesia. To fix the 
central nervous system of animals studied, transcardial perfusion/fixation was 
carried out. A 16-gauge needle attached to a perfusion pump (Gilson, USA) was 
inserted into an aperture in the apex of the heart and the vena cava was 
transected to allow exanguination. To wash out residual blood, 10mM 
phosphate buffer in 0.9% saline (PBS; pH=7.4) was perfused at a rate of 
0.02L/min for 5 minutes; this was followed by 10 minutes in 4% 
paraformaldehyde (PFA) in 10mM phosphate buffered saline solution (PBS; 
pH=7.4) at the same flow rate. 
Facial nerve injury experiments 
For histology and immunohistochemistry, wild type or TDP-43 mice that 
underwent a unilateral facial nerve transection were killed between 0 to 42 
days, and those that received a facial nerve crush were killed between 7 to 14 
days. Here, the hindbrains were dissected using a scalpel blade.   
SODG93A project 
SODG93A mice were killed at two different time points in the progression of 
disease: day 70 (before the onset clinical symptoms) or day 104-116 (End 
stage, which due to ethical reasons, is taken as the onset of complete bilateral 
hind-limb paralysis) (Figure 2). Here, hindbrains, spinal cords, ventral roots and 
gastrocnemius muscle were dissected. 
 
 
Figure 2. Time line of SODG93A disease progression, indicating in blue the 
time points at which animals were sacrificed. 
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Tissue Post-fixation and Cryoprotection 
Hindbrain, spinal cord, and muscle tissue were separately immersed in 2% 
PFA/PBS (pH=7.4). Tissue was placed to rotate at 8 rpm for 1 hour. For 
cryoprotection, tissue was immersed in 30% sucrose in 0.1 M PBS buffer (pH=7.4); 
tissue was left to rotate at 8 rpm for 48 hours. Unless otherwise stated, tissue was 
embedded in OCT and frozen with dry ice. All tissue samples were stored at -80˚C 
prior to use.  
Tissue sectioning  
Unless otherwise stated, tissue was sectioned using a cryostat (Leica, Germany) 
with the chamber set at -20˚C. Tissue was thaw-mounted on warm, 0.5% gelatine-
coated, slides (MECK). Sections were then refrozen on dry ice and stored at –80˚C 
until further processing. 
Hypoglossal nucleus 
Coronal sections through the hindbrain were cut caudal to rostral, with a 
thickness of 25um. Sections were collected on the appearance of the 
perinuclear white matter and collection stopped when the 4th ventricle became 
enlarged. Fifty consecutive sections were collected. 
Facial motor nucleus 
Coronal sections through the hindbrain were cut caudal to rostral, with a 
thickness of 20um. Prior to collection, the nucleus ambiguus was used to 
visually make the left and right side of the hindbrain symmetrical. Fifty 
consecutive sections were collected, from the start of the facial motor nuclei 
until the nuclei disappeared.   
Spinal Cord 
For immunohistochemistry studies, spinal cords were dissected at the cervical 
region. Fifty consecutive transverse sections through the cervical enlargement 
of the spinal cord were collected at a 40um thickness. For Hematoxylin and 
Eosin (H&E) stain, the spinal cord was dissected from the start to the end of the 
lumbar 5 segment. The L5 region of the spinal cord was then embedded in 
paraffin wax. Sections throughout the L5 region were cut using a microtome at 
5um thickness.  
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Ventral roots 
L5 ventral roots were placed in Barnett Fix (2.5% gluteraldehyde/PBS) for 6 
days, and subsequently underwent osmication and dehydration so that they can 
be embedded in Araldite (Fluka, Basel/Sitzerland). Using a microtome, 1μm 
transverse sections were taken from the ventral root and placed on SuperFrost 
Plus slides (VWR International). 
Gastrocnemius Muscle 
Four 50um longitudinal sections per gastrocnemius were obtained at the 
cryostat. Using a 24-well plate, two sections of muscle were placed per well 
containing distilled water. Sections were kept at 4 degrees for further analysis.  
Histology 
Immunohistochemistry (IHC) 
Tissue sections were rehydrated in distilled water and spread under a 
dissecting microscope. After being left to dry for 5 minutes, the sections were 
fixed in a solution of 4% formaldehyde in 100mM PB (pH=7.4) for 5 minutes. 
Sections were transferred into a cuvette containing 100mM PB (pH=7.4) for 5 
minutes. The sections were then defatted by placing them in different 
concentrations of acetone solutions (50% for 2 minutes; 100% for 2 minutes; 
50% for 2 minutes), before being washed twice for 2 minutes in PB solution and 
once for 2 minutes in 0.1% bovine serum albumin (PB/ BSA: Sigma,-Aldrich).  
A block of 5% goat serum (Vector: containing goat IgG) in 100mM PB was 
pipetted (90µl) onto the sections at room temperature for a minimum of 30 
minutes. Subsequently, the sections were washed in PB/BSA (0.1%) PB 
(100mM), PB (100mM) and PB/BSA (0.1%) before being incubated overnight at 
4°C with 90µL of the optimally diluted primary monoclonal or polyclonal 
antibody against the specific antigen required. Table 1 shows the antibodies 
and concentrations used. 
The sections were then washed in 3 Falcon tubes each containing 0.1% 
PB/BSA; 100mM PB or 100mM PB, before being incubated with a 1:100 diluted 
biotinylated secondary antibody at room temperature for 1 hour. Depending 
upon the source of the primary antibody, the corresponding secondary 
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antibodies used included, goat anti-rabbit, Goat anti-Hamster or Goat anti-Rat 
(Table 1).  
The sections were once again washed in 3 Falcon tubes and incubated for 1 
hour with 90 µL of the ABC reagent (avidin- biotinylated horseradish peroxidase 
complex;Vector) at a dilution of 1:100. Subsequently, to allow visualization of 
the detected antigen, the sections were washed in 100mM PB before being 
placed in a diluted solution of diaminobenzidine/H2O2 (DAB/H2O2; Sigma) for 
approximately 2 minutes.  
Sections that were immunostained for CD3 with DAB were enhanced by the 
addition of 0.25g/l Cobalt chloride (CoCl2) and 0.2g/l Nickel sulphate (NiSO4). 
The slides were then washed in distilled water, dehydrated in alcohol and 
xylene solutions before finally being mounted with DPX (BDH,UK). 
Table 1. Primary and secondary antibodies used in this study. The table lists 
the antibodies and their specific antigens and dilution used as well as the 
company they were acquired from and catalogue numbers. 
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Antigen 
Antibody 
(code and type) 
Dilution Source 
Primary antibodies 
Alsin 
 
C-term-1644a.a, 
Rabbit polyclonal 
 
1:1600 
 
Everest 
Biotech 
catalogue 
number 
EB05316 
Alpha 7 Anti-alpha7, 
Rabbit polyclonal 
1:5000 Ulrike Meyer, 
UEA Norwich, 
United Kingdom 
Alpha M 5C6,  
Rat monoclonal 
1:6000 Serotec, United 
Kingdom, 
catalogue 
number 5C6 
Alpha X Anti-Alpha X, 
Hamster 
polyclonal 
1:400 Chemicon, United 
Kingdom,  
β1-integrin MB1.2,  
Rat monoclonal, 
IgGa, Kappa 
1:3000 Chemicon, United 
Kingdom, 
catalogue 
number 
MAB1997 
B7.2 Anti-CD86, 
Rat monoclonal 
1:3000 Pharmigen, 
United States, 
Catalogue 
number 
553689 
CD3 
 
Anti-CD3,  
Rat monoclonal 
1:100 Serotec, United 
Kingdom,  
CD44 MAB2137,  
Rat monoclonal, 
IgG2b 
1:5000 Chemicon, United 
Kingdom, 
catalogue 
number 
MAB2137 
c-Jun Anti-c-Jun, 
Rabbit polyclonal 
1:200 Santacruz 
Biotechnology, 
United Kingdom  
 
CGRP (Calcitonin 
gene related 
peptide) 
Anti-CGRP,  
Rabbit polyclonal 
1:400 Bachem, United 
Kingdom, T-
4032.0050 
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Haematoxylin and Eosin Stain 
Lumbar spinal cords sections were deparaffinized and rehydrated by placing 
slides for 3 minutes in xylene, then in decreasing concentrations of Ethanol 
(100%, 95%, 70%, 50%), and finally in distilled water (ddH2O). Next, slides 
were placed in haematoxylin stain for 2 minutes, dipped in ddH2O to remove 
excess stain, and acid alcohol to differentiate sections. Acidic alcohol was 
rinsed with ddH2O and neutralised with ammonia until the stain in the nucleus 
turned blue. Subsequently, slides were rinsed thoroughly for 8 minutes in 
running ddH2O and dehydrated by dipping the slides 10 times through 
increasing concentrations of ethanol (50%, 70%, 95%,100%) and 100% 
Methanol. Slides were stained with eosin for 2 minutes and then underwent ten 
FUS 400a.a-450a.a, 
Rabbit polyclonal 
 Novus, 
catalogue 
number 
NB100-561 
Galanin Anti-galanin, 
Rabbit polyclonal 
1:400 Bachem, United 
Kingdom, T-
4334.0050 
GFAP (Glial 
fibrillary acidic 
protein) 
Anti-GFAP,  
Rabbit polyclonal 
1:6000 Vector, United 
Kingdom 
TDP-43 C-term-154 a.a, 
Rabbit polyclonal 
1:2000 Proteintech 
catalogue no. 
12892-1-AP 
lot no. 1 
Secondary 
antibodies 
   
Rabbit  
immunoglobulin 
(Ig) 
Biot. anti- rabbit Ig, 
Goat polyclonal 
1:100 Vector, United 
Kingdom 
Hamster  
immunoglobulin 
(Ig) 
Biot. anti-hamster 
Ig, goat polyclonal 
1:100 Vector, United 
Kingdom 
Rat 
immunoglobulin 
(Ig) 
Biot. anti-rat Ig, 
goat polyclonal 
1:100 Vector, United 
Kingdom 
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dips in 100% Methanol, 100% Ethanol and Xylene before permanently affixing 
coverslips with resinous mounting medium DPX (Sigma). 
Cresyl violet (Nissl) Stain 
Hindbrain sections were rehydrated in ddH2O, spread under a dissecting 
microscope, and were allowed to dry at room temperature for 5 minutes. Tissue 
sections were then placed in 4% Formaldehyde overnight (BDH, UK). 
Subsequently, the sections were changed to 70% ethanol and left overnight. 
Prior to staining, 4g of cresyl violet powder (BDH, UK) in 40ml of 100% Ethanol 
was mixed for 15 minutes to make 1% cresyl violet or Nissl. This mixture was 
added to 360ml ddH2O and then filtered using Whatman size 4 filter paper. 
Slides were placed in Nissl solution for 6-8 minutes. Then, slides were 
transferred to water and increasing concentrations of Ethanol (70%, 90%, 96%) 
to remove excess Nissl solution. Following this, slides were immersed in 96% 
Ethanol containing 6 drops of glacial acetic acid (Sigma) and the level of 
reaction was evaluated under a light microscope. To stop this reaction, sections 
were transferred into 100% Ethanol, isopropanol, followed by xylene. Finally, 
coverslips were permanently mounted using Depex (BDH, UK).  
Toluidine Blue Stain 
Ventral root sections were allowed to dry under a lamp. Then, Toluidine Blue 
was prepared by dissolving 1g sodium borate in 100ml ddH2O plus 1g toluidine 
blue (Electron Microscopy Science, Hatfield). Solution was filtered before use. 
Subsequently, a few drops of toluidine-blue solution were placed on the warm 
slide for 2-5 minutes. The excess stain was rinsed off with several washes of 
water. Then, slides were dehydrated with 96% and 100% Ethanol, and then 
passed into xylene. Sections were covered with a cover slip using Depex (BDH, 
UK). 
Cholinesterase and Silver Stain  
In order to visualize the endplates and axons at the neuromuscular junction, the 
muscle sections were incubated in wells with the following solutions and 
reagents. The incubations were carried out in the order presented in table 2 and 
for the time indicated. Following the last incubation in distilled water, tissue was 
carefully removed from wells, placed onto gelatinised slides, and spread as 
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needed under the microscope with fine brushes. All slides were then left 
overnight to dry in the oven at 37 0Cbefore being covered with a glass coverslip 
using DPX. The list of reagents for each solution can be found in table 3, 4 and 
5. Reagents were obtained from Sigma, unless otherwise stated. 
 
Table 2. Incubation steps for the Cholinesterase and Silver Stain 
Solution Time 
Incubation Solution 1 5 mins 
Distilled Water 30 secs 
8mM Potassium Ferricyanide  10 mins 
Distilled Water 5 mins 
Absolute Ethanol 30 mins 
Distilled Water  30 secs 
Silver Solution * 60 mins 
Reducer Solution ** 4 mins 
Distilled Water 30 secs 
 
*All incubations were carried out at room temperature except for incubation in 
silver solution, which was at 37 0C (in oven). 
 ** This last incubation was carried out with the plate under the microscope in 
order to determine extent of reaction. 
Table 3. Reagents required for Incubation Solution 1 used in the Cholinesterase 
and Silver Stain 
Regent  Volume 
Maleate buffer (0.1M sodium hydrogen 
maleate) 
 Maleic acid  1.16g 
 Sodium hydroxide 0.62g 
 Made up to 200ml with distilled water 
13ml 
Tri-sodium citrate 100mM 1ml 
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Copper sulphate (anhydrous) 30mM 2ml 
Distilled water 2ml 
Potassium ferricyanide 5mM 2ml 
Sucrose 3g 
Acetylthiocholine iodide 10mg 
 
Table 4. Reagents required for Silver solution used in the Cholinesterase and 
Silver Stain. The preparation of this solution first required CaCO3 to be added to 
distilled water and mixed gently. This solution was then filtered. Subsequently, 
CuSO4.5H2O was also dissolved followed by silver nitrate. This was incubated for 
at least 1 hour at 37˚C prior to use. 
Reagent Volume 
Distilled water  50ml 
CaCO3 0.05g 
CuSO4.5H2O 0.025g 
AgNO3 5g 
 
Table 5. Reagents required for Reducer Solution used in the Cholinesterase 
and Silver Stain. The reagents below were dissolved in distilled water to make 
up 100ml. 
Reagent Volume 
Hydroquinone  1g 
NaSO3 10g 
 
Immunofluorescence 
Hindbrain sections were treated using the same protocol as for the 
immunohistochemistry, up to and including the incubation step with the 
secondary antibody. Subsequently, sections were washed with 1% PB/BSA and 
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100mM PB (pH=7.4), then sections were dabbed dry and incubated with Alexa 
flour 488 for 1 hour (Anti-rabbit IgG-Alexa flour 488 produced in goat; Life 
Technologies, UK). Excess antibody was removed using 10mM PB. A glass 
coverslip was mounted on top of the tissue section with VectaShield (Vector, 
UK). The slides were stored in the dark at 4°C until confocal scanning. 
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Quantifications 
All quantifications were carried out by an experimenter unaware of the mouse 
genotype or days after facial axotomy. 
Motor Function 
SODG93A mice survival measure 
SODG93A mice were examined for the onset of complete bilateral hind-limb 
paralysis. The age, in days, at which mice reached end stage was used for 
survival analysis. 
Whisker Motor Function Assessment of TDP-43 mutant mice 
Mouse whisker movement was assessed from 7 to 28 days following facial 
nerve injury. Whisker movement ipsilateral to the facial nerve injury was 
compared to that of the un-operated side and scored using a scale of 0.0 (no 
movement) to 3.0 (normal movement as on the un-operated side) in 0.5 
increments (Raivich et al., 2004). 
To obtain an average motor score, independent of time, functional recovery 
index (FRI) for each animal was determined by calculating the area under the 
curve for its whisker hair motor performance scores from day 7 to 28. The 
average motor score represents the average of the functional recovery indices 
from all animals in each group.  
 
𝐹𝑅𝐼 =
∑(𝑥𝑛 − 𝑥𝑛−1)(𝑦𝑛−1 + 𝑦𝑛)
𝑥𝑛
 
Where 𝑥 = days post injury, 𝑦 = whisker hair motor performance score, and 
𝑛=day post injury. 
Cellular counts and immunoreactivity analysis 
SOD1G93A project 
Neuronal Counts in the Spinal Cord 
Transverse sections of L5 spinal cord stained for H&E were visualised with a 
Zeiss Axiolab light microscope (Carl Zeiss, UK) using a x10 objective lens. 
Then, the left or right ventral horns of the spinal cords were divided into two 
imaginary parts; ventro-medial and lateral areas (Figure 3). Motor neurons in 
each of these areas were counted at high power using a x40 objective lens. 
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Nucleated α-motor neurons in the ventral horn of the spinal cord were counted 
in every 10th section (by a blinded investigator). Counts across the entire L5 
segment were averaged per area of interest. This average was multiplied by the 
total number of pf sections per L5 segment. This total number of α-motor 
neurons per area of interest were added together to obtain the total number of 
α-motor neurons in the L5 segment. 
 
 
 
Figure 3. Schematic representation of a section through the L5 spinal cord. The 
thin lines resent the borders between the four areas in which motor neurons 
were counted. Lat: Lateral and MV: medio-ventral. The black circles represent 
the nucleated motor neurons that were counted.  
Neuronal Cell Diameter in the Spinal Cord 
Digital images of the ventral horn of spinal cord stained for H&E were obtained 
using a Sony 3 CCD video camera (AVT-Horn, Aachen, Germany). Optimas 6.2 
software (Bothwell, WA) was used to draw around the circumference of every 
neuron present in the vental horn and to calculate the area of the neuron in 
question. Assuming the neuron is nearly spherical; the mean diameter (d) was 
calculated from the mean area (A) using the following formula: 
𝑑 = √(4 𝑥 𝐴/𝜋) 
All α-motor neurons per slide whenre measured in every 10th slide until a total of 
50 motor neurons were assessed per animal. 
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Cell and Cellular Nuclei Counts in the Spinal Cord 
For quantifications of glial cells, T-cells, or neuronal-like cells or nuclei, 4µm-
thick transverse sections trough the cervical spinal cords were immunostained 
for various inflammatory markers (αM, αX, GFAP or CD3) or regeneration-
associated molecules (c-Jun, CGRP, CD44 and α7), were divided into the 
dorsal and ventral regions by drawing an imaginary horizontal line through the 
central canal (Fig. 4). The ventral region of the transverse spinal cord was 
further divided into the left and right side of the spinal cord by drawing an 
imaginary vertical line from the central canal down to the anterior median fissure 
(Fig. 4). Cells expressing inflammatory markers and regeneration associated 
molecules were counted in the grey matter of left and right ventral horns. The 
white matter of the spinal cord was also evaluated, specifically the lateral and 
anterior funiculi ventral to the imaginary line horizontally traversing the central 
canal, which will be collectively known as the ventral white matter. Cells 
expressing inflammatory markers were counted in the left and right ventral white 
matter.  
The numbers of αM- or αX-positive microglial cells and microglial clusters 
(defined as > 3 microglial cell), GFAP-positive astrocytes with a stellar 
morphology, CD3-postive T-cells, c-Jun-positive neuronal-like nuclei, or CGRP-, 
CD44- or α7-positive cells with a neuronal morphology, were manually counted 
in the left and right ventral horn and/or ventral white matter of the spinal cord. 
Nuclei or cell counts were carried out under a light microscope at high power 
using a x40 objective lens. Four sections, 10 sections apart, across the cervical 
enlargement were sampled. The mean numbers of nuclei or cells were 
calculated by averaging the left and right side of the ventral horn or ventral 
white matter of the spinal cord, then obtaining an average per animal.  
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Figure 4. Quantification of non-neuronal cells in the spinal cord. Dorsal and 
ventral regions were divided by a horizontal line in the plane of the central 
canal. The ventral region was further divided into the left and right side by a 
perpendicular line stemming from the central canal. The spinal cord section 
shown here has been stained for Nissl, as the distinct Nissl staining in the grey 
matter allows easy discrimination of grey and white matter. The ventral horns 
and the ventral white matter were analysed in this project.  
Immunoreactivity quantification in the spinal cord 
To quantify the staining intensity of αM, GFAP or CD44 in the ventral horn and 
the ventral white matter, the Mean and standard deviation algorithm was used 
(Moller et al., 1996)(Fig 5-green outline). Three pictures were taken from the 
same slide containing a transverse section through the cervical spinal cord: 1) 
the left side of the spinal cord ventral to the central canal (Fig. 5-left red 
square), 2) the right side of the spinal cord ventral to the central canal (Fig. 5-
right red square), 3) and an area of the glass slide without the tissue section. 
The images were obtained using x10 objective lens connected to a Sony 3 CCD 
video camera. Images were 8 bit digital, based on a 0–255 scale of optical 
luminosity values (OLV). Using the OPTIMAS 6.2 imaging system (Media 
Cybernetics Inc, Silver Spring, MD), the Mean and Standard Deviation of the 
optical luminosity value for the areas of interest were obtained. The ventral horn 
and ventral white matter were selected using the Optimas sketch tool.  For 
these areas, the optical luminosity value was calculated by subtracting the 
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Standard Deviation from the corresponding Mean value. Then, the OLV (Mean-
SD) for a selected area of the glass slide picture was subtracted by the OLV 
(Mean-SD) of the left and right ventral horns or ventral white matter. The values 
for  the ventral horn and the ventral white matter were calculated by averaging 
the OLVs of the left and right side ventral horn or ventral white matter. The 
mean OLV of the ventral horn and ventral white matter per animal was 
averaged across sides, sections and animals calculated by averaging across 
the OLVs of ventral horn and ventral white matter of 4 slides, 10 tissue sections 
apart. The mean OLV per animal was used to calculate the OLV per group.  
 
Figure 5. Quantification of immunoreactivity in the ventral horn and the ventral 
white matter. Pictures of the left and right spinal cord regions ventral to the 
central canal (red squares) were taken to quantify the staining intensity of the 
left and right ventral horns or the ventral white matter (green outline). 
Neuronal Counts in the Hindbrain 
The left and right facial and hypoglossal nuclei were analysed (Fig.6). Using a 
Zeiss light microscope at high power (x40 objective lens), the number of 
neuronal cells whithin the left and right nuclei were counted and corrected for 
cell size using the Abercrombie Correction coefficient (Abercrombie and 
Johnson, 1946). 
𝑁 =  𝑛 𝑥 [
𝐷
𝐷 +  𝑑
] 
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Where N is the corrected neuronal number; n is the counted number of neurons; 
D is the section thickness (25um) and d is the mean neuronal diameter, which 
was calculated using the same method as in the spinal cord. 
 
Figure 6. Quantification of motor neurons in the hypoglassal nucleus. 
Micrograph shows an example of a section through the hypoglossal nuclei 
stained with Nissl. The dashed lines show the border of the hypoglossal 
nucleous (Hyp). The line originating from the central canal allows the split of the 
left and right hypoglossal nuclei. 
Non-Neuronal cell and Neuronal-like cell counts in the hindbrain 
Quantification of the number of αM- or αX-positive microglia as well as GFAP- 
or CD44-positive astrocytes were counted in the left and right hypoglossal or 
facial nuclei (Fig.7), using a x40 objective lens. In addition, c-Jun-positive 
neuronal-like nuclei, or CD44-, α7- , β1- or galanin-positive cells with a neuronal 
shape were counted in left and right hypoglossal or facial nuclei using a Zeiss 
light microscope with a x40 objective lens. For each stain, the mean number of 
cells per motor nuclei, across 4 sections (200 microns away from each other), 
was calculated per animal. 
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Figure 7. Quantification of non-neuronal or neuronal-like cells in the facial 
motor nucleous. Micrograph shows an example of a section through the facial 
nuclei stained for microglia. The regions outlined with dashed lines show the left 
and right facial motor nucleus (FMN).  
Ventral Root Axon Counts 
The L5 ventral roots (Fig.8) were stained with toluidine blue to visualise 
myelinated axons. In the ventral root, the total number of large, small, and dying 
axons were counted at high power using a x100 objective lens. The mean 
number of axons across 5 consecutive sections was calculated per animal. 
 
 
Figure 8. Quantification of axons in the ventral root. Micrograph shows an 
example of a transverse section through the L5 ventral root stained with 
toluidine blue. The dashed white line demarcates the circumference of the 
ventral root.  
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Neuro Muscular Junction Quantification 
Longitudinal sections through the gastrocnemius muscle were stained using the 
Cholinesterase and Silver method. The total numbers of fully innervated, 
partially innervated or denervated neuromuscular junctions were counted. The 
mean number of neuromuscular junction in each of the three categories was 
calculated across 4 consecutive slides per animal.  
Facial nerve axotomy projects 
Facial motor neurons 
In mice that underwent facial nerve injury, the facial nucleus ipsilateral to the 
facial nerve injury is known as the injured or experiment facial motor nucleus, 
while the contralateral nucleus is known as the uninjured or control facial motor 
nucleus. Using a x20 magnification lens, the total fluorogold-, Nissl- or CD-44-
positive motor neurons, αM- or B7.2-positive microglial clusters, CD3-positive T-
lymphocytes, as well as Galanin- or CGRP-positive sprouts, were counted in 
the injured and uninjured facial motor nucleus. The mean number of cells or 
sprouts across 5 sections, 10 slides apart, was calculated per facial motor 
nuclei and then per animal. 
Immunoreactivity Quantification  
The staining intensity was quantified by taking a picture of the left and right 
facial nuclei, using a Sony 3 CCD video camera. The images were 8 bit digital, 
based on a 0–255 scale of optical luminosity values. The immunohistochemical 
staining was quantified using the OPTIMAS 6.2 imaging system (Media 
Cybernetics Inc, Silver Spring, MD) and the Mean and Standard Deviation 
algorithm. The overall mean optical luminosity (OLV) value for the antibody 
staining intensity was determined for each facial motor nucleus, and 
subsequently the staining intensity of the adjacent glass was subtracted, as 
described above for spinal cord quantifications. 
Neuronal Nuclei Quantification 
To quantify the intensity of nuclear immunoreactivity the OLV (Mean-SD)  
algorithm was modified. The staining intensity was quantified by taking a picture 
of the left and right facial nuclei, using a Sony 3 CCD video camera. Using the 
OPTIMAS 6.2 imaging system (Media Cybernetics Inc, Silver Spring, MD) 
optical luminosity values were used two define a low and high immunoreactivity 
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(OLV) thresholds. Low optical luminosity threshold was mean plus 1 standard 
deviation (SD) of the axotomised image OLV. High optical luminosity threshold 
was calculated using the formula: (Control mean + 2SD) / (Control mean – 
0.5SD) x (Axotomy mean – 0.5SD). Next, an area range was set using Object 
Classes Function: ArPixelCounts>200 to identify areas big enough to be a 
motor neuron nucleus. The use of the low optical luminosity threshold and 
object recognition area range allowed all motor neuron nuclei within the facial 
nucleus to be counted using an automatic quantification algorithm in Optimas. 
Next, the high optical luminosity threshold and the same object recognition area 
range were used to detect and quantify only the intensely labelled nuclei. The 
ratio between low threshold counts and high threshold counts on control side 
was calculated and the same was done for the axotomised side. 
Image acquisition 
A Sony 3CCD colour video camera was used to obtain 8-bit digital images. 
Digital micrographs of fluorescently labelled sections were taken using Leica 
TCS SP2 confocal laser microscope with the software Application Suite 
2.6.0.7266 (Leica). Images were further edited using Optimas 6.2 software. 
Statistical analysis 
Survival curves were generated using the Kaplan–Meier method. Normal 
distribution was assessed using D'Agostino & Pearson omnibus normality test. 
Differences in survival between SOD1G93A jun-competent mice and those 
lacking neural jun was determined by log-rank (Mantel–Cox Test) and Gehan–
Breslow–Wilcoxon Test and Student T-test using GraphPad Prism.  
To determine the difference in immunohistochemical staining intensities, and 
cellular, axonal or neuromuscular junction counts between SOD1G93A jun-
competent mice and those lacking neural jun, TDP-43 and wild type mice, or 
injured and intact mice, a two-tailed unpaired Student’s T-test was used.  
When more than two groups were tested, for example when gender specific 
effects on survival were evaluated, a three-way ANOVA was used followed by a 
post-hoc Tukey test. The mean and standard error of the mean (SEM) was 
collected for all data. For all statistical analyses, significance was determined 
when P<5% and were carried out using Microsoft EXCEL.  
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Chapter 3: The role of c-Jun in amyotrophic lateral sclerosis 
Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder 
characterised by the degeneration of motor neurons. Approximately 10% of ALS 
cases are familial (familial ALS or FALS), about 20% of which are caused by 
mutations in the gene that encodes for cytosolic superoxide dismutase 1 
(SOD1) (Bruijn et al., 2004). Transgenic mice overexpressing a variety of 
mutant human SOD1 associated with FALS, such as SOD1G93A, recapitulate 
several aspects of ALS and have been widely used to test pharmacological and 
gene-based therapies (Borchelt et al., 1998). In addition to the motor neuron 
degeneration observed in the spinal cord, there are also substantial 
degenerative changes in some cranial motor nuclei (e.g. facial and hypoglossal) 
of ALS patients and SOD1G93A transgenic mice (Haenggeli and Kato, 2002, 
Dalcanto and Gurney, 1994). This neuronal degeneration is spatiotemporally 
correlated with neuroinflammatory changes, which include activation of 
microglia and astrocytes and the infiltration of T-cells (Alexianu et al., 2001). 
The molecular pathways leading to the death of neurons in the disease remain 
elusive. However, the transcription factor c-Jun has been found upregulated in 
areas or cells undergoing neurodegeneration in both ALS patients and 
SOD1G3A mice (Jaarsma et al., 1996, Virgo and Debelleroche, 1995).  
In normal physiology, peripheral nerve transection (axotomy) causes a strong 
upregulation of c-Jun by injured motor neurons, and degenerative changes 
similar to those observed in ALS, such as loss of target innervation at the 
neuromuscular junctions, axonal loss and in some cases motor neuron death 
(Fischer et al., 2004). However, following such injury, motor neurons also mount 
a regenerative effort, which is characterised by the upregulation and de novo 
expression of axotomy-response/regeneration-related proteins (e.g. the 
integrins α7 and β1, the neuropeptide galanin, cytoskeletal adaptor molecule 
GAP-43 and the proteoglycan CD44) (Patodia and Raivich, 2012a). Such 
regenerative responses have also been described in ALS cases and mouse 
models of the disease (Malaspina et al., 2010, Parhad et al., 1992, Ikemoto et 
al., 1999, Wagey et al., 1998, Jaarsma et al., 1996, Lobsiger et al., 2007). 
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Previously in mice,  deletion of the floxed c-Jun gene (jun) in neurons and glia, 
using cre::recombinase driven by the nestin-promoter (nes::cre), has been 
found to cause an almost complete disappearance in axotomy mediated motor 
facial neuron death and a reduction in reactive gliosis and T-cell infiltration 
(Raivich et al., 2004). However, these neuroprotective and anti-inflammatory 
effects were also accompanied by a severe impairment in axonal regeneration, 
associated with the failure of motor neurons to upregulate axotomy-
response/regeneration-related proteins following injury (Raivich et al., 2004). 
In ALS and mouse models of ALS there is degeneration of motor neurons in the 
spinal cord and brainstem, associated with inflammatory changes and the 
expression of regeneration associated genes in degenerating motor neurons 
(Malaspina et al., 2010, Parhad et al., 1992, Ikemoto et al., 1999, Wagey et al., 
1998, Jaarsma et al., 1996, Lobsiger et al., 2007). In this chapter I shall 
examine whether c-Jun is necessary for the development of the pathological 
changes found in SOD1G93A transgenic mice. 
To determine the role of jun in SOD1-related ALS disease, we crossed the high 
copy number strain of SOD1G93A transgenic mice with mice carrying floxed gene 
encoding c-Jun (junf) and those that express Cre recombinase under the control 
of nestin-promoter (nes::cre) that can be used to remove floxed genes in cells 
expressing nestin (i.e. most brain precursor cells, including those that will 
develop into motor neurons). In this way we generated SOD1G93A junf/f littermate 
mice with or without nes::cre, with the former lacking jun inside their brain and 
spinal cord (SOD1G93A junΔN). As both groups of mice are littermates and share 
the same genetic background any differences between them would be only due 
to the nes::cre recombinase-mediated deletion of jun. 
Results 
Effects of deletion of the neuronal c-Jun gene on the lifespan of SOD1G93A 
mice  
To investigate the effect of neuronal jun deletion on the survival of SOD1G93A 
mice, transgenic SOD1G93A junΔN mice (n=12) and litter mate controls-SOD1G93A 
junf/f (n=10), were examined for the onset of complete bilateral hind-limb 
paralysis. For ethical reasons, this measure was defined as the end-stage 
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where mice underwent euthanasia. The age, in days, at which mice reached 
end-stage was used for survival analysis.  
The Kaplan-Meier survival plot in Figure 1 shows that the life-span of the jun 
deficient SOD1G93A junΔN mutants (Fig.1-red circles) was extended in 
comparison to jun competent SOD1G93A junf/f control littermates (Fig.1-blue 
circles). Survival data from each group underwent D'Agostino & Pearson 
omnibus normality tests which demonstrated the data in each group to have 
normal distribution (SOD1G93A junf/f; p=23% and SOD1G93A junΔN; p=65%), 
suggesting that mean, media and mode are equal in each group. On average, 
SOD1G93A junΔN mice survived 114±2 days which was significantly more than 
SOD1G93A junf/f mice which survived 104±3 days (MEAN±SEM p<2.5%, student 
t-test). 
To investigate possible gender specific effects on survival (Scott et al., 2008), 
the effects of genotype, sex and combination of both was analysed, using a 3-
way ANOVA. This confirmed a statistically significant effect for genotype 
(F1,16=5.17, p=3%), but revealed no effect for sex (F1,16=1.0, p=34%), or the 
sex and genotype combination (F3,16=0.1, p=97%) (Data not shown). 
 
 
Figure 1. Neural deletion of jun prolongs survival of SOD1G93A mice. Kaplan-
Meier survival plot for SOD1G93A mice lacking neural jun (junΔN, red) and their 
littermate controls (junf/f, blue). On average SOD1G93A jun ΔN mutants (n=12) 
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survived 10 days longer than SOD1G93A jun f/f controls (n=10). Gehan-
Breslow-Wilcoxon, p=2.31%; Mantel-Cox log-rank, p=1.03%. 
 
Neuroinflammation and glial activation is reduced in jun deficient SOD1G93A 
mice 
SOD1G93A mediated neurodegeneration in mice is characterised by a 
neuroinflammatory response, which begins early on, before the onset of 
disease, and peaks at the end, when mice die (Alexianu et al., 2001). In order to 
determine the effect of jun deletion in the early as well as late stages of this 
inflammatory response, we analysed the ventral horns and the ventral white 
matter, comprising of the lateral and anterior funiculi ventral to an imaginary 
horizontal line traversing the central canal, of cervical enlargement spinal cords 
of SOD1G93A junΔN mutant mice and their SOD1G93A junf/f control littermates, at 
two time points: a pre-symptomatic stage, where mice were allowed to survive 
for 70 days after birth (D70), or reach end-stage (ES), when the mice had to be 
culled. To study these changes immunohistochemistry was used to label 
cellular markers of neuroinflammation including, αM or αX (upregulated in 
activated microglia), GFAP or CD44 (upregulated in astrocytes), or CD3 (a pan-
marker of T-cells) in sections of the spinal cord. 
Microglial activation 
αM 
Microglia become activated in response to neuronal injury (Raivich et al., 1999). 
Microglial activation can be characterised by changes in cell morphology and 
expression of different cell membrane molecules (Raivich et al., 1999). During 
early activation, microglia increase the expression of the αM integrin (Raivich et 
al., 1999). To evaluate the effect of jun on early microglial activation in the 
ventral horn and the ventral white matter of SOD1G93A mice, transverse sections 
through the cervical enlargements of SOD1G93A junΔN mutant mice and their 
SOD1G93A junf/f controls, at 70 days of age or end-stage, were immunostained 
for αM and the morphology of the microglia studied. 
In mice at 70 days of age, there was little difference in the level of αM-
immunostaining in the ventral white matter of the spinal cord of SOD1G93A junf/f 
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mice (Fig. 2A) and SOD1G93A junΔN mice (Fig. 2B). However, a difference 
between groups could be observed in the morphology of microglia in the grey 
matter of the ventral horn of the spinal cord. Microglia in SOD1G93A junΔN mice 
(Fig. 2B) were ramified, while in SOD1G93A junf/f mice (Fig. 2A), microglia had 
rounded cell bodies with short processes that were strongly αM-positive. In 
addition, more large aggregates of αM-positive microglia could be found in the 
ventral horn of the spinal cord of SOD1G93A junf/f mice (Fig. 2A), than SOD1G93A 
junΔN mice (Fig. 2B). At end-stage, αM staining was strong in the spinal cords of 
SOD1G93A junf/f mice (Fig. 2C) and SOD1G93A junΔN mice (Fig. 2D). Microglia 
appeared to be activated, as demonstrated by presence of the short and thick 
processes protruding from their cell bodies in both the ventral horn and the 
ventral white matter. As at day 70, SOD1G93A junf/f mice (Fig. 2C) had more αM-
positive clusters in the ventral horn of the spinal cord, than SOD1G93A junΔN mice 
(Fig. 2D). 
To quantify the level of early microglial activation, αM immunoreactivity was 
measured in the ventral horn and the ventral white matter, using the Mean-SD 
algorithm (as described in the Material and Methods section) (Fig. 3A). It was 
found that αM immunoreactivity was not affected by jun deletion in SOD1G93A 
mice at either of the two studied time points (Fig. 3). Since microglial cluster 
formation was observed, the total numbers of αM-positive clusters in the ventral 
horn and the ventral white matter were manually counted at high power (using a 
x40 objective lens). At day 70, jun deficient SOD1G93A mice had 1±0.2 αM-
positive microglial clusters in the grey matter of the ventral horn, which was 
significantly more than the 0.3±0.1 microglial clusters in SOD1G93A junΔN mice. 
Similarly, more microglial clusters could be found in the white matter SOD1G93A 
junf/f mice (Mean±SEM: 0.1±0.1), than SOD1G93A junΔN mice (0±0) (p<5% 
between junf/f and junΔN groups, using unpaired Student’s T-test). This 
difference disappeared at end-stage, when the αM-positive clusters became 
much more numerous in both groups; indicating that αM-positive cluster 
formation was only delayed, not prevented, in the junΔN group. 
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αX integrin 
In the presence of abundant neuronal debris, microglia change from a ramified 
to an amoeboid morphology, which is characteristic of phagocytic microglia 
undergoing late-phase activation (Raivich et al., 1999). Coinciding with the 
morphological changes, microglia express αX de-novo (Raivich et al., 1999). To 
evaluate the effect of jun on late-phase microglial activation in the ventral horn 
and ventral white matter of SOD1G93A mice, transverse sections through the L5 
spinal cords of SOD1G93A junΔN mutant mice and their SOD1G93A junf/f littermate 
controls, at 70 days of age or end-stage, were immunostained for αX.  
At day 70, little to no αX-positive phagocytic microglia could be observed in 
transverse sections through the spinal cord of spinal cord of SOD1G93A junΔN 
(Fig.2F) mutant mice or their SOD1G93A junf/f littermate controls (Fig.2E). 
However, at end-stage, SOD1G93A junf/f mice (Fig.2G) had abundant αX-positive 
microglia with a rounded morphology and αX-positive nodules within the ventral 
horn. In contrast, only a few αX-positive nodules could be found in the ventral 
horn of SOD1G93A junΔN mutant mice (Fig.2H). 
The number of αX-positive phagocytic microglial clusters in the ventral horn and 
the ventral white matter of the SOD1G93A mice at day 70 and end-stage were 
quantified at high power (using a x40 objective lens). As observed above, the 
spinal cord of SOD1G93A mice showed no αX-positive cluster formation at day 
70. However, by end-stage there was a dramatic increase in the number of 
these phagocytic clusters, in both the ventral horn and the ventral white matter 
(Fig.3C). However, a significant jun-mediated effect was only observed in the 
ventral horn. Deletion of jun significantly decreased the number of αX-positive 
clusters found in the ventral horn at end-stage, with SOD1G93A junf/f controls 
having 8±1 αX-positive phagocytic microglial clusters per ventral horn, while 
SOD1G93A junΔN mutant mice having 5±1 (p<5% between junf/f and junΔN groups, 
using unpaired Student’s T-test). This may suggest that jun deletion results in 
less neuronal debris and therefore less phagocytosis at end-stage. 
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Astrocyte activation 
GFAP  
Astrocyte activation is observed in regions of the CNS undergoing degeneration 
in ALS (Alexianu et al., 2001). During activation, astrocytes upregulate the 
expression of GFAP (Raivich et al., 1999). To evaluate the effect of jun on 
astrocyte activation in the ventral horn and ventral white matter of SOD1G93A 
mice, transverse sections through the cervical enlargement of SOD1G93A junΔN 
mutant mice and their SOD1G93A junf/f littermate controls, at 70 days of age or 
end-stage, were immunostained for GFAP. 
Astrocyte activation, as characterised by enhanced GFAP immunostaining, 
increased with disease progression in both the ventral horn and the ventral 
white matter of SOD1G93A mice irrespective of jun deletion (Fig.2I-L). At 70 
days, GFAP expression was weak and there was only a few GFAP-positive 
astrocytes within the ventral horn and the ventral white matter (Fig.2I & J). At 
end-stage GFAP-immunoreactivity was strong in the ventral horn and the 
ventral white matter of control (Fig.2K) as well as mutant mice (Fig.2L). In 
addition, GFAP-immunoreactivity was more or less similar between mutant 
(Fig.2J & L) and control transgenic mice (Fig.2I & K) at day 70 and end-stage.  
To quantify astrocyte activation, GFAP immunoreactivity (IR) was measured in 
the ventral horn and the ventral white matter of SOD1G93A junΔN mutant mice 
and their SOD1G93A junf/f littermate controls, using the Mean-SD algorithm (Fig. 
3D) (Moller et al., 1996). It was found that the level of GFAP immunoreactivity in 
the ventral horn and the ventral white matter of SOD1G93A mice, at both 70 days 
of age or end-stage, was not affected by the deletion of jun. 
To further describe the response of astrocytes to disease progression, the 
number of GFAP-positive astrocytes in the ventral horn and the ventral white 
matter of SOD1G93A junΔN mutant mice and their SOD1G93A junf/f littermate 
controls, were manually counted at high power using a x40 objective lens 
(Fig.3E). As shown in Figure 3E, the number of astrocytes in the ventral white 
matter of SOD1G93A mice, was similar at day 70 and end-stage. In contrast, the 
number of activated astrocytes in the ventral horn of end-stage SOD1G93A mice 
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was 4 times more than that observed at day D70. However, astrocyte numbers 
in both the ventral horn and white matter were not altered in mice lacking c-Jun 
in neural cells, confirming the GFAP-immunoreactivity measurements.  
CD44 
In the presence of high levels of neuroinflammation or severe neural injury grey 
matter astrocytes express the proteoglycan CD44 (Jones et al., 2000, Makwana 
et al., 2007). To evaluate the effect of jun on severe astrocyte activation in the 
ventral horn and ventral white matter of SOD1G93A mice, transverse sections 
through the cervical enlargement of SOD1G93A junΔN mutant mice and their 
SOD1G93A junf/f littermate controls, at 70 days of age or end-stage, were 
immunostained for CD44. 
At the pre-symptomatic stage, CD44 staining was confined to the ventral white 
matter of both mutant (Fig. 2N) and control mice (Fig.2M). However, CD44 
immunoreactivity at end-stage was found in both the ventral horn and the 
ventral white matter of both mutant (Fig. 2Q) and control mice (Fig. 2P). CD44 
staining had a mottled appearance characteristic of astrocytic CD44 (Fig. 
2P&Q) (Jones et al., 2000, Makwana et al., 2007). Mutant mice showed less 
CD44 immunoreactivity in the ventral horn (Fig. 2Q), than control mice at end-
stage (Fig. 2P), but no difference in the levels of CD44 staining in the ventral 
white matter was observed. 
To quantify this effect, CD44 immunoreactivity (IR) was measured in the ventral 
horn and the ventral white matter, using the Mean-SD algorithm (Fig. 3F). In line 
with the observations above, immunoreactivity was significantly lower in the 
ventral horn of jun-deficient SOD1G93A mice (Fig. 3F-red bar) compared to jun 
competent littermate controls at end-stage (Fig. 3F-blue bar) (p<5% between 
junf/f and junΔN groups, using unpaired Student’s T-test). No other differences 
between the two jun genotypes were found in the white matter at end-stage or 
in the grey and white matter at day 70. 
T-cell infiltration 
T-cell infiltration into areas undergoing neurodegeneration has been observed 
in ALS (Alexianu et al., 2001). To evaluate the effect of jun on T-cell infiltration 
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into ventral horn or ventral white matter of SOD1G93A mice, transverse sections 
through the spinal cord of SOD1G93A junΔN mutant mice and their SOD1G93A junf/f 
controls, at 70 days of age or end-stage, were immunostained for the T-cell 
marker CD3. 
At day 70, there were little to no CD3-positive T-cells in both the ventral horn 
and ventral white matter of SOD1G93A junΔN (Fig.2R) or SOD1G93A junf/f mice 
(Fig.2Q). However, at end-stage, T-cells appeared to preferentially infiltrate the 
ventral white matter of SOD1G93A junΔN (Fig.2T) and SOD1G93A junf/f mice 
(Fig.2S). Although T-cell infiltration could be seen in jun deficient and competent 
mice, there were fewer T-cells present in the jun deficient mice (Fig.2T) than jun 
competent littermate controls (Fig.2S). 
To quantify T-cell infiltration, CD3-positive T-cells were manually counted in the 
ventral horn or ventral white matter at high power (using a x40 objective lens) 
(Fig.3G). There were little to no T-cells present in the spinal cord of SOD1G93A 
junΔN mice or SOD1G93A junf/f littermate controls at D70. However by end-stage, 
the deletion of jun was found to reduce T-cell infiltration in SOD1G93A mice (Fig. 
3G). There were 8±1 T-cells present per ventral white matter of SOD1G93A junf/f 
mice, which was significantly more than 5±1 T-cells found in the SOD1G93A junΔN 
mice (p<5% between jun f/f and junΔN groups, using unpaired Student’s T-test) 
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Figure 2. Neural deletion of jun reduces neuroinflammation in the spinal cord of 
SOD1G93A transgenic mice. (A-T) Immunoreactivity for inflammatory cellular 
markers, in the spinal cord of jun-competent (junf/f) and jun-deficient (junΔN) 
SOD1G93A mice at day 70 and end-stage (ES). (A-D) Alpha-M positive microglial 
clusters can be observed in junf/f spinal cords (A), but not in junΔN spinal cords 
(B), at day 70. However, at end-stage, the number of microglial clusters 
increased to similar levels in both jun genotypes (C&D). (E-H) Immunoreactivity 
for the phagocytic microglial marker, Alpha-X, shows many phagocytic clusters 
in the spinal cord of jun-competent (G), but only a few in jun-deficient (H) mice, 
at end-stage. However, note the absence of these clusters in both jun 
genotypes at day 70 (E&F). (I-L) Astrogliosis identified by glial fibrillary acidic 
protein (GFAP) immunoreactivity is not affected by jun deletion; low levels were 
observed at day 70 (I&J) and these increase dramatically to similar levels in 
both jun genotypes at end stage (K&L). (M-P) Astrocyte CD44 immunoreactivity 
in the grey matter of the spinal cord, normally associated with high levels of 
inflammation, was absent at day 70 (M&N), was present at end-stage in jun 
competent mice (O) but was visibly lower in jun-deficient mice (P). (Q-T) T-cells, 
labelled by CD3 immunoreactivity, were absent from the spinal cord at day 70 
(Q&R). At end-stage, many T-cells were present in the spinal cord white matter 
of jun-competent mice (S), but less can be observed in jun-deficient mice (T). 
Scale bar 500μm. 
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Figure 3. Quantitation of neuroinflammatory changes in the spinal cord of 
SOD1G93A mice. Immunoreactivity (IR in Optical Luminosity Values-OLV) in A, 
D and F was quantified using the Mean+SD algorithm as described in Chapter 
2. B, C, E and G show the number of microglial clusters (B&C), astrocytes (C) 
and T-lymphocytes (G) in the grey (GM) and white matter (WM) of the spinal 
cord. Compared to jun-competent mice (jun f/f), those lacking neural jun (jun ΔN) 
show a significant reduction in alpha-M-positive microglial clusters at day 70 
(D70) (B), as well as a reduction in alpha-X-positive microglial clusters (C), 
CD44 immunoreactivity (F), and T-lymphocyte infiltration (G) at end-stage (ES). 
However, jun deletion had no effect on alpha-M (A) or GFAP (D) 
immunoreactivity, or in the number of activated astrocytes (E). n= 11 for junf/f 
and n=8 for junΔN, at day 70; n=10 and 12, respectively at end-stage. *p<5% 
between jun f/f and jun ΔN groups, using unpaired Student’s T-test.  
 
Neural deletion of jun reduces motor neuron loss without affecting cell body 
diameter  
Motor neuron loss and atrophy are features of the SOD1G93A mediated disease 
(Gould et al., 2006). Using the SOD1 mouse model of ALS, we aimed to 
examine the effect of deleting neural jun on the loss and atrophy of motor 
neurons in the ventral horn and ventral white matter of the L5 spinal cord. 
SOD1G93A junf/f and SOD1G93A junΔN mutants were analysed at 70 days of age 
or at end-stage. To control for the effects jun gene deletion on motor neuron 
number and atrophy, irrespective of the SOD mutation, junf/f and junΔN mice 
without the SOD1G93A transgene (WT (-SOD)), were also investigated. Initially, 
WT (-SOD) were studied at 70 or 110 days of age. However, because motor 
neuron counts and neuronal atrophy measurements in the WT (-SOD) mice 
revealed no significant difference between day 70 and day 110 (data not 
shown), the data was pooled into a single WT (-SOD) group (Fig. 4G & H). 
Transverse sections though the spinal cord were stained with Haematoxylin and 
Eosin to visualise neurons in ventral horn of the spinal cord (Fig 4 A-F). Motor 
neurons in the ventral horn of WT junf/f (Fig. 4A), WT junΔN (Fig. 4B), SOD1G93A 
junf/f (Fig. 4C & E), or SOD1G93A junΔN (Fig. 4D & F) at day 70 and end-stage, 
have a triangular cell body shape, with acidophilic (red) background staining of 
the cytoplasm and nucleus, as well as prominent basophilic (blue) nucleolus 
and tigroid pattern of staining in the cytoplasm. Motor neurons at day 70 in 
SOD1G93A mice had a similar morphology and size as those in WT mice, 
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irrespective of jun genotype. At end-stage, in both jun deficient and competent 
SOD1G93A mice motor neurons appeared smaller, had cytoplasmic vacuoles, as 
described in previous studies (Gurney et al., 1994), and were visibly less 
numerous. 
Using the method described in Chapter 2, the total number of nucleated α-motor 
neurons in the ventral horn of the spinal cord was manually counted using a 
X40 objective lens (Fig. 4G). Analysis of WT (-SOD) mice, revealed that jun 
deletion had no effect on spinal motor neuron numbers; junf/f had 1316 ±147 
motor neurons per ventral horn (Fig.4G- left blue bar; n=9) and junΔN had 
1208+/-73 neurons per ventral horn (Fig. 4G- left red bar; p=48%; unpaired 
Student’s T-test; n=6). Similarly, the number of spinal motor neurons at day 70, 
did not differ between the jun competent SOD1G93A junf/f mice (Fig. 4G- middle 
blue bar; n=20) and the jun deficient SOD1G93A junΔN (Fig. 4G-middle red bar; 
n=11); SOD1G93A junf/f had 1057±66 motor neurons per ventral horn and 
SOD1G93A junΔN had 1038±69 motor neurons per ventral horn (p=81%; unpaired 
Student’s T-test). In contrast, at end-stage there were 471±46 motor neurons 
per ventral horn in SOD1G93A junΔN mice (Fig. 4G-right red bar; n=12), which 
was significantly more than 309+/-31 neurons per ventral horn in SOD1G93A junf/f 
mice (Fig. 4G-right blue bar; n=10) (p<5%; unpaired Student’s T-test). 
Interestingly, motor neuron loss from day 70 to end-stage, was significantly 
ameliorated in the jun deficient mutants. SOD1G93A junΔN only lost 55% of motor 
neurons per ventral horn compared to the SOD1G93A junf/f controls, which lost 
71% from day 70 to end-stage. To identify the effects of jun deletion on 
SODG93A mediated motor neuron atrophy, the cell body diameter of spinal motor 
neurons in the ventral horn was measured using the method described in 
Chapter 2. Figure 3G shows the cumulative distribution curves for motor neuron 
diameter measurements. It demonstrates that motor neuron diameter in mice 
not carrying the SOD1G93A transgene was similar irrespective of jun deletion, 
with mean motor neuron diameter being 30.8±0.3 µm for junf/f mice and 31.1 ± 
0.4 µm for junΔN mice ( p>40% using unpaired Student’s T-test). Likewise, 
SOD1G93A junf/f mice had similar motor neuron cell body diameters (29.9±1.8 
µm) as jun deficient SOD1G93A junΔN mice, at day 70 (30.4 ± 0.5 µm; p=79%, 
using unpaired Student’s T-test). At end-stage, the diameter of motor neurons in 
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both SOD1G93A jun genotype groups was smaller compared to day 70; the mean 
motor neuron diameter significantly decreased to 21.7 ± 0.6 µm in SOD1G93A 
junf/f mice and to 22.0 ± 0.8 µm in SOD1G93A junΔN mice (p<5% using unpaired 
Student’s T-test between day 70 and end-stage groups for each genotype). This 
SOD1G93A mediated atrophy was independent of jun deletion. 
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Figure 4. Neural deletion of jun reduces SOD1G93A-mediated motor neuron 
loss, but does not affect neuronal atrophy. (A-F) Haematoxylin and eosin-
stained ventral horns of non-transgenic wild type mice (WT, top row), and 
SOD1G93A mice at day 70 (middle row) and end-stage (bottom row). Sections 
from jun-competent (junf/f) mice are seen in the first column and those from jun-
deficient mice in the second (junΔN). The scale bar represents 150 µm. (G) 
Quantification of alpha motor neurons in the ventral horn of the 5th lumbar 
segment of the spinal cord. Note that neural deletion of jun does not affect the 
number of motor neurons in wild type [WT (-SOD)] mice (n=9 for junf/f and n=6 
for junΔN) or in SOD1G93A animals at day 70 (n=20 and n=11), but SOD1G93A 
mice lacking jun (n=12) reach end-stage with a significantly greater number of 
spinal motor neurons than those expressing jun (n=10). *p<5% using unpaired 
Student's T-test between junf/f and junΔN groups. (H) Cumulative distribution of 
spinal motor neuron cell body diameter. (WT, n=6 and n=8; SOD1G93A D70, n=7 
and n=7; SOD1G93A ES, n=7 and n=10 for junf/f and junΔN groups, respectively). 
Note the severe reduction in motor neuron diameter at end-stage which is not 
affected by neural deletion of jun.  
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Motor neuron loss, neuroinflammation and glial activation at the brainstem is 
attenuated by deletion of neural jun  
SOD1G93A mediated disease in mice involves the degeneration of some 
brainstem motor nuclei (Haenggeli and Kato, 2002). Here we characterised the 
effect of jun on neuronal survival, inflammation and glial activation in SOD1G93A 
mice. The number of motor neurons, microglia and astrocytes were analysed in 
the hypoglossal nuclei and facial nuclei of jun competent or jun deficient  
SOD1G93A mice. 
Motor Neurons 
Coronal sections through the hypoglossal nuclei or facial nuclei of WT (-SOD) 
junf/f and WT (-SOD) junΔN, or SOD1G93A junf/f and SOD1G93A junΔN at 70 days of 
age or end-stage, were Nissl stained to visualise motor neurons. The total 
number of motor neurons in the hypoglossal or facial nuclei were counted at 
high power, using a x40 objective lens. 
It has been previously reported that jun deletion leads to a 19% increase in the 
number of motor neurons in the facial nucleus of uninjured adult mice, without 
affecting the number of hypoglossal motor neurons (Raivich et al., 2004). 
However, in the current study, quantification of motor neurons in the brainstem 
sections of junf/f or  junΔN mice (Fig. 5-blue bars), without the SOD1G93A 
transgene, showed that jun deletion had no effect on motor neuron number in 
the hypoglossal or the facial nuclei. junf/f mice had 1093 ± 38 motor neurons in 
the hypoglossal nuclei (Fig. 5-HYP), which was similar to 1041 ± 73 neurons 
found in junN. In addition, the number of motor neurons in the facial nuclei (Fig. 
5-FAC) of junf/f were 2411±30, which was similar to 2318±87 found in the junN 
animals (p>5% using unpaired Student's T-test between jun f/f and junΔN 
groups). 
SOD1G93A mice expressing jun showed evidence of neuronal loss in the 
hypoglossal nucleus, with 1078±90 hypoglossal motor neurons at end-stage 
(Fig. 5A & E), which was significantly less than the 1317±55 motor neurons 
found at day 70 (Fig. 5C & E) (p<5% using unpaired Student's T-test between 
day 70 and end-stage in SOD1G93A junf/f mice). In addition, there was a trend for 
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fewer motor neurons at end-stage (1807±114) than at day 70 (1972±44) in the 
facial nuclei of SOD1G93A junf/f mice (Fig.5E) (p=18% using unpaired Student's 
T-test between day 70 and end-stage in SOD1G93A junf/f mice). The motor 
neuron loss mediated by SOD1G93A disease was abolished in jun deleted mice. 
The hypoglossal nuclei of SOD1G93A junΔN contained 1200±68 neurons at day 
70 (Fig. 5B & E), which was similar to 1295±53 motor neurons found at end-
stage (Fig. 5D & E). In the same way, the facial nuclei of SOD1G93A junΔN had 
2118±93 motor neurons at day 70, which did not differ from 2072±63 motor 
neurons counted at end-stage (Fig.5E) (p>5% using unpaired Student's T-test 
between day 70 and end-stage in SOD1G93A junΔN mice). The increased survival 
of motor neurons in the cranial motor nuclei of SOD1G93A mice deficient in jun is 
reminiscent of that observed at the spinal cord. 
Neuroinflammation and astrocyte activation 
The effect of jun deletion on SOD1G93A mediated neuroinflammation in 
brainstem motor nuclei was investigated. To do this, coronal sections through 
the hypoglossal nuclei or facial nuclei of end-stage SOD1G93A junf/f and 
SOD1G93A junΔN were stained for αM, αX, GFAP or CD44 to visualise microglial 
and astrocyte activation. The total number of microglia or astrocytes in the 
hypoglossal or facial nuclei were counted, using a x40 objective lens. 
Microglial activation 
Corroborating the reduction in motor neuron loss at end-stage, jun deficient 
SOD1G93A mice had 70% fewer αX-positive microglial clusters in the 
hypoglossal nuclei than jun competent controls (Fig. 5G). The SOD1G93A junf/f 
mice had 7±2 αX-positive microglial clusters in the hypoglossal nuclei, which 
was significantly more than 2±1 αX-positive microglial clusters found in 
SOD1G93A junΔN mice (p<5% using unpaired Student's T-test between SOD1G93A 
junf/f mice and SOD1G93A junΔN mice). However, no difference was observed in 
the facial nucleus. There were 8±2 αX-positive microglial clusters in the facial 
nuclei of SOD1G93A junf/f, which was not significantly different from the 11±5 αX-
positive microglial clusters found in SOD1G93A junΔN (p>5% using unpaired 
Student's T-test between SOD1G93A junf/f mice and SOD1G93A junΔN mice).  
134 
 
Neural deletion of jun had no effect on the number of αM-positive microglia 
found in the hypoglossal and facial nuclei. The SOD1G93A junf/f mice had 12±2 
αM-positive microglial clusters in the facial nucleus, which did not differ 
significantly from 14±4 found of SOD1G93A junΔN mice. In the same way, the 
hypoglossal nuclei of SOD1G93A junf/f had 9±2 αM-positive microglial clusters, 
which was similar to 12±3 found in SOD1G93A junΔN mice (p>5% using unpaired 
Student's T-test between SOD1G93A junf/f mice and SOD1G93A junΔN mice).  
Astrocyte activation 
The number of GFAP-positive astrocytes in the hypoglossal or facial nuclei of 
SOD1G93A mice at end-stage was minimal and was not affected by jun deletion 
(Fig. 5H) (p>5% using unpaired Student's T-test between SOD1G93A junf/f mice 
and SOD1G93A junΔN mice). However, as shown in Figure 5I, the number of 
CD44-positive astrocytes was significantly reduced in both the hypoglossal and 
facial nuclei of jun-deficient mice compared to jun-competent littermates. In the 
hypoglossal nucleus, SOD1G93A junf/f mice had 3±1 CD44-positive astrocytes, 
which was significantly more than 1±0.5 found in SOD1G93A junΔN. Similarly, in 
the facial nucleus, the SOD1G93A junf/f had 6±1 CD44-positive astrocytes, while 
SOD1G93A junΔN only had 2±1 CD44-positive astrocytes (p<5% using unpaired 
Student's T-test between SOD1G93A junf/f mice and SOD1G93A junΔN mice).  
Thus, deletion of jun reduces SOD1G93A mediated motor neuron loss and 
neuroinflammation in the brainstem as well as the spinal cord. This indicates 
that c-Jun has an important role in mediating SOD1G93A neuropathology 
irrespective of the motor neuron pool studied. 
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Figure 5. Neural deletion of jun reduces motoneuron loss and 
neuroinflammation in the brainstem of SOD1G93A mice. (A-D) Nissl stained 
sections through the hypoglossal nucleus of jun-competent (junf/f) and jun-
deficient (junΔN) SOD1G93A mice at day 70 (D70) and end-stage (ES). Note the 
absence of motor neuron loss from day 70 to end-stage in jun-deficient mice 
(B&D). Scale bar 250µm. (E) Quantification of motor neurons in the hypoglossal 
(HYP) and facial (FAC) nuclei. Neural deletion of jun does not affect the number 
of motor neurons in wild type [WT (-SOD)] mice (n=4 for junf/f and junΔN) or in 
SOD1G93A animals at day 70 (n=11 and n=9). However, SOD1G93A mice lacking 
jun reach end-stage with a significantly greater number of hypoglossal motor 
neurons than those expressing jun (n=12 and n=10). *p<5% using unpaired 
Student's T-test between SOD D70 and SOD ES groups. (F-I) Quantitation of 
microglia clusters and astrocytes in the brainstem of SOD1G93A mice and the 
effect of jun deletion. Number of cellular profiles immunoreactive for the 
microglial markers αM (F) and αX (G), and the activated astrocyte markers 
GFAP (H) and CD44 (I), in the hypoglossal (HYP) and facial (FAC) nuclei of jun-
competent (junf/f) and jun-deficient (junΔN) SOD1G93A mice, at end-stage. *p<5% 
using unpaired Student’s T-test between junf/f and junΔN groups; n=10 and 12, 
respectively. 
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Deletion of jun protects axons in SOD1G93A mice  
In the SOD1G93A mouse model of ALS, axonal degeneration appears to be the 
primary deficit, which precedes symptom onset and motor neuron death 
(Fischer et al., 2004, Pun et al., 2006, Gould et al., 2006). To investigate the 
role of jun on axonal degeneration of SOD1G93A mice. Transverse sections 
through the ventral roots, from lumbar segment 5 (L5), of WT (-SOD) junf/f and 
WT (-SOD) junΔN, or SOD1G93A junf/f and SOD1G93A junΔN at 70 days of age or 
end-stage, were stained with toluidine blue to visualise myelinated axons. 
It has been confirmed that degenerative changes in axons of SOD1G93A mice 
can be seen in the pre-symptomatic stages (Fig. 6). By 70 days of age, the 
large calibre myelinated axons in the L5 ventral roots of jun competent 
SOD1G93A mice are surrounded by numerous small calibre axons (Fig. 6A). In 
contrast, in the L5 ventral roots of jun deficient SOD1G93A mice, medium and 
large size axons can be seen in the vicinity of only a few small myelinated fibres 
(Fig. 6B). By end-stage, there are a few myelinated axons in the L5 ventral 
roots of jun competent SOD1G93A, which appear shrunken and of an irregular 
shape (Fig. 6C). Axons in L5 ventral roots of jun-deficient SOD1G93A mice were 
numerous and predominantly of a large size although they did not have a 
normal appearance (Fig. 6D). 
Using a x100 objective lens, the total number of axons in the L5 ventral roots of 
WT (-SOD) junf/f and WT (-SOD) junΔN, or SOD1G93A junf/f and SOD1G93A junΔN 
at 70 days of age or end-stage, were counted. As with motor neuron number, 
age (day 70 vs day 110) did not affect the number of axons in wild type mice 
without the SOD1G93A transgene (data not shown), and neither did the deletion 
of jun in such mice (junf/f, 922 ± 76; junN, 945 ± 159) (Fig. 6E). This 
demonstrates that the baseline ventral root axonal counts in jun deficient mice 
are the same as controls. By day 70, SOD1G93A mice expressing jun showed a 
30% fewer in axon number compared to their jun deficient SOD1G93A 
littermates. SOD1G93A junf/f mice had 692±45 axons in the ventral roots, which 
was significantly fewer than SOD1G93A junN mice that had 987 ± 98 axons 
(p<5% using unpaired Student's T-test between SOD1G93A junf/f mice and 
SOD1G93A junΔN mice at day 70). By end-stage, both groups lost around 40% of 
their axons from their day 70 baseline. However, SOD1G93A mice lacking jun still 
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had a greater number of axons compared to the jun-expressing mice. The 
ventral roots of SOD1G93A junf/f had 413±20 axons, while SOD1G93A junN had 
550±50 (p<5% using unpaired Student's T-test between SOD1G93A junf/f mice 
and SOD1G93A junΔN mice at day 70) (Fig. 6E). The reduction in the number of 
axons from day 70 to end-stage was approximately 25% in both jun competent 
and jun deficient SOD1G93A mice.  
 
Figure 6. Axonal loss in SOD1G93A mice is attenuated by neural deletion of jun. 
(A-D) Toluine blue-stained L5 ventral roots of jun-competent (junf/f) and jun-
deficient (junΔN) SOD1G93A mice at day 70 (D70) and end-stage (ES). Note the 
extensive axonal degeneration in junf/f at end-stage, and compare to the 
healthier junΔN ventral root. Scale bar 20µm. (E) Quantification of myelinated 
axons in cross sections of the 5th lumbar ventral root. Axon number in wild type 
mice [WT (-SOD)] is not affected by jun deletion (n=5 for junf/f and n=8 for 
junΔN). However, at day 70, jun-competent SOD1G93A mice (n=17) have 
around 30% fewer myelinated axons than jun deficient littermates (n=8). This 
difference continues to end-stage, despite extensive axonal loss in both groups 
(n=10 and n=7). *p<5% using unpaired Student’s T-test between junf/f and junΔN 
groups. 
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Neuromuscular junction dennervation is not affected by deletion of jun  
Previous studies on SOD1G93A mice have demonstrated dissociation between 
motor neuron loss and the overall length of survival. Instead, a better correlation 
has been observed between length of survival and neuromuscular junction 
(NMJ) denervation (Gould et al., 2006). For this reason, longitudinal sections 
through the gastrocnemius muscle of WT (-SOD) mice competent for jun, or 
SOD1G93A mice, with or without jun, at end-stage were stained to visualise NMJs 
using a combined silver impregnation and acetyl-cholinesterase histochemistry 
technique. 
Using a x40 objective lens, the total number of fully innervated (Fig.7A), partially 
innervated (Fig.7B) and denervated NMJs (Fig.7C) in the gastrocnemius muscle 
were quantified (Fig.7D). As Figure 7D shows, almost 100% of NMJs are fully 
innervated in mice that do not carry the SOD1G93A transgene. However, 
SOD1G93A mice, with or without jun, reach end-stage with only proximally half of 
their NMJs fully innervated. There was a trend for jun deficient mice to have 
slightly higher percentages of fully innervated NMJs (54±2) than jun competent 
mice at end-stage (49±2) (p=9.7% using unpaired Student's T-test between 
junf/f and junΔN groups, n=4 per group). However, when the total innervation 
index was calculated (=1*fully innervated + 0.5*partially innervated), the amount 
of innervation was similar for both SOD1G93A junΔN (61.2%±1.8%) and SOD1G93A 
junf/f mice (65.2%±1.0%) (p>5%; using unpaired Student's T-test between 
SOD1G93A junf/f mice and SOD1G93A junΔN; n=4 per group). This demonstrates 
that whilst jun deletion protected SOD1G93A mice from disease-associated motor 
neuron and axonal loss, it did not prevent the NMJ denervation which ultimately 
causes paralysis and death of animal. 
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Figure 7. Neural deletion of jun does not protect neuromuscular junctions 
(NMJ) from SOD1G93A-mediated denervation. (A-C) NMJs in the gastrocnemius 
muscle stained using silver impregnation and acetylcholinesterase (AChE) 
histochemistry to visualize motor axons (silver) and muscle endplates (AChE). 
Scale bar represents 50µm. (A) Fully innervated NMJs showing prolific terminal 
axon branching; (B) partial innervated, with the terminal axon passing across 
the NMJ and (C) denervated, with no axon inside the AChE demarcated 
endplate. (D) Percentage of full, partial and not innervated NMJs, demonstrates 
that SOD1G93A mice reach end-stage with similar levels of denervation, 
regardless of jun deletion (jun f/f and jun ΔN groups, n=4 per group). 
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SOD1G93A mice mount a jun-dependent, disease-mediated axotomy response  
Axonal disconnection from peripheral targets, following nerve transection, 
causes a retrograde chromatolytic response in the cell bodies of injured 
neurons (axotomy response), which involves the upregulation of transcription 
factors and regeneration-associated molecules (Raivich, 2011). As described in 
this study, SOD1G93A causes axonal disconnection in the form muscle 
denervation and axonal loss. This suggests that a disease mediated motor 
neuron axotomy response might occur in SOD1G93A mice. In order to determine 
whether such response does in fact exist, transverse sections through the 
cervical enlargement of jun-competent or jun-deficient SOD1G93A mice, at 70 
days of age or end-stage were immunostained for the regeneration associated  
proteins: α7, β1, galanin, CD44 as well as c-Jun itself (Figs. 8&9). 
Motor neurons in the spinal cord of SOD1G93A mice deficient in jun show an 
axotomy response at end-stage 
To examine whether the nestin-driven CRE recombination effectively deletes 
jun from the motor neurons of the spinal cord of SOD1G93A mice, the expression 
of c-Jun protein was studied in SOD1G93A mice. SOD1G93A junf/f mice showed c-
Jun being expressed in the nuclei of cells confined to the ventral horn, at day 70 
(Fig.8A). At end-stage, the expression of c-Jun increased in the ventral horn of 
jun-competent SOD1G93A mice (Fig.8B). The large size of the c-Jun-positive 
nuclei suggests that they belong to neurons (Fig. 8B-insert). In contrast, 
SOD1G93A junΔN mice failed to show any c-Jun-positive cell nuclei in the spinal 
cord at both day 70 (Fig.8C) and end-stage (Fig. 8D). 
The total numbers of c-Jun-positive neuronal nuclei were counted in the ventral 
horn of the spinal cord, using a x40 objective lens (Fig. 9A & B). In line with the 
observations above, c-Jun-positive nuclei of putative motor neurons in the 
ventral horn of SOD1G93A jun competent mice, doubled in number from day 70 
to end-stage. There were 2±1 c-Jun-positive nuclei per ventral horn of 
SOD1G93A junf/f mice at day 70, which was significantly fewer than 4±1 c-Jun-
positive nuclei counted per ventral horn of SOD1G93A jun f/f mice at end stage 
(p<5%; using unpaired Student's T-test between SOD1G93A junf/f mice at day 70 
and end-stage). In contrast, the number of c-Jun-positive neuronal nuclei in the 
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ventral horn of the spinal cord of SOD1G93A junΔN mice was similar at day 70 and 
end-stage, with less than one c-Jun-positive neuronal nucleus per ventral horn 
(p>5%; using unpaired Student's T-test between SOD1G93A junf/f mice at day 70 
and end-stage). A comparison between jun-competent and jun-deficient 
SOD1G93A mice revealed that jun-competent SOD1G93A mice had more c-Jun 
nuclei in the ventral horn of the spinal cord than jun-deficient SOD1G93A mice at 
day 70 and end-stage. Nes::cre mediated deletion of jun significantly abolished 
the number of c-Jun positive nuclei by 89-98% in the ventral horn. At day 70, 
SOD1G93A junf/f mice had 2.5±0.6 c-Jun positive neuronal nuclei per ventral 
horn, while SOD1G93A junΔN mice at end stage had 0.3±0.2 c-Jun positive nuclei 
per ventral horn. Similarly, SOD1G93A junf/f mice had 4±0.7 c-Jun positive nuclei 
per ventral horn, which was significantly more than 0.1±0.1 c-Jun positive 
neuronal nuclei per ventral horn of SOD1G93A junΔN mice (p<1%; using unpaired 
Student's T-test between SOD1G93A junf/f mice and SOD1G93A junΔN). 
As postulated above, the overexpression of the SOD1G93A transgene in mice did 
in fact cause the de-novo expression of axotomy response markers in motor 
neuron like cellular profiles. At end-stage putative motor neurons were highly 
CD44- (Fig.8G), α7- (Fig.8K) or β1-positive (Fig.8O) in the ventral horns of the 
spinal cord of SOD1G93A junf/f mice (Fig.8G). In contrast, SOD1G93A junΔN mice 
had a few very faintly stained CD44- (Fig.8H), α7- (Fig.8L) or β1-positvie 
neurons in the spinal cord at end-stage (Fig.8P). The expression of these 
regeneration-associated proteins was not observed in the spinal cords of 
SOD1G93A junf/f (Fig.8E, I &M) or SOD1G93A junΔN at day 70 (Fig.8F, J &N). 
Using a x40 magnification lens, the total number of CD44-, α7-, β1-, or galanin-
positive neurons were counted in ventral horn of the spinal cord of SOD1G93A 
junf/f or SOD1G93A junΔN mice, at 70 days of age (Fig.9A) or end-stage (Fig.9B). 
Galanin-positive neurons were not present in the ventral horn of the different jun 
groups, at the two different time-points. However, at day 70, approximately one 
CD44-, α7-, or β1-positive neuron was counted in the ventral horn of SOD1G93A 
junf/f or SOD1G93A junΔN mice. A comparison between jun competent and jun 
deficient SOD1G93A mice, revealed no difference in the number of neurons 
expressing the aforementioned proteins in the ventral horn (p>5%; using 
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unpaired Student's T-test between SOD1G93A junf/f mice and SOD1G93A junΔN, at 
day 70). At end-stage, the number of CD44-, α7-, or β1-positive neurons 
increased in the spinal cord of SOD1G93A junf/f or SOD1G93A junΔN mice. The 
increase in the expression of these proteins appeared to be reduced by jun 
deletion. However, only CD44 expression that was significantly affected; 
SOD1G93A junf/f mice had 3±0.4 CD44-positive neurons per ventral horn, which 
was significantly more than 1±0.2 CD44-positive neurons found per ventral horn 
of SOD1G93A junΔN mice (p<5%; using unpaired Student's T-test between 
SOD1G93A junf/f mice and SOD1G93A junΔN, at end-stage).  
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Figure 8. Spinal motor neurons in end-stage SOD1G93A mice mount a jun-
dependent disease-associated axotomy response. (A-P) Immunoreactivity for 
axotomy response markers c-Jun (A-D), CD44 (E-H), α7 (I-L), and β1 (M-P) in 
the ventral horn of jun-competent (junf/f) and jun-deficient (junΔN) SOD1G93A 
mice, at day 70 and end-stage. Scale bar 300µm. Note the complete absence of 
c-Jun immunoreactivity from junΔN spinal cords at both day 70 (B) and end-
stage (D). Importantly, notice that CD44 (G), α7 (K) and β1 (O) immunoreactive 
motor neurons can only be observed in the spinal cord of jun competent 
SOD1G93A mice at end-stage. Asterisks mark immunoreactive motoneurons 
magnified (x3) inset. 
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Figure 9. Quantitative description of SOD1G93A mediated axotomy response and 
the effect of jun deletion. (A-B) Number of spinal motor-neuron-like cellular 
profiles immunoreactive for axotomy response markers in the ventral horn of the 
spinal cords of jun-competent or jun-deficient SOD1G93A at day 70 or end-stage 
(*p<5% using unpaired Student’s T-test between junf/f and junΔN groups, n=10 
for jun f/f and n=12 for jun ΔN). 
 
SOD1G93A mice deficient in jun show an axotomy response in the brainstem 
Next the present project investigated whether other motor neuron pools of 
SOD1G93A mice mounted a jun-dependent axotomy response, similar to that 
found in the spinal cord. To do this, coronal sections through the hypoglossal 
and facial nuclei, of jun-competent or jun-deficient SOD1G93A mice at end-stage, 
as well as the facial nucleus of wild type animals 14 days after facial nerve 
axotomy, were immunostained for: α7, β1, galanin, CD44 as well as c-Jun 
(Figs. 10&11). 
To further demonstrate that the nestin-driven CRE recombination efficiently 
deletes jun from the motor neurons of SOD1G93A mice, coronal sections through 
the brainstem of jun-competent or jun-deficient SOD1G93A mice, were stained for 
c-Jun, at end-stage. Strong c-jun expression was found in the nuclei of putative 
motor neurons of the facial (Fig.10B) and hypoglossal nucleus of jun-competent 
SOD1G93A mice (Fig.10D). Like in the spinal cord, jun deficient SOD1G93A mice 
failed to express c-Jun in the facial (Fig.10E) and hypoglossal nuclei (Fig.10F). 
Quantifications of c-Jun-positive nuclei present in the facial (Fig. 11A) or 
hypoglossal nucleus, revealed that c-Jun expression was significantly reduced 
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by 93% in the facial nucleus and 99% in the hypoglossal nuclei of SOD1G93A 
junΔN mice (Facial Nucleus: 2.0±0.8; Hypoglossal Nucleus: 0.4+/-0.4) compared 
to SOD1G93A junf/f mice (27.0±7.8; 27.0±4.6) (p<5%; using unpaired Student's T-
test between SOD1G93A junf/f mice and SOD1G93A junΔN, at end-stage). 
Neurons positive for axotomy response markers were found in the facial as well 
as hypoglossal nucleus of jun-competent SOD1G93A mice. Coronal sections 
through the facial (Fig. 10G, L, Q & V) or the hypoglossal nuclei (Fig. 10I, N, S 
& X) revealed strongly stained CD44- (Fig.10G&I), α7- (Fig.10L&N) or β1-
positve neuronal-like  profiles (Fig.10Q&S). However, it was only in the facial 
nucleus (Fig.10V), rather than the hypoglossal nucleus (Fig.10X), where 
galanin-positive putative neurons could be found. In jun deficient SOD1G93A 
mice, little to no neurons positive for CD44 (Fig.10H&J), α7 (Fig.10M&O), β1 
(Fig.10R&T), or galanin were observed (Fig.10W&Y), in the facial (Fig.10H, M, 
R & W) or hypoglossal nuclei (Fig.10J, O, T & Y). 
In line with the observations above, neuronal quantifications revealed that jun 
deletion reduces the expression of axotomy markers in the facial (Fig. 11A) as 
well as the hypoglossal nuclei at end-stage (Fig.11B). The hypoglossal nuclei of 
SOD1G93A junf/f mice had significantly more neurons expressing CD44 (junf/f vs 
junΔN: 3.5± 0.9 vs 0.3±0.2), α7 (3.9±0.7 vs 0.1±0.1) or β1 (0.3±0.09 vs 0.08 
±0.08), than SOD1G93A junΔN mice (p<5%; using unpaired Student's T-test 
between SOD1G93A junf/f mice and SOD1G93A junΔN, at end-stage). In the same 
way, the facial nuclei of SOD1G93A junf/f mice had significantly more neurons 
expressing CD44 (junf/f vs junΔN: 2.4±0.9 vs 0.3±0.6), α7 (4.8±0.8 vs 1.0±0.8), 
β1 (0.3±0.1 vs 0.0±0.0), or galanin (0.2±0.06 vs 0.0±0.0), than SOD1G93A junΔN 
mice (p<5%; using unpaired Student's T-test between SOD1G93A junf/f mice and 
SOD1G93A junΔN, at end-stage). 
Magnitude of SOD1G93A mediated axotomy response correlates with the level 
of motor neuron degeneration 
To compare the axotomy response observed in SOD1G93A disease with that 
induced after peripheral nerve transection in wild type mice, specifically after 
facial nerve axotomy (FNA), a ratio of motor neurons expressing the different 
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axotomy response markers using the number of c-Jun-positive motor neurons 
as a baseline denominator, was calculated (Fig.11D). 
Of the total c-Jun-positive motor neuron population, the ventral horn of jun-
competent SOD1G93A mice contained approximately 70-90% motor neurons that 
expressed axotomy response markers α7 and CD44, at end-stage. However, in 
line with previous literature (Werner et al., 2000) and our current data (Fig. 9D), 
in the ventral horn of jun-competent SOD1G93A mice only a small proportion of 
the motor neurons undergoing an axotomy response expressed β1 at end-stage 
(15% of c-Jun+ population). The marker galanin was completely absent from 
motor neurons, as described by previous work on injured spinal motor neurons 
(Zhang et al., 1993). 
In contrast to the ventral horn of the spinal cord (Fig. 9B), the facial and 
hypoglossal nuclei of jun-competent SOD1G93A mice contained axotomy 
response markers – alpha7, beta 1 and CD44 – that, on average, were present 
on just 5-20% of the total c-Jun-positive motor neuron population (Fig. 10A&B). 
In addition, only the facial but not the hypoglossal nucleus of jun-competent 
SOD1G93A mice contained a very low number of galanin-immunoreactive motor 
neurons (Figs. 10A&B). In contrast, the percentage of motor neurons 
expressing axotomy related markers α7 (Fig. 9K) and CD44 (Fig. 9F), 14 days 
after facial nerve axotomy (FNA) mice was around 90% (Fig. 9D). These 
numbers were similar to those observed in the ventral horn of the spinal cord of 
end-stage jun-competent SOD1G93A mice, but about 5 times higher than those 
observed in the end-stage hypoglossal or facial nucleus of jun-competent 
SOD1G93A mice (Figs. 10A-B). Thus the proportion of motor neurons undergoing 
a disease-mediated axotomy response at end-stage is greater in the spinal cord 
than in the hypoglossal and facial nuclei. 
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Figure 10. Cranial motor neurons in SOD1G93A mice mount a jun dependent 
disease-mediated axotomy response, which was minute in comparison to that 
following nerve cut in wild type mice. (A-Y) Immunoreactivity for axotomy 
response markers [c-Jun, CD44, integrins α7 and beta 1, and neuropeptide 
galanin (galn)] in the facial nucleus (FAC) of: (first column) wild type mice, 14 
days after facial nerve cut (Ax 14 WT), which serves as a positive control for the 
immunostaining for the axotomy response markers in the facial nuclei of; 
(second column) jun-competent SOD1G93A mice at end-stage (SOD1 junf/f); and 
(third column) jun-deficient SOD1G93A mice at end-stage (SOD1 junΔN). The third 
and fourth columns demonstrate the hypoglossal nuclei (HYP) of jun-competent 
and jun-deficient SOD1G93A mice at end-stage, respectively. Observe the large 
number of facial motor neurons in WT mice, which are immunoreactive for the 
studied axotomy response markers, 14 days following axotomy (first column). 
Compare this to the very small number of immunoreactive motor neurons in the 
facial and hypoglossal nuclei of jun-competent SOD1G93A mice (second and 
fourth column, respectively). Note that neural deletion of jun abolishes c-Jun  
immunoreactivity and the presence of axotomy markers in the facial and 
hypoglossal nuclei of SOD1G93A mice (third and fifth column). Asterisks mark 
immunoreactive motoneurons magnified (x3) inset. Scale bar 300 µm. 
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Figure 11. Quantitative description of SOD1G93A mediated axotomy response 
and the effect of jun deletion. (A-B) Number of motor-neuron-like cellular 
profiles immunoreactive for axotomy response markers, in the hypoglossal (A; 
HYP) and facial nuclei (B; FAC) of SOD1G93A junf/f mice and SOD1G93A junΔN 
mice at end-stage (*p<5% using unpaired Student’s T-test between junf/f and 
junΔN groups, n=10 for junf/f and n=12 for junΔN). (C) Number of c-Jun positive 
motor neurons in the facial nucleus of wild type mice, 14 days after facial nerve 
cut (D14 FNA), and of jun-competent SOD1G93A mice (SOD1 junf/f), at end-
stage. (D) Proportion of motor neurons expressing axotomy response proteins 
out of the number of c-Jun positive motor neurons in: the facial nucleus of wild 
type mice 14 days after axotomy (green bars) and in jun competent SOD1G93A 
mice at end-stage (orange bars). (C&D) n=4 for D14 FNA and n=10 for SOD1 
jun f/f. 
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Discussion 
ALS is a neurodegenerative disease characterised by neuromuscular junction 
denervation, axonal loss, motor neuron death and associated 
neuroinflammatory changes (Boillee et al., 2006a). The transcription factor c-
Jun has been found upregulated in motor neurons affected by the disease 
(Jaarsma et al., 1996). To determine the functional role of c-Jun in ALS, the 
current study investigated the effect of neural deletion of the c-Jun gene (jun) on 
the SOD1G93A mouse model of ALS. This chapter shows that neural deletion of 
jun extends the lifespan of SOD1G93A mice and reduces disease associated 
motor neuron death, axonal loss and neuroinflammation. In addition, it 
describes a disease mediated axotomy response mounted by motor neurons in 
SOD1G93A mice that is dependent on jun. 
Generation of SOD1G93A mice lacking neural c-Jun 
The current study demonstrated that neural deletion of jun,mediated by the cre-
lox system, driven by the nestin promoter, abolishes the expression of c-Jun 
protein from neurons in SOD1G93A mice. 
To investigate the role of c-Jun in ALS mediated neurodegeneration triple 
transgenic mutant mice were generated. Three mouse strains were bred 
together to create a SOD1G93A mouse model of ALS which either expressed 
or did not express the murine jun gene. Each of the progenitor strains carried in 
their genome either: 1) multiple copies of ALS associated SOD1G93A transgene, 
2) endogenous murine jun alleles flanked by lox sites or 3) cre-recombinase 
gene driven by the nestin promoter. This type of genetic approach has been 
widely used in the past to elucidate the molecular pathways involved in ALS 
degeneration (Turner and Talbot, 2008). 
The 28 copy number SOD1G93A transgenic mouse was chosen for investigation 
because it is the most widely used animal model of ALS (McGoldrick et al., 
2013). The clinical and histopathological changes observed in this model 
closely resemble those observed in ALS (Gurney et al., 1994). In addition, these 
mice reach end-stage relatively early in their lives compared to other SOD1 
transgenic mouse models (Turner and Talbot, 2008). However, the 
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generalizability of this model has been criticised as the genetic mutation carried 
by these mice is only found in a small population of those affected with ALS 
(Benatar, 2007). Nonetheless, similar arguments can be made about other 
models of the disease e.g. ALS associate mutant TDP-43 transgenic mice. This 
model may be considered to be more generalizable since TDP-43 positive 
inclusions are found in almost all cases of ALS at post mortem (Mackenzie et 
al., 2010). However, the TDP-43 transgenic mouse models of ALS expresses 
mutations which are just as rare as SOD1G93A and the clinical and 
histopathological changes in these mice do not resemble ALS as closely as 
those seen in SOD1G93A mice (McGoldrick et al., 2013). Thus, despite the 
recent development of new animal models of ALS, the SOD1G93A mouse 
continues to be useful in ALS research (McGoldrick et al., 2013). 
The current study made use of neural specific jun conditional knock out mice 
previously described (Raivich et al., 2004). These mice use the cre-lox system 
driven by the nestin promoter to specifically and effectively remove the murine 
jun gene from neural cells. Phenotypically, jun deficient mice have normal motor 
behaviour as well as normal brain and nerve architecture (Raivich et al., 2004). 
The conditional method used to delete jun is necessary for in vivo studies since 
global deletion of jun is embryonically lethal (Hilberg et al., 1993, Johnson et al., 
1993, Behrens et al., 2002). Nestin, the promoter driving the deletion, is an 
intermediate filament protein primarily expressed by neural stem cells 
(Zimmerman et al., 1994). For this reason it has been widely used as a 
transgene expression promoter to mediate genetic changes within the nervous 
system (Tronche et al., 1999, Raivich et al., 2004). However, nestin is also 
expressed in other cell types (Zimmerman et al., 1994). Thus, the cre-lox 
system driven by the nestin promoter may result in the deletion of jun from a 
number of cell types in addition to neurons. These may include astrocytes, 
oligodendrocytes and their precursors which all have described roles in the 
process of ALS disease (Boillee et al., 2006a). It is therefore possible that any 
effects neural deletion of jun has on SOD1G93A mediated degeneration may be 
due to its effect on a number of cells including neurons. However, evidence 
from neuronal specific deletion of jun, driven by the synapsin promoter, 
suggests that the effects of neural deletion of jun on the response of motor 
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neuron to axonal injury are likely secondary to its deletion from neurons (Ruff et 
al., 2012). 
The effect of neural c-Jun on the survival of SOD1G93A mice 
The current study demonstrates that genetic deletion of neural jun significantly 
prolonged the lifespan of SOD1G93A mice. This effect was modest, with jun 
deficient SOD1G93A mice surviving 10 days longer than jun competent SOD1G93A 
mice. For ethical reasons, the clinical end point (end-stage) was defined as the 
onset of complete hind-limb paralysis. Using this definition, the mean lifespan of 
control jun competent SOD1G93A mice was measured to be approximately 104 
days. This falls within the range of survival-measures previously reported for the 
28 transgene copy SOD1G93A mice, which vary from 102 to 166 days 
(Heiman-Patterson et al., 2005, Heiman-Patterson et al., 2011). Nonetheless, 
the lifespans described in this study are at the lower end of this range. 
The relatively shorter lifespan of SOD1G93A mice reported in the current study 
may be explained by the unique genetic background of the mice used here. 
Genetic background affects the onset and progression of SOD1G93A associated 
disease in mice (Ludolph et al., 2010, Heiman-Patterson et al., 2011). The 
crossing of SOD1G93A mice in a B6/SJL background, with jun transgenic mice in 
a mainly B6 background but which originally had FVB and 129 background, 
might have accelerated the onset or progression of SOD1G93A mediated 
disease. In support of this, there is evidence that ALS associated mutant 
SOD1G93A mice in the FVB background have an average lifespan of around 107 
days, close to what is reported here (Heiman-Patterson et al., 2011). 
The definition of clinical end point is another factor which can affect the 
measure of survival. Over 20 different definitions of humane end points have 
been used in the past to determine SOD1G93A mouse survival, and these are 
thought to be responsible for the wide range of reported lifespans (Scott et al., 
2008, Ludolph et al., 2010). The use of a universal definition for a humane end 
point to measure survival in SOD1 mutant mice has been suggested (Scott et 
al., 2008, Ludolph et al., 2010, Niessen et al., 2006). It is suggested that end-
stage should be defined as the time at which an animal cannot no longer right 
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itself within 30 seconds after being placed on its side (Scott et al., 2008, 
Ludolph et al., 2010). The majority of previously published studies, which report 
on survival, have used this righting reflex definition of end-stage (Scott et al., 
2008, Ludolph et al., 2010). This postural reflex can be achieved by either upper 
or lower limbs (Tupper and Wallace, 1980). Thus it is possible that the clinical 
end point used in the current study may have underestimate lifespan because it 
took into account only lower limb function. 
The current study reports that jun deletion extends the lifespan of SOD1G93A 
mice. Effects of therapeutic interventions on survival can be confounded by a 
number of factors, including: genetic background, gender, and SOD1G93A 
transgene copy number (Scott et al., 2008, Ludolph et al., 2010). The design of 
the current study controls for some of these factors. Differences in genetic 
background were unlikely to occur as jun deficient SOD1G93A mice were 
compared to their littermate jun competent SOD1G93A control mice. Confounding 
effects due to gender are also unlikely, since animal groups were gender 
matched. It is important to note that although previous groups have reported 
gender effects on survival, the presence of these depend on genetic 
background (Heiman-Patterson et al., 2011). In line with this, statistical analysis 
failed to demonstrate an effect of gender on SOD1G93A mouse survival.  
Drop in SOD1G93A transgene copy number can occur in the mutant mice used in 
this study and it is known to affect survival (Scott et al., 2008, Ludolph et al., 
2010). The lifespan of mice carrying a low number of transgene copies has 
been reported to be at least 40% to 140% greater than those carrying a high 
number (Ludolph et al., 2010). In the current study, transgene copy number was 
not quantified and potentially could have confounded the survival data. 
However, the difference in lifespan between the shortest-surviving and longest-
surviving mouse in either group was very similar, 24 days for jun-competent and 
25 for jun-deficient SOD1G93A mice. This equates to a maximum increase in 
survival of only 27% if the longest-surviving mouse was compared to shortest-
surviving mouse in each group. This is below what would be expected if 
transgene copy number had affected survival in at least one of the mice. Thus, 
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it seems unlikely that either of the groups were biased by a drop in transgene 
number. 
The increase in measured survival due to jun deletion may be secondary to a 
delay in the onset of disease or the slowing of disease progression. Commonly, 
onset of disease is measured as the time by which mice develop first signs of 
tremor and hind-limb splay defects or a reduction in rotarod performance 
(Ludolph et al., 2010). However, the current study did not use a clinical measure 
to determine disease onset or whether prolonged survival was accompanied by 
effects on motor behaviour. 
Inflammatory changes in SOD1G93A mice deficient of c-Jun 
The current study demonstrates that deletion of neural jun attenuates the 
neuroinflammation associated with disease in SOD1G93A mice. This is 
consistent with previous studies which have shown that neural or neuron 
specific deletion of jun significantly diminishes the inflammatory response after 
axotomy (Raivich et al., 2004, Ruff et al., 2012). Deletion of neural jun reduces 
early and late microglia activation, as well as late astrocyte activation and T-cell 
recruitment around axotomised motor neurons following facial nerve transection 
(Raivich et al., 2004). Similar effects are observed in the current study, with 
reduced formation of perineuronal microglia clusters in the spinal cord of 
SOD1G93A mice in early (day 70) and end-stages of the disease, as well as, 
reduced astrocyte activation and T-cell recruitment at end-stage.  
It has been previously suggested (Raivich et al., 2004), that neural deletion of 
jun might affect neuroinflammation through two mechanisms, each working at 
different stages of the neuronal response to injury. The early stage mechanism 
may involve a reduced production of jun-dependent pro-inflammatory cytokines 
in the absence of tissue damage. While, the late stage mechanism may involve 
the reduced presence of pro-inflammatory neural debris secondary to the 
attenuation of jun-dependent neuronal cell death (Raivich et al., 2004). These 
two stages fit well with the description of alternative (M2) and classic (M1) 
activation of microglia continuum. M2 describes an anti-inflammatory microglial 
response that is neuroprotective and M1 a pro-inflammatory microglial response 
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that is neurotoxic (Buechler et al., 2000, Gordon and Martinez, 2010, 
Tiemessen and Kuhn, 2007). 
In the current study, microglia activation was assessed by the quantification of 
alpha M immunoreactivity and microglia cluster formation. Although not formally 
assessed, these two measures may represent M2 and M1 activation. On the 
one hand, the early microglial activation measured by levels of alpha M 
immunoreactivity may best quantify M2 microglia activation at day 70 in the 
spinal cord of SOD1G93A mice were mild microglial changes with no motor 
neuron cell loss have occurred. On the other hand, microglia cluster counts may 
represent M1 activation as they dramatically increase at end stage in the spinal 
cord of SOD1G93A mice. Interestingly, alpha M immunoreactivity was not 
affected by neural jun deletion at day 70 or end stage but microglia cluster 
formation was at both time points. This suggests the neural jun may not be 
involved in M2 microglia activation but plays an important role in M1 activation 
in SOD1G93A mice. 
In the current study, the T-cell pan marker CD3 was used to identify T-cell 
infiltration, however the CD4/CD8 identity of this infiltration was not assessed. 
As with microglia, T-cells appear to have both anti and pro-inflammatory 
functions in SOD1G93A mouse disease (Beers et al., 2011, Banerjee et al., 2008) 
and may be functionally divided into T helper cells (CD4+) and cytotoxic T cells 
(CD8+).The infiltration of T-cells into the ventral horn of the spinal cord of 
SOD1G93A mice occurs with increasing numbers as the disease progresses 
(Beers et al., 2008). In the early stages only CD4+ cells can be found in the 
spinal cord of SOD1G93A mice. By end stage an influx of CD8+ cytotoxic T-cells 
is found in the spinal cord of SOD1G93A mice (Beers et al., 2008). However, it is 
important to recognise that the majority of T-cells found in the spinal cord of 
SOD1G93A mice at all stages of the disease are CD4+ (Beers et al., 2008). 
CD4+ T-cells have been subdivided into two groups: regulatory (tregs; 
CD4+CD25HighFoxP3) and effector (teffs; CD4+CD25-). Interestingly, tregs have 
been found to influence ALS disease progression in human cases and mice, 
with reduced number of tregs being associated with rapidly progressing disease 
in both species (Beers et al., 2011, Henkel et al., 2013). Recent studies have 
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shown that tregs directly steer the differentiation of macrophages and microglia 
toward the M2 activation state and that teffs promote the M1 microglial 
activation state (Li et al., 2010, Liu et al., 2011, Mahnke et al., 2007, Reynolds 
et al., 2009). Furthermore, in SOD1G93A mice the number of tregs decreases 
while the number of teffs increases as disease progresses (Beers et al., 2011). 
As both late (M1) microglia activation and T-cell infiltration are decreased by 
neural jun deletion in SOD1G93A mice, it may be important to characterise the 
immunopathological signature in more detail. Subtyping the T-cells infiltrate, 
characterising the microglia activation state (M1/M2), and analysing pro and 
anti-inflammatory gene expression in the spinal cord of SOD1G93A jun deficient 
mice, may help identify the mechanism by which the deletion of neural jun 
mediates reduced neuroinflammation in SOD1G93A mice. 
Motor neurons survive in the CNS of c-Jun deficient SOD1G93A mice  
The current study demonstrates that neural deletion of jun reduces motor 
neuron loss in SOD1G93A mice. This is line with previous studies which show 
that neural or neuronal jun deletion protects motor neurons from axotomy 
induced death (Raivich et al., 2004). However, the protective effect of jun 
deletion on SOD1G93A mediated motor neuron loss, reported here, was only 
28%, which is smaller than the 72% neuroprotective effect reported following 
axotomy (Raivich et al., 2004). This suggests that the mechanism driving motor 
neuron cell loss in SOD1G93A mice is different from that of promoting motor 
neuron death following axonal injury. Axotomy induced motor neuron death is 
associated with the induction of the TNFR1 death receptor pathway in wild type 
mice (Haulcomb et al., 2014). In contrast, axotomy in SOD1G93A, which results 
in exacerbated axotomy induced death, activates the Fas death pathway more 
strongly than the TNFR1 pathway (Haulcomb et al., 2014). Activation of the Fas 
pathway has been suggested as a mechanism specific for motor neuron cell 
death in ALS (Raoul et al., 2002; Holasek et al., 2005). In addition, genetic 
inhibition of the Fas pathway increases survival and reduces motor neuron cell 
death in SOD1G93A mice (Petri et al., 2006). It is important to note that c-Jun 
regulates expression of the Fas gene (Ivanov et al., 2002). Thus, the 
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neuroprotection mediated by neural deletion of jun may be secondary to 
inhibitory effects on the Fas pathway. 
The neuroprotective effect of jun deletion was modest, demonstrating that motor 
neuron loss is not completely dependent on jun expression. Gould et al. (2006) 
reported that SOD1G93A mediated motor neuron death is completely abolished 
by genetic deletion of the BAX gene in mice. Thus, the neuroprotection provided 
by jun deletion is likely to represent an upstream effect on the BAX pathway, 
that delays, rather than prevents motor neuron cell loss. In support of this, c-Jun 
is known to regulate the expression of Bim, which itself regulates BAX (Whitfield 
et al., 2001). However, c-Jun is only one of the many regulatory proteins of the 
BAX pathway (Whitfield et al., 2001). 
The ALS disease process is associated with progressive motor neuron atrophy 
(Gould et al., 2006, Kiernan and Hudson, 1993). In the current study, neural 
deletion of jun failed to protect motor neurons from SOD1G93A disease 
associated atrophy. This suggests that the motor neuron atrophy in SOD1G93A 
mice is not driven by jun. It has been previously suggested that motor neuron 
atrophy is driven by the loss of peripheral trophic support due to the denervation 
of motor neuron targets (Farah et al., 2003, Dasuri et al., 2013). Neural deletion 
of jun prevents axonal regeneration and target reinnervation following axotomy 
and therefore is unlikely to prevent atrophy in SOD1G93A mice (Raivich et al., 
2004). In fact it is important to note, that the neuroprotective effect of jun 
deletion following axotomy is associated with marked atrophy of surviving 
neurons (Raivich et al., 2004). Therefore, jun deletion could have exacerbated 
motor neuron atrophy in the SOD1G93A mouse. However, although jun deficient 
SOD1G93A mice reached end-stage with a greater number of motor neurons 
than jun competent mice, surviving motor neurons in both groups had similar 
cell body diameters. 
Axonal loss in c-Jun-deficient SOD1G93A mice 
In the current study, jun deletion was associated with reduced axonal loss in 
SOD1G93A mice. This effect was observed both at the pre-symptomatic time 
point and end-stage. There is currently no evidence to suggest that jun plays a 
direct role in axonal degeneration. The maintenance of axon structure depends 
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on axonal transport. SOD1G93A mediated disease is characterised by 
compromised axonal transport (Boillee et al., 2006a). Interventions that reduce 
the burden on axonal transport, such as genetic removal of neurofilaments 
(Nguyen et al., 2001), have been associated with decreased neurodegeneration 
and improved survival in SOD1 mutant mice (Boillee et al., 2006a). There is 
evidence of a regenerative effort in ALS and SOD1G93A mice, characterised by 
axonal sprouting (Fischer and Glass, 2007, Gordon et al., 2004, Frey et al., 
2000b). Such regenerative efforts would invariably cause a burden on axonal 
transport. Deletion of jun is known to dramatically reduce axonal regeneration 
following axotomy (Raivich et al., 2004). Thus, it is possible that jun deletion 
may curtail the axonal regenerative efforts mounted by SOD1G93A mice and in 
this way reduce axonal degeneration and loss. To determine whether jun 
deletion does reduce the axonal regenerative effort in SOD1G93A mice, axonal 
sprouting could be investigated. 
Neuromuscular junction dennervation in c-Jun deficient SOD1G93A mice 
Previous studies have suggested that loss of NMJ innervation is the 
predominant pathological feature driving disease in SOD1G93A mice (Fischer et 
al., 2004, Gould et al., 2006). In the current study, SOD1G93A mice reached end-
stage with the same level of neuromuscular junction innervation independent of 
jun deletion. Here, end-stage was defined as the onset of complete hind limb 
paralysis. Since motor function depends on NMJ innervation, the fact that there 
was no difference in NMJ innervation at end-stage between SOD1G93A mice 
irrespective of jun deletion, is unsurprising. It is important to note that SODG93A 
mice lacking neural jun reached end-stage with a greater numbers of motor 
neurons and axons compared to jun competent mice. This is in line with 
previous evidence which demonstrates that NMJ denervation precedes or 
occurs independently of pathological changes at the nerve or motor neuron 
level (Fischer et al., 2004, Gould et al., 2006, Pun et al., 2006). In fact, when 
motor neuron death in SOD1G93A mice is completely abolished by genetic 
deletion of BAX, end-stage is reached with the same level of NMJ innervation 
irrespective of BAX deletion (Gould et al., 2006). However, the evidence 
presented in the current studies does not exclude the possibility that jun 
deletion may affect NMJ innervation in wild type mice or in SOD1G93A mice at 
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earlier time points. Assessment of the effect of jun deletion on NMJ innervation 
in wild type mice and day 70 SOD1G93A mice may shed light on this. 
The axotomy response in motor neurons of SOD1G93A mice 
The current study demonstrates that neurons in SOD1G93A mice mount a 
disease mediated axotomy response. This response was characterised by the 
expression of regeneration-associated proteins in neurons of the ventral horn of 
the spinal cord, hypoglossal and facial nuclei of SOD1G93A mice. Pro-
regenerative efforts have been previous described in human cases of ALS and 
SOD1G93A mice (Fischer and Glass, 2007, Gordon et al., 2004, Frey et al., 
2000b). However, there is little evidence on pro-regenerative changes at the 
level of motor neuron cell body. Nonetheless, previous neuropathological 
studies of ALS cases have suggested that motor neurons undergo 
chromatolysis, which is a morphological feature of the normal axotomy 
response (Kiernan and Hudson, 1993). In addition, a recent study has 
demonstrated that motor neurons from the facial nucleus of SOD1G93A mice 
upregulate mRNA of pro-regenerative genes, namely GAP-43 and βII-Tubulin 
(Haulcomb et al., 2014). In the current study, neurons were found to be 
immunoreactive for the pro-regenerative proteins c-Jun, CD44, alpha7 and 
beta1 integrins. These proteins are expressed the novo or upregulated in motor 
neurons in response to axotomy and have described functional roles in axonal 
regeneration (Raivich et al., 2004). 
The present study shows that the disease mediated axotomy response 
observed in SOD1G93A mice is dependent on the expression of jun. It has been 
previously demonstrated that the molecular response of facial motor neurons to 
axotomy is dramatically reduced in mice when neural jun is deleted (Raivich et 
al., 2004). In line with this, neural deletion of jun significantly reduced the 
expression of axotomy associated proteins in the ventral horn of the spinal cord, 
hypoglossal nucleus and facial nucleus. The similarity between the molecular 
responses seen in SOD1G93A mice and following peripheral nerve axotomy in 
wild type mice, suggests that the upregulation of regeneration associated 
proteins by neurons in SOD1G93A mice may indeed represent a disease 
associate axotomy response. 
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The apparent magnitude of the axotomy response observed in SOD1G93A mice 
correlates with the level of motor neuron loss in different motor neuron pools. 
Motor neuron degeneration in ALS cases and SOD1G93A mice has been 
described to occur at different rates in different neuroanatomical areas (Ravits 
and La Spada, 2009, Haenggeli and Kato, 2002). In line with previous evidence 
(Haenggeli and Kato, 2002), the present study demonstrates that the level of 
motor neuron loss was severe in the spinal cord, moderate in the hypoglossal 
nucleus and not detectable in the facial motor nucleus of jun-competent 
SOD1G93A mice. Interestingly, the level of axotomy response in these motor 
neuron pools correlated well with the levels of motor neuron loss. Furthermore, 
the axotomy response was almost absent at the pre-symptomatic stage were no 
motor neuron loss was observed. This suggests that the disease mediated 
axotomy response mounted by surviving motor neurons in SOD1G93A mice, may 
represent a last ditch attempt at survival prompted by severe motor neuron 
injury occurring before cell death. 
Finally, in line with the observation made in the spinal cord, neural jun deletion 
prevented motor neuron loss and reduced neuroinflammation in the hypoglossal 
nucleus and in the facial nucleus, of end-stage SOD1G93A mice. This suggests 
that the role of jun in SOD1G93A mediated neurodegeneration observed in the 
spinal cord is generalizable to different motor neuron pools. Thus, therapeutic 
intervention targeting jun may ameliorate ALS neurodegeneration in the 
different motor neuron pools which are affected in humans and rodent disease. 
Limitations 
The effects of neural jun deletion on the motor function and weight SOD1G93A 
mice was not assessed. Rotarod performance could be used to determine 
whether jun deletion affected motor function and weight could be used to 
determine overall effect on disease progression. These measures may permit 
determining whether jun deletion delayed onset of disease. Data from such 
assessment would help determine if prolonged survival in jun deficient 
SOD1G93A mice was secondary to an effect on disease onset. 
The current study fails to describe the cellular localisation of c-Jun expression in 
the central nervous system of jun-competent or jun-deficient SOD1G93A mice. 
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Double immunofluorescent labelling for c-Jun and markers for neurons, 
astrocytes, oligodendrocytes, oligodendrocyte precursor cell, microglia or 
myocytes in jun competent or jun deficient SOD1G93A mouse tissue could be 
carried out. Analysis of this would clarify which cell type is responsible for the 
effects jun deletion, driven by the nestin promoter, has on SOD1G93A mediated 
disease. 
Data on the effect of jun deletion on neuroinflammatory markers, neuromuscular 
junction innervation and the expression of axotomy related proteins in mice 
lacking the SOD1G93A transgene is absent. Obtaining such data would validate 
the conclusion formed in this study. 
The observations made regarding axotomy related proteins requires the 
identification of the cells expressing these proteins. Double immunofluorescent 
labelling for the different axotomy related proteins and markers for neurons, 
astrocytes, oligodendrocytes, oligodendrocyte precursor cell and microglia 
should be carried out. Analysis would confirm that the expression of axotomy 
related proteins is indeed neuronal. 
Conclusion  
Neural deletion of the transcription factor c-Jun prolongs the lifespan of 
SOD1G93A mice and reduces disease associated motor neuron death, axonal 
loss and neuroinflammation. Interestingly, in addition to the described 
neuropathological changes, SOD1G93A mice also demonstrate a disease 
mediated axotomy response, which is mounted by motor neurons in late stage 
disease and which depends on c-Jun. In light of the critical role of c-Jun in 
peripheral nerve regeneration, the observed axotomy response in SOD1G93A 
mice is likely to be a regenerative effort mounted by motor neurons in a last 
ditch attempt to recover physiological function. 
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Chapter 4: Nuclear clearing of ALS associated proteins 
following peripheral nerve axotomy 
Introduction 
Familial ALS is associated with mutations in TDP-43, FUS and alsin genes 
(Andersen and Al-Chalabi, 2011). Histopathological studies of ALS cases have 
demonstrated changes in the pattern of immunoreactivity for TDP-43 and FUS 
protein in degenerating motor neurons (Neumann et al., 2006, Neumann et al., 
2009). These include the clearing of normally nuclear staining and presence of 
immunoreactive cytoplasmic inclusions (Neumann et al., 2006, Neumann et al., 
2009). The role of such changes in ALS degeneration and the functions of TDP-
43, FUS and alsin in motor neurons remain elusive. 
Peripheral nerve injury is associated with a molecular response within the 
injured neuron which can culminate in either axonal regeneration and survival, 
or degeneration and death (Patodia and Raivich, 2012a). This response is 
orchestrated by changes in gene expression which involve the up-regulation of 
cytoskeletal proteins, cell adhesion molecules, and growth and cell death 
associated genes (Patodia and Raivich, 2012a). Transcription factors play a 
central role in driving these changes (Patodia and Raivich, 2012b). For 
example, c-Jun, which is found upregulated in motor neuron cell nuclei following 
axotomy, plays a crucial role in the response to axonal injury (Raivich et al., 
2004, Ruff et al., 2012). Its genetic deletion from neurons results in impaired 
axonal regeneration and functional recovery but abolishes motor neuron death 
following facial nerve transection in mice (Raivich et al., 2004, Ruff et al., 2012). 
Some of the cellular and molecular changes that occur in ALS resemble those 
observed following axonal injury (Dadon-Nachum et al., 2011, Fischer et al., 
2004). Interestingly, as well as playing a role in ALS, TDP-43, FUS and alsin 
are all involved in processes related to the neuronal response to axonal injury 
(Hadjebi et al., 2008, Li et al., 2013a). TDP-43 and FUS are involved in gene 
transcription and translation (Li et al., 2013a), while alsin has roles in retrograde 
signalling and growth cone dynamics (Hadjebi et al., 2008). However, the roles 
of these ALS associated proteins in the response to axonal injury have not yet 
been characterised. 
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The aim of this chapter is to describe the pattern of immunoreactivity for TDP-
43, FUS and alsin following axonal injury, using the facial nerve axotomy model. 
It reports the immunoreactivity changes that occur over time following facial 
nerve transection. It also describes the effects different severities of axonal 
injury have on the immunoreactivity of TDP-43 and alsin. 
Results 
Time course of TDP-43 immunoreactivity in regenerating facial motor nucleus 
Peripheral nerve transection produces protein changes within axotomised 
neurons which can be associated with regenerative and degenerative 
processes (Patodia and Raivich, 2012a). TDP-43 is a ubiquitously expressed 
nuclear protein involved in gene transcription and mRNA translation (Li et al., 
2013a). In ALS, TDP-43 protein is found to leave its nuclear location and form 
cytoplasmic inclusions within motor neurons (Neumann et al., 2006). To 
investigate the pattern of TDP-43 immunoreactivity following peripheral nerve 
axotomy, C57BL/6 mice underwent a unilateral facial nerve transection and 
were allowed to survive for 0, 1, 4, 7, 14, 21, and 42 days following axotomy 
(n=4 per time point). Coronal sections through the facial motor nuclei of these 
animals underwent immunohistochemistry for TDP-43 protein and were 
analysed using light microscopy. 
TDP-43 immunoreactivity in the uninjured facial nucleus was mainly confined to 
the nuclei of motor neurons and surrounding glial cells (Fig. 1 left column). 
Some weak immunoreactivity was also observed in the cytoplasm of these two 
cell types (Fig. 1A). However, transection of the facial nerve resulted in a strong 
increase in TDP-43 immunoreactivity in the axotomised facial motor nucleus 
(Fig. 1), starting at day 4 (Fig. 1F) and reaching a peak at day 7 after injury (Fig. 
1H). This apparent rise in overall immunoreactivity was associated with clearing 
of TDP-43 staining from the nuclei of injured motor neurons which started at day 
7 (Fig. 1H insert) and was most obvious at day 14 (Fig. 1J insert). Nuclear 
clearing was accompanied by a marked increase in diffuse cytoplasmic staining 
which extended to the dendrites of axotomised neurons (Fig. 1H&J inserts). At 
day 14, TDP-43 immunoreactivity was also found in perineuronal sprouts (Fig. 
1J bottom insert). Cytoplasmic and neurite TDP-43 staining diminished from day 
21 post facial nerve transection and gave way to increasing nuclear staining 
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(Fig. 1M insert). By day 42, the pattern of TDP-43 staining returned to that 
observed in uninjured motor neurons (Fig, 1M and N). 
Optical luminosity quantifications (Fig. 2) demonstrated that uninjured facial 
nuclei had steady levels of TDP-43 immunoreactivity at all time-points studied. 
In contrast, a peak in TDP-43 immunoreactivity was confirmed at day 7 after 
axotomy. This was followed by a decline to baseline levels by day 42. TDP-43 
optical luminosity levels were higher in the axotomised compared to uninjured 
facial nuclei from day 2 up to day 21. However, the difference was only 
statistically significant at day 7 (p<5%; using unpaired Student's T-test between 
control facial motor nuclei (FMN) and axotomy FMN, at day 7), with TDP-43 
immunoreactivity levels that were 57% higher in the axotomised facial nuclei 
compared to the non-injured facial nucleus. 
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Figure 1: TDP-43 immunoreactivity increases in the facial nucleus after facial 
nerve injury. Coronal sections through the uninjured (Co) and injured (Ax) facial 
motor nucleus at 0 (A&B), 1 (C&D), 4 (E&F), 7 (G&H), 14 (I&J), 21 (K&L), and 
42 days (M&N) after facial nerve transection. Sections were immunostained for 
TDP-43. From day 4 to day 28, there is more TDP-43 immunostaining in the 
injured facial motor nucleus compared to the uninjured (Co) facial motor 
nucleus. Bar scale represent 100um. High magnification inserts show that at 7 
(G) and 14 days (I) after facial nerve injury TDP-43 nuclear staining is absent. 
However, TDP-43 immunostaining returns to the nucleus at 21 days after facial 
nerve injury (K). At day 14, staining is also evident in neuronal sprouts (green 
arrow). Neurons of the uninjured facial motor nucleus show strong nucleic 
staining at all time-points post injury. Bar scale represents 50um. 
 
 
 
 
Figure 2. Quantitative analysis of TDP-43 immunoreactivity following peripheral 
nerve transection. Line graph showing the mean TDP-43 immunoreactivity, 
quantified using the MEAN-SD algorithm, at 0, 1, 4, 7, 14, 21 and 42 days after 
facial nerve injury. Black and white circles represent quantifications of uninjured 
(Co) and axotomised (Ax) facial nucleus, respectively. *p<5% using unpaired 
Student’s T-test between uninjured and injured groups. n=4 for both groups. 
(OLV: Optical Luminosity Values) 
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 Time-course of Alsin immunoreactivity after facial nerve injury. 
Alsin is 1657 amino acid protein encoded by the ALS associated gene ALS2. Its 
known functions in retrograde signalling and growth cone dynamics suggest a 
potential role in the response to axonal injury (Tudor et al., 2005, Hadano et al., 
2010). To study the pattern of Alsin immunoreactivity following peripheral nerve 
axotomy, C57BL/6 mice underwent a unilateral facial nerve transection and 
were allowed to survive for 0, 1, 4, 7, 14, 21, and 42 days following axotomy 
(n=4 per time point). Coronal sections through the facial motor nuclei of these 
animals underwent immunohistochemistry for Alsin protein and were analysed 
using light microscopy. 
Alsin immunoreactivity in the uninjured facial nucleus was confined to the nuclei 
of motor neurons (Fig. 3 left column). Staining was strong in the nucleus but 
absent from the cytoplasm (Fig. 3C). Transection of the facial nerve resulted in 
markedly diminished nuclear staining, which started at day 4 (Fig. 3D insert) 
and was most obvious at day 7 (Fig. 3F insert). Nuclear clearing was not 
associated with changes in cytoplasmic immunoreactivity (Fig. 3D&F). Nuclear 
alsin immunoreactivity began to return to normal at day 14 (Fig. 3H insert) after 
axotomy and reached pre-injury levels at day 21 (Fig. 3K&L). 
Quantification of nuclear alsin immunoreactivity (Fig. 4) demonstrated that the 
uninjured facial nuclei had steady levels at all time-points studied. In contrast, a 
trough in nuclear immunoreactivity was confirmed at day 7 after axotomy. This 
was followed by an increase to baseline levels at day 21. Nuclear 
immunoreactivity levels for alsin were significantly lower in the axotomised 
compared to uninjured nuclei from day 4 up to day 14 (p<5%; using unpaired 
Student's T-test between control FMN and axotomy FMN, at day 4 to 14). 
However, the difference was greatest at day 7, with levels of nuclear 
immunoreactivity being around 60% lower in the axotomised facial nuclei 
compared to the non-injured facial nucleus. 
169 
 
 
170 
 
Figure 3: Alsin immunoreactivity decreases in the nuclei of neurons of the facial 
motor nucleus after facial nerve injury. Coronal sections through the uninjured 
(Co) and injured (Ax) facial motor nucleus at 0 (A&B), 1 (C&D), 4 (E&F), 7 
(G&H), 14 (I&J), 21 (K&L), and 42 (M&N) after facial nerve transection. Sections 
were immunostained for alsin. From day 4 to 14 after facial nerve injury, there is 
less nuclear alsin immunostaining in the injured facial motor nucleus compared 
to the uninjured (Co) facial motor nucleus. Bar scale represents 100um. High 
magnification inserts show that Alsin staining is nucleic in neurons of the injured 
(D, F, H, J) and uninjured facial motor nucleus (C, E, G, I). Neurons of the 
uninjured facial motor nucleus show strong nucleic staining at all time-points 
post injury. Bar scale represents 25um. 
 
 
 
 
Figure 4. Quantitative analysis of nuclear alsin immunoreactivity following 
peripheral nerve transection. Line graph showing nuclear alsin 
immunoreactivity, quantified using a variation of the MEAN-SD algorithm, at 0, 
1, 4, 7, 14, 21 and 42 days after facial nerve injury. Black and white circles 
represent quantifications of uninjured (Co) and axotomised (Ax) facial nucleus, 
respectively. *p<5% using unpaired Student’s T-test between uninjured and 
injured groups. n=4 for both groups. 
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Time course of FUS immunoreactivity in regenerating facial motor nucleus 
FUS is a 526 amino acid protein which has roles in gene transcription and 
translation (Li et al., 2013a). It is ubiquitously expressed and normally found in 
the nucleus, but can shuttle between the nucleus and cytoplasm (Li et al., 
2013a). Mutations in the FUS gene are associated with familial ALS (Andersen 
and Al-Chalabi, 2011). In addition, abnormal patterns of FUS immunoreactivity 
have been described in motor neurons of ALS cases (Neumann et al., 2009). 
To study the pattern of FUS immunoreactivity following peripheral nerve 
axotomy, C57BL/6 mice underwent a unilateral facial nerve transection and 
were allowed to survive for 0, 1, 4, 7, 14, 21, and 42 days following axotomy 
(n=4 per time point). Coronal sections through the facial motor nuclei of these 
animals underwent immunofluorescent labelling for FUS protein and analysis 
with confocal microscopy. 
FUS immunoreactivity in the uninjured facial nucleus was mainly restricted to 
the nuclei of motor neurons and surrounding glial cells (Fig. 5 left column). 
Some weak immunoreactivity was also observed in the cytoplasm of both of 
these cell types (Fig. 5 left column). Transection of the facial nerve resulted in a 
modest decrease in nuclear FUS immunoreactivity at 14 days after injury (Fig. 
5H insert). This reduction was still discernible at day 21 (Fig. 5J insert). 
However, FUS nuclear staining returned to baseline at day 42 (Fig. 5N). 
Quantification demonstrated that nuclear FUS immunofluorescence in the intact 
facial nuclei was similar at all time-points studied. In contrast, injured motor 
neurons showed a drop in FUS immunofluorescence, which started at day 14 
after injury and was followed by a return to baseline at day 42. Nuclear FUS 
immunofluorescence levels were lower in the axotomised compared to 
uninjured nuclei at day 14 and 21. However, the difference was only statistically 
significant at day 14 (p<5%; using unpaired Student's T-test between control 
FMN and axotomy FMN, at day 14), with levels of FUS immunofluorescence 
being around 20% lower in the axotomised facial nuclei compared to the non-
injured facial nucleus. 
172 
 
 
173 
 
Figure 5: Nuclear FUS immunofluoresence decreases in the nuclei of neurons 
of the facial motor nucleus after facial nerve injury. Coronal sections through the 
uninjured (Co) and injured (Ax) facial motor nucleus at 0 (A&B), 1 (C&D), 4 
(E&F), 7 (G&H), 14 (I&J), 21 (K&L), and 42 days (M&N) after facial nerve 
transection. Sections are immunofluorescently labelled for FUS. Labelling was 
evident in the nuclei of glial and neuronal cells in both injured and uninjured 
facial motor nucleus at all time-points. Bar scale represents 100um. Inserts 
(J&L) show that from day 14 to day 21 after facial nerve injury, there is less 
nuclear FUS labelling in axotomised motor neurons compared to the uninjured 
ones (I&K). Bar scale represents 25um. Cells of the uninjured facial motor 
nucleus show strong neuronal nuclei staining at all time-points post injury. 
 
 
 
 
Figure 6. Quantitative analysis of nuclear FUS immunoreactivity following 
peripheral nerve transection. Line graph showing nuclear FUS 
immunoreactivity, quantified using a variation of the MEAN-SD algorithm, at 0, 
1, 4, 7, 14, 21 and 42 days after facial nerve injury. Black and white circles 
represent quantifications of uninjured (Co) and axotomised (Ax) facial nucleus, 
respectively. *p<5% using unpaired Student’s T-test between uninjured and 
injured groups. n=4 for both groups. 
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Effects of injury severity on TDP-43 and Alsin immunoreactivity 
Severity of axonal injury is known to affect the cellular and molecular response 
to axotomy (Makwana et al., 2010). To investigate whether severity of nerve 
injury affects axotomy-induced changes in TDP-43 and alsin immunoreactivity, 
C57BL/6 mice underwent either a unilateral facial nerve transection or crush, 
and were allowed to survive for 7, 10, and 14 following axotomy (n=3 per time 
point). Coronal sections through the facial motor nuclei of these animals 
underwent immunohistochemistry for TDP-43 or alsin protein and were 
analysed using light microscopy. 
TDP-43 
Ten days after facial nerve cut (Fig. 7C) or crush (Fig. 7B) injuries, the motor 
neurons within the facial nucleus demonstrated nuclear clearing of TDP-43 
staining, which was associated with pronounced TDP-43 staining in the 
cytoplasm. Optical luminosity quantifications (Fig. 7A) showed that TDP-43 
immunoreactivity in the injured facial nucleus was greater after nerve cut rather 
than after nerve crush at all time-points after injury. However, the difference 
between cut and crush injury was only statistically significant at day 10 (p<5%; 
using unpaired Student's T-test between cut and crush injury, at day 10). At this 
time point, nerve cut resulted in an increase in TDP-43 immunoreactivity which 
was about 40% greater than that caused by nerve crush.  
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Figure 7. Facial nerve cut produces greater axotomy induced changes in TDP-
43 immunoreactivity than crush. (A) Quantitative analysis of TDP-43 
immunoreactivity following peripheral nerve injury. Histograms show the 
difference between TDP-43 immunoreactivity in the facial nuclei ipsilateral to a 
nerve cut or crush injury, which was quantified using the MEAN-SD algorithm, 
at 7, 10 and 14 days after facial nerve injury. Grey and black bars represent 
quantifications of crush and cut, respectively. *p<5% using unpaired Student’s 
T-test between crush and cut groups. n=3 for both groups. (B&C) Coronal 
sections through the injured facial motor nucleus at day 10 after facial nerve 
crush (B) or cut (C). Sections were immunostained for TDP-43. TDP-43 
immunostaining appears stronger in the cut facial nucleus (C) compared to 
crush (B) Bar scale represents 100um. High magnification inserts show that 
nerve cut (C insert) results in more obvious TDP-43 nuclear clearing and 
increased cytoplasmic staining compared to crush (B insert). Bar scale 
represents 50um. 
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Alsin 
Ten days after facial nerve cut (Fig. 8C) or crush (Fig. 8B) injuries, the facial 
motor neurons demonstrated Alsin staining confined to the cellular nucleus 
rather than the cytoplasm. Nuclear alsin immunoreactivity quantifications (Fig. 
8A) revealed that the levels of alsin immunoreactivity was similar at 7, 14 or 21 
days after a cut or crush injuries. At all studied time-points nuclear alsin 
immunoreactivity was greater after cut rather than after nerve crush injury. 
However, the difference between cut and crush injury was only statistically 
significant at day 10 (p<5%; using unpaired Student's T-test between cut and 
crush injury, at day 10). At this time point, nerve cut resulted in clearing of 
nuclear alsin immunoreactivity which was around 80% greater than that caused 
by nerve crush. 
 
 
 
Figure 8. Facial nerve cut produces greater axotomy induced changes in alsin 
immunoreactivity than crush. (A) Quantitative analysis of alsin immunoreactivity 
following peripheral nerve transection. Histograms show the difference between 
the immunoreactivity of alsin in the nucleus of facial motor neurons that have 
undergone a facial nerve cut or crush injury, which was quantified using a 
modified MEAN-SD algorithm, at 7, 10 and 14 days after facial nerve injury. 
Grey and black bars represent quantifications of crush and cut, respectively. 
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*p<5% using unpaired Student’s T-test between crush and cut groups. n=3 for 
both groups. (B&C) Coronal sections through the injured facial motor nucleus at 
10 days after facial nerve crush (B) or cut (C). Sections were immunostained for 
alsin. Alsin immunostaining appears weaker in the cut facial nucleus (C) 
compared to crush (B) Bar scale represents 100um. High magnification inserts 
show that there is less alsin staining in the neuronal nucleus after facial nerve 
injury (C) than after nerve crush (B insert). Bar scale represents 50um. 
Discussion 
ALS is associated with cellular and molecular changes which resemble those 
observed following peripheral nerve injury (Dadon-Nachum et al., 2011). 
Axotomy causes changes in the immunoreactivity of a number of growth and 
death associated proteins within neurons (Patodia and Raivich, 2012a). TDP-
43, FUS and ALS2 are genes which cause familial ALS (Andersen and Al-
Chalabi, 2011) and have functions which may implicate them in the neuronal 
response to axotomy (Hadjebi et al., 2008, Li et al., 2013a). This study 
investigated whether facial nerve axotomy produces changes in the normal 
immunoreactivity pattern of TDP-43, FUS and Alsin protein within injured 
neurons. It also investigated whether these changes depend on the severity of 
nerve injury. It demonstrates that neuronal TDP-43, FUS and Alsin 
immunoreactivity changes following axotomy, in a time-dependent manner after 
injury. It also shows that changes in TDP-43 and Alsin immunoreactivity are 
affected by the severity of axonal injury. 
TDP-43 immunoreactivity in the facial motor nucleus following facial nerve 
axotomy 
The current study demonstrates that TDP-43 immunoreactivity in the facial 
motor nucleus changes following facial nerve axotomy in a time-dependent 
manner. In line with previous studies, TDP-43 immunohistochemical staining 
was localised to the cellular nucleus of neurons and glia in the uninjured facial 
nucleus (Moisse et al., 2009b, Sato et al., 2009). Following facial nerve cut, 
TDP-43 staining moved out from the neuronal nucleus into the cytoplasm, 
increasing the overall level of immunoreactivity in the injured facial nucleus. 
These changes were transient, returning to normal by around the time when 
peripheral target reinnervation occurs in the facial nerve axotomy model 
(Makwana et al., 2010). The observations reported here are consistent with 
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previous studies which have described similar changes in TDP-43 
immunoreactivity in the sciatic nerve motor pool following peripheral nerve cut 
and in the hypoglossal nucleus after nerve ligation (Moisse et al., 2009b, Sato 
et al., 2009). 
It is unclear whether the increase in overall TDP-43 immunoreactivity following 
axotomy represents an increase in TDP-43 expression at the protein level or a 
redistribution of the protein. Previous studies have suggested that TDP-43 is 
upregulated in injured neurons at both the mRNA and protein level following 
sciatic nerve cut and hypoglossal nerve ligation (Moisse et al., 2009b, Sato et 
al., 2009). However, whether this is the case in facial motor neurons following 
axotomy remains to be determined. 
This study also describes for the first time the localisation of TDP-43 in putative 
regenerative perineuronal sprouts following axotomy. TDP-43 immunoreactive 
structures, morphologically characterised by a bulb and tail (Makwana et al., 
2010), were found in the perineuronal white matter in the injured facial nucleus. 
Previous in-vitro studies have reported that TDP-43 translocates to axons and 
dendrites following axonal injury and repetitive depolarisation (Wang et al., 
2008a, Sato et al., 2009), but none have described TDP-43 in regenerating 
neurites in vivo. Perineuronal sprouting in the facial nucleus has been 
suggested to correlate with the regenerative potential of neurons after injury 
(Makwana et al., 2010, Makwana et al., 2009). Previous studies have implicated 
TDP-43 in mRNA transport and translation at the synapse, and axonal growth 
(Fallini et al., 2012, Liu-Yesucevitz et al., 2011, Tripathi et al., 2014). Thus, 
TDP-43 may be functionally involved in the process of axonal regeneration. This 
hypothesis is tested in vivo with the use of TDP-43 transgenic mice and the 
facial nerve axotomy model in the next chapter of this thesis. 
Alsin immunoreactivity in the facial motor nucleus following facial nerve 
axotomy 
The current study describes, for the first time, alsin immunoreactivity in the 
nucleus of motor neurons. This is in contrast to previous immunohistochemical 
studies which show normal alsin localisation to be cytoplasmic (Tudor et al., 
2005, Otomo et al., 2003, Devon et al., 2005) in line with its known functions in 
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endosomal trafficking and neurite outgrowth (Hadano et al., 2010, Tudor et al., 
2005). 
It is possible that the motor neuron nuclear staining obtained in the current 
study was not specific for alsin. The commercially available antibody used here 
was raised against a purified synthetic peptide sequence within the c-terminal of 
the alsin protein (LKACYYQIQREKLN) (Everest Biotech, 2014). The specificity 
of antibodies raised against peptides can be affected by contamination from 
other proteins during antibody production and by cross reactivity with proteins 
which contain similar sequences in vivo (Ramos-Vara, 2005). No previous 
studies have used this antibody to detect alsin. In order to determine whether 
the nuclear staining described in this study is due to alsin, the specificity of the 
antibody must be validated. Future work should use western blotting to 
determine if the molecular weight of the protein detected by the antibody 
matches that of alsin, and immunohistochemistry on a negative control tissue, 
such as alsin deficient mouse brain, to demonstrate that nuclear staining from 
the antibody is absent when alsin protein is not present. 
Although not previously described, endogenous alsin protein may indeed be 
localised to the cellular nucleus. Alsin is a large protein with six RCC1 like 
domains (RLDs) in its N-terminus (Hadjebi et al., 2008). The RCC1 protein, 
from which the term originates, is made up of 7 homologous amino acid repeats 
which fold into a seven-bladed β-propeller domain (Hadjebi et al., 2008). Loops 
within the RCC1 β-propeller domain interact with the histone component and 
DNA component of the nucleosome core particle in the cell nucleus (Makde et 
al., 2010). Thus, immunohistochemistry for RCC1 protein demonstrates nuclear 
immunoreactivity (Hadjebi et al., 2008). The RLDs in alsin are thought to take a 
similar β-propeller structure in vivo (Hadjebi et al., 2008) and thus may 
potentially bind to the nucleosome and be localised in the nucleus, as described 
in the current study. 
Gros-Louis et al. (2008) produced two antibodies against alsin with differential 
immunohistochemical staining patterns. One, raised against a short sequence 
in the N-terminal of alsin, resulted in cytoplasmic labelling within neurons of the 
central nervous system. The other, which was raised against a peptide 
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sequence in the C-terminal, showed both cytoplasmic and nuclear labelling 
within neurons (Gros-Louis et al., 2008). The immunoreactivity obtained with the 
anti C-terminal alsin antibody was reported as absent in lysates from ALS2 
knock out mice brains, suggesting that the antibody was specific (Gros-Louis et 
al., 2008). The antibody used in the current study was also raised against a 
peptide sequence in the c-terminal. Thus, alsin may reside in the nucleus of 
neurons and may be detectable using antibodies against the c-terminal of the 
protein. 
The majority of previous descriptions of the subcellular localisation of alsin used 
antibodies which have not been raised against the C-terminal of the protein 
(Tudor et al., 2005, Otomo et al., 2003, Devon et al., 2005, Yamanaka et al., 
2003). The majority have been raised against the N-terminal and middle portion 
of alsin and have described cytoplasmic immunoreactivity within neurons (Tudor 
et al., 2005, Otomo et al., 2003, Yamanaka et al., 2003). Nonetheless, some 
studies using antibodies raised against the c-terminal have failed to report 
nuclear staining (Topp et al., 2004). However, when exogenous alsin tagged 
with eGFP is overexpressed by cells in vitro, it localises to the nucleus as well 
as the cytoplasm of cells (Topp et al., 2004). Importantly, when truncated 
sections of eGFP-alsin protein are expressed by cells in vitro, those which 
contain the RCC1 domain localise to the nucleus and those without it do not 
(Topp et al., 2004). 
Overall, it is possible that antibodies raised against the N-terminal and middle 
portions of alsin protein may not detect nuclear alsin because the antigenic 
portions of the protein could be interacting with nuclear structures via the RCC1 
like domains. The antibody used in this study may avoid this antigen masking 
by binding with a part of the protein which does not interact with nuclear 
structures. Similarly, the lack of cytoplasmic alsin immunoreactivty, found using 
the antibody in the current study, may be explained by antigen masking. The 
antibody was raised against a sequence within the c-terminal of alsin protein. 
The cellular functions mediated by alsin in the cytoplasm depend on domains 
within its c-teminus. In order to carrying out these functions the target amino 
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acids may be engaged with other proteins via its antigenic epitopes in its c-
terminus, thus the antibody may be prevented from binding to cytoplasmic alsin. 
Axotomy produces transient clearing of nuclear alsin immunoreactivity. It is 
uncertain whether this is the result of down regulation, degradation or 
redistribution of alsin protein. Quantitative RT-PCR and western blotting with 
subcellular fractionation for alsin would help elucidate the mechanism of nuclear 
clearing. It is interesting to note that RCC1 leaves the nucleus during cellular 
stress (Kelley and Paschal, 2007). The cellular stress caused by axotomy may 
release alsin from its putative RLD-mediated nuclear localisation. This would 
allow it to carry out its known cytoplasmic functions which appear to involve it in 
axonal regeneration (Hadano et al., 2010, Tudor et al., 2005). Therefore, 
potentially axotomy induce nuclear clearing may represent the redistribution of 
alsin from the nucleus to the cytoplasm to promote axonal regeneration. 
FUS immunoreactivity in the facial motor nucleus following facial nerve axotomy 
The current study describes clearing of FUS immunofluorescence from the cell 
nucleus of motor neurons after axotomy. Prior to injury, labelling for FUS was 
nuclear in neurons and glial cells of the facial nucleus. Facial nerve transection 
resulted in a late and transient clearing of nuclear immunofluorescence. 
Previous studies have described clearing of FUS immunoreactivity from the 
nucleus of degenerating motor neurons in cases and animal models of ALS 
(Huang et al., 2011, Neumann et al., 2009). In addition, FUS has been 
described as part of stress granules (SG), structures which are involved in 
managing RNA homeostasis during cellular stress (Li et al., 2013a). It has been 
previously reported that FUS shuttles from the nucleus to the cytoplasm upon 
cellular stress induction (Li et al., 2013a). Once in the cytoplasm it rapidly 
associated with SGs. When the instigated stress resolves, SGs resolve and 
FUS returns to the nucleus (Li et al., 2013a). Thus, while FUS nuclear clearing 
occurs following cellular stress has been reported in the past, the current study 
is the first to described clearing of FUS from the nucleus of motor neurons 
following peripheral nerve injury. 
The redistribution of nuclear FUS may have functional effects in either the 
cytoplasm or nucleus. Previous studies have demonstrated that activation of 
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mGluR5 neuron receptors results in the recruitment of FUS to dendrites where it 
mediates a rise in local RNA content (Fujii et al., 2005). FUS appears to have 
functional effects in the dendrite, since neurons lacking FUS demonstrate 
abnormal dendritic spine morphology and density, in vitro (Fujii et al., 2005). In 
addition, FUS has roles in nucleus, including mRNA splicing, RNA stability, and 
transcriptional regulation (Lagier-Tourenne et al., 2012). Depletion of FUS in 
vivo has been associated with increase Jun and CD44 expression (Lagier-
Tourenne et al., 2012), which are both genes important in nerve regeneration. 
Thus, nuclear clearing of FUS protein in the nucleus following peripheral nerve 
axotomy may mediate processed involved in axonal regeneration. 
Effect of injury severity on axotomy induced changes in TDP-43 and alsin 
immunoreactivity 
The current study demonstrates that severity of nerve injury determines the 
magnitude of axotomy induced changes in TDP-43 and alsin immunoreactivity 
in motor neurons. Facial nerve transection resulted in more pronounced 
changes in immunoreactivity for both proteins compared to nerve crush. These 
observations are consistent with previous studies which have shown that the 
neuronal response to axotomy dependens on the severity of nerve injury 
(Moran et al., 2001, Matteoli et al., 1986, Lieberman, 1971, Saika et al., 1991a, 
Saika et al., 1991b, Saika et al., 1993, Makwana et al., 2010). Nerve cut is more 
severe than crush because as well as severing the perineurum and axons; it 
also injures the epineurium of a nerve. Compared to crush, nerve transection is 
associated with longer and more robust electrophysiological, morphological and 
molecular changes in the injured neuronal cell body (Moran et al., 2001, 
Matteoli et al., 1986, Lieberman, 1971, Saika et al., 1991a, Saika et al., 1991b, 
Saika et al., 1993, Makwana et al., 2010). However, reinnervation is known to 
occur earlier, more promptly, and with less error after nerve crush than after cut 
(Nguyen et al., 2002, Witzel et al., 2005). Thus the greater changes in TDP-43 
and alsin immunoreactivity observed following nerve transection, compared to 
crush, may be explained by greater injury signals from the initial injury and by 
delayed trophic support from reinnervation of targets. 
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Nuclear clearing of ALS associated proteins 
Histopathological studies of ALS cases describe the clearing of normal nuclear 
TDP-43 or FUS immunoreactivity in affected motor neurons (Neumann et al., 
2006, Neumann et al., 2009). The nuclear clearing of TDP-43 and FUS 
described in the current study mirror the changes that occur in motor neurons 
affected by ALS. This suggests that nuclear clearing of these proteins in ALS 
could be a normal physiological response to disease and not necessarily a 
change that drives it. Nuclear clearing of TDP-43 or FUS is often accompanied 
by cytoplasmic inclusions of either protein within ALS affected motor neurons 
(Neumann et al., 2006, Neumann et al., 2009). In the current study, FUS or 
TDP-43 cytoplasmic inclusions were not identified within axotomised motor 
neurons. This suggests that nuclear clearing of TDP-43 or FUS is not sufficient 
to drive the formation of cytoplasmic inclusions in normal motor neurons. 
Nuclear-cytoplasmic shuttling of TDP-43 and FUS has also been described 
during RNA-protein (RNP) formation (Li et al., 2013a). During cellular stress, 
both proteins leave the nucleus bind to non-translating mRNAs forming SGs. 
This process is physiological and reversible but has been implicated in the 
formation of cytoplasmic inclusions in ALS (Li et al., 2013a). Although not 
previously described, it is possible that the cellular stress caused by axotomy 
may result in the formation of SGs within motor neurons. However, the current 
study did not look for TDP-43 or FUS positive SGs. Future work should aim to 
determine whether axotomy induces SG formation and whether TDP-43 and 
FUS located to these. 
Timing of changes and how they marry with what happens in facial nerve 
axotomy 
Axotomy induced the clearing of alsin, TDP-43 and FUS immunostaining from 
the nucleus of motor neurons. All of these proteins have cytoplasmic functions 
which may be involved in driving the regenerative process following axonal 
injury (Hadjebi et al., 2008, Li et al., 2013a). TDP-43 nuclear clearing was 
associated with increased cytoplasmic staining. However, increase in 
cytoplasmic staining was not observed after alsin and FUS nuclear clearing. 
Nonetheless, this does not mean that alsin and FUS could not have been 
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redistributed to cytoplasm after axotomy. This is because conformational 
changes and protein binding on nuclear-cytoplasmic shuttling can hide target 
epitopes which would be normally recognised by the antibodies used (Ramos-
Vara, 2005). Thus, it is possible that alsin, TDP-43 and FUS nuclear clearing 
after axotomy is associated with the redistribution of all those proteins to the 
cytoplasm. 
Cytoplasmic redistribution following axotomy may promote alsin, TDP-43 and 
FUS to carry out the functions which may be important in axonal regeneration. 
Interestingly, the timing of nuclear clearing matches well the known function of 
each of the proteins. Alsin nuclear clearing is earliest, beginning at day 4 after 
injury. Its known function in retrograde signalling (Tudor et al., 2005, Hadano et 
al., 2010), and the importance of this process in the early stages following 
axonal injury (Patodia and Raivich, 2012a), may make its redistribution to the 
cytoplasm at this time-point appropriate. TDP-43 nuclear clearing and 
cytoplasmic redistribution begins at day 7. At this time-point the process of 
axonal elongation and sprouting takes central stage (Makwana et al., 2010). 
TDP-43 has been implicated previously in these processes (Fallini et al., 2012, 
Liu-Yesucevitz et al., 2011, Tripathi et al., 2014). Finally, FUS clearing begins at 
day 14, a time point which the process of reinnervation and NMJ maturation 
begins (Makwana et al., 2010). The known function of FUS in synapse 
stabilisation make its putative redistribution to the cytoplasm at this time point 
appropriate (Fujii et al., 2005). These hypotheses regarding the potential 
functional roles of alsin, TDP-43 and FUS could be tested using the facial nerve 
axotomy on mutant mice which lack or overexpress the respective genes. 
Limitations 
In the current study, the changes of protein expression after facial nerve injury 
of three candidate proteins, TDP-43, alsin and FUS, was chosen for analysis 
because of their known biological functions and their relation to motor neuron 
disease. However, the expression of other proteins was not analysed in the 
current study. Thus it is possible that the changes observed in TDP-43, alsin 
and FUS protein expression may be stereotypic to all protein. However, 
previous studies have demonstrated that protein expression changes in a 
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variety of ways depending on the protein analysed (Patodia and Raivich, 2012a, 
Patodia and Raivich, 2012b, Moran and Graeber, 2004). In addition, in Chapter 
3 the expression of c-Jun, CD44, alpha7, Beta1 and galanin proteins are 
described as raised in the motor neurons of facial nucleus 14 days following 
facial nerve transection. Time course of the expression of these proteins and 
others following facial nerve axotomy have been previously published (Raivich 
et al., 1992, Raivich et al., 1995, Moller et al., 1996, Jones et al., 1997, Werner 
et al., 1998, Bohatschek et al., 1999, Jones et al., 2000, Werner et al., 2000, 
Vogelezang et al., 2001, Raivich et al., 2004). Nonetheless, expression of such 
proteins should be analysed in the tissues collected for the current study to 
ensure that the findings described for TDP-43, alsin and FUS are not 
stereotypic for all proteins. 
In this study, commercially available antibodies were used to detect TDP-43, 
alsin and FUS. The antibodies for TDP-43 and FUS have been used in previous 
published reports (Moisse et al., 2009b, Neumann et al., 2009). In addition, the 
immunoreactivity pattern observed for TDP-43 and FUS in the current study 
match previous descriptions. However, the specificity of the antibodies used in 
the current study needs to be validated using western blotting and 
immunohistochemistry in positive and negative control tissue (such as normal 
and knock CNS tissue). This is particularly important for to confirm the 
observations made regarding alsin immmunoreactivity. This is because the 
antibody for alsin, has never been used in a published study, and the 
subcellular localisation of alsin immunoreactivity found with this antibody has 
never been described in the past. 
The description of changes in immunoreactivity in the current study has only 
focused on motor neurons. However, previous post mortem studies of ALS 
cases have demonstrated similar changes to FUS and TDP-43 
immunoreactivity in glial cells as those observed in motor neurons (Neumann et 
al., 2009, Neumann et al., 2006). The current study did not examine patterns of 
immunoreactivity in glial cells. Future work could make use of double 
immunolabelling for glia and TDP-43, alsin or FUS to determine if changes in 
immunoreactivity for this ALS associated occur in glial cells after axotomy. 
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In the current study, the changes observed in immunoreactivity for TDP-43 were 
quantified using the MEAN-SD algorithm (Moller et al., 1996). The changes in 
nuclear immunoreactivity of alsin and FUS were measured using a modified 
version of the algorithm, which quantified the percentage of nuclei with 
immunoreactivity above a certain threshold. The MEAN-SD algorithm has been 
used to measure changes in immunoreactivity in a number of published reports 
(Moller et al., 1996, Ruff et al., 2012, Raivich et al., 2004, Makwana et al., 
2009). However, the accuracy of this method in measuring changes in protein 
expression depends on the quality and specificity of immunohistochemical 
labelling, which can vary from slide to slide (Moller et al., 1996). Western 
blotting is a more robust method of determining changes in protein expression, 
which could be used to validate the results in the current study. This method 
coupled with subcellular fractionation may provide a more definitive description 
to the observations made here. In addition, changes in mRNA levels of TDP-43, 
alsin and FUS following axotomy should be measured using RT-PCR, to 
determine whether changes in mRNA mirror those at the protein level. 
Conclusion 
The current study has demonstrated that peripheral nerve axotomy results in 
the clearing of TDP-43 and FUS from the nucleus of injured motor neurons. In 
addition, after axotomy TDP-43 immunoreactivity is increased to the cytoplasm 
and localises to proregenerative perineuronal sprouts. Although the observation 
of nuclear clearing for TDP-43 and FUS resemble those in ALS affected motor 
neurons, the effects of axotomy on the proteins are reversible and physiological. 
In addition, this study describes for the first time alsin to be subcellularly 
localised to the nucleus of motor neurons. Similar to FUS and TDP-43, alsin is 
also cleared from nucleus following axotomy. Finally, the magnitude of axotomy 
mediated effects on TDP-43 and alsin appear to be dependent on the severity 
of nerve injury. Overall this study suggests that TDP-43, FUS and alsin may 
have a functional role in the neuronal response to axotomy. 
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Chapter 5: The effect of ALS related mutant TDP-43 on 
peripheral nerve regeneration 
Introduction 
Epidemiological studies have linked trauma resulting in injury to the nervous 
system with the development of ALS (Chen et al., 2007). Injury to the central 
and nervous system of SOD1G93A mice results in a defective cellular and 
molecular response (Malaspina et al., 2010, Yip and Malaspina, 2012, Mesnard 
et al., 2011a, Haulcomb et al., 2014, Mesnard-Hoaglin et al., 2014). However, 
the response to peripheral nerve injury in TDP-43 mutant mice has not been 
assessed. 
Peripheral nerve injury induces a number of molecular and cellular changes 
within the injured neuron and neighbouring cells (Navarro et al., 2007). At the 
cellular level, motor neurons undergo chromatolysis in the cell body and mount 
perineuronal axonal sprouting (Makwana et al., 2010). In addition, astrocytes 
and microglia become activated and there is T-lymphocytes infiltration around 
axotomised neurons (Raivich et al., 1999). At the molecular level, there are 
dramatic changes in gene expression, orchestrated by transcription factors, 
such as c-Jun (Patodia and Raivich, 2012b). There is increased expression of 
regeneration related proteins such as adhesion molecules (CD44) and 
neuropeptides (CGRP and galanin) (Patodia and Raivich, 2012a). These 
changes normally culminate on axonal regeneration, target reinnervation and 
functional recovery in mice (Raivich et al., 2004). However, following axotomy a 
number of injured neurons die, most likely due to failed target reinnervation and 
loss of neurotrophic support (Sendtner et al., 1996). 
TDP-43 is a ubiquitously expressed 414-amino acid protein with DNA, RNA, 
and protein binding motifs (Buratti and Baralle, 2001). TDP-43 is involved in 
gene transcription, mRNA transport and translation (Buratti and Baralle, 2008, 
Fallini et al., 2012). It is a major component of the proteinaceous inclusions 
within motor neurons which are characteristic of ALS (Neumann et al., 2006). 
Mutations in TDP-43 have been found in families suffering from inherited ALS 
and in sporadic cases of the disease (Pesiridis et al., 2009, Sreedharan et al., 
2008). Transgenic mice overexpressing human TDP-43 carrying ALS 
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associated mutations have been used to model the disease (Lee et al., 2012). 
One of these models is the A315T TDP-43 mutant mouse which demonstrates 
ALS-like changes including axonal degeneration and motor neuron loss 
(Wegorzewska et al., 2009).As described in the previous chapter, the normally 
nuclear immunoreactivity of TDP-43 protein changes after peripheral nerve 
injury (Moisse et al., 2009b), suggesting a possible functional role in the 
response to axonal injury. To begin to elucidate such role, the current study 
investigates the effect of A315T mutant TDP-43 overexpression on the normal 
physiological response to peripheral nerve injury. 
The following chapter on reports the motor function assessment of whisker 
movements and histological and immunohistochemical analysis of the facial 
nucleus following facial nerve transection in A315T mutant TDP-43 
overexpressing mice and their littermate wild-type controls.  
Results 
Mutant TDP-43 reduces functional recovery after facial nerve transection 
without affecting target reinnervation 
Facial nerve transection in mice results in a transient paralysis of the muscles 
which control whisker movement. Functional recovery is gradual following 
injury, by four weeks, whisker movement is back to almost normal levels in wild 
type mice (Raivich et al., 2004). 
To find out whether A315T mutant TDP-43 affects the normal recovery of 
function observed following peripheral nerve injury in mice, transgenic TDP-43 
mice were used. These expressed a human TDP-43 construct containing the 
A315T mutation, seen in patients with familial ALS, under the control of the 
mouse prion protein promoter (Wegorzewska et al., 2009). 
TDP-43 mutant mice (n=5) and their non-transgenic wild-type littermates (n=8) 
underwent a unilateral facial nerve transection (Moran and Graeber, 2004). 
Whisker hair motor performance on the ipsilateral side to injury was scored from 
0 (no movement) to 3 (strong, normal movement as on the uninjured side) by 
two observers, unaware of the genotypes, from 7 to 28 days after injury (Raivich 
et al., 2004). 
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Recovery of whisker function occurred in both mutant (Fig. 1A- red bars) and 
non-transgenic control mice (Fig. 1A- blue bars). Motor scores increased 
gradually over time reaching a measured peak at day 28 in both groups. 
However, the level of functional recovery was similar for TDP-43 mutant mice 
and their non-transgenic littermate controls up to day 11 (Mean score ± SEM: 
0.5 ± 0.1 for both groups). By day 14, functional recovery in the TDP-43 mutant 
mice began to lag behind; with average scores for control mice being 0.8 ± 0.1 
compared to 0.6 ± 0.1 for mutants (p<5% in an unpaired Student T-test). This 
lag continued until day 25 were the difference between motor scores for 
controls (2.0 ± 0.2) and mutants (1.2 ± 0.3) was greatest (p<5% using unpaired 
Student T-test). By day 28, there was only a trend for poorer motor function in 
the TDP-43 mutant mice (control: 2.2 ± 0.1 vs mutant: 1.4 ± 0.3, p=7% in an 
unpaired Student T-test). 
To obtain an average motor score independent of time, a functional recovery 
index (FRI) for each animal was determined by calculating the area under the 
curve for motor scores of mutant and control mice at 7 days to 28 days after 
facial nerve injury. Overall, control animals showed an average motor score of 
1.8 ± 0.1, which was significantly less than 1.2 ± 0.2 motor score in TDP-43 
mutant mice (p <5% using unpaired Student T-test). 
To determine if the defective whisker movement in TDP-43 mutant mice was 
due to differences in target reinnervation, the fluorescent tracer Fluorogold (FG) 
was applied into the injured and uninjured whisker pads 28 days after facial 
nerve injury (Raivich et al., 2004). The retrograde tracer was allowed to act for 2 
days and coronal sections through the facial nucleus were then collected. FG 
labelled neurons in the control and axotomised facial nuclei were counted using 
fluorescent microscopy at low power using a x20 objective lens. 
There was no significant difference between the total number of FG labelled 
motor neurons in the uninjured facial nucleus of mutant TDP-43 (154 ± 25, n=5) 
and control mice (173 ± 12, n=8). The overall ratio of labelled neurons on the 
axotomised versus the contralateral side was calculated (Fig. 1C). TDP-43 
mutant mice had 22% ± 8% motor neurons labelled which was not significantly 
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different to 18% ± 5% in control mice. This showed that there was no difference 
in target reinnervation between the studied groups at day 28. 
 
 
Figure 1. Overexpression of ALS associated A315T mutant TDP-43 delays 
recovery of motor function but does not affect target reinnervation following 
facial nerve axotomy. (A) Time course of whisker hair motor function. Functional 
recovery was measured at the indicated time points after axotomy, on a scale of 
0 (no movement) to 3 (normal, strong movement as on the unoperated side); 
n=5 for A315T mutant TDP-43 mice and n=8 for WT littermate control mice. 
*p<5% between TDP-43 and WT groups using unpaired Student's T-test. (B) 
Functional recovery index (FRI), calculated by integrating the motor function 
score of each studied time point across the time course (A). *p=1.1% using 
unpaired Student’s T-test. (C) Quantification of retrograde labelling of facial 
motor neurons with fluorogold, performed 28 days after facial nerve cut. The 
overall ratio of labelled neurons in the operated/unoperated side is shown (n=5 
for TDP-43 and n=8 WT). 
ALS mutant TDP-43 does not affect axotomy induced cell death 
Facial nerve transection in mice is associated with the loss of a proportion of 
motor neurons in the facial nucleus (Raivich et al., 2004). ALS is also 
characterised by motor neuron death (Wegorzewska et al., 2009) and mutant 
TDP-43 has been shown to be neurotoxic in vitro (Suzuki et al., 2011). 
To characterise the effect of ALS mutant TDP-43 on axotomy induced neuronal 
cell death, coronal sections through the facial nuclei were obtained 30 days 
following facial nerve cut. Serial section underwent cresyl violet staining and 
subsequent motor neuron quantification by light microscopy using a x20 
objective. 
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The number of motor neurons in the uninjured facial nucleus of TDP-43 mutants 
was 1167 ± 27 (n=5), which was not significantly different from 1175 ± 41(n=8) 
motor neurons counted in the wild-type mice (Fig. 2A-blue bars). 30 days 
following facial nerve injury the number of neurons within the facial motor 
nucleus ipsilateral to the side of axotomy was significantly lower than the control 
side in both the mutant and the control groups (Fig. 2A-red bars). To determine 
the overall level of neuronal cell death, a ratio between motor neuron counts in 
axotomised versus control side was calculated (Fig. 2B). TDP-43 mutant mice 
had 42% ± 4% neuronal death, which was not significantly different when 
compared to 38% ± 5% neuronal death found in their wild-type littermate 
controls (Fig. 2B) (p>5% using unpaired Student’s T-test). 
 
Figure 2. Overexpression of ALS associated mutant TDP-43 does not result in 
motor neuron loss in the injured facial nucleus and does not affect axotomy 
induced motor neuron cell death. (A) Quantification of motor neuron number in 
the facial nucleus in mutant (TDP-43; n=5) and wild-type littermate (WT; n=8) 
mice on the control (blue bars) and operated side (red bars, 30 days after facial 
nerve cut (*p<5% between control and operated side using unpaired Student's 
T-test) (B) Motor neuron cell death (NCD) in the facial nucleus of TDP-43 (n=5) 
and WT mice (n=8), calculated as the overall ratio of motor neurons in the 
operated/unoperated side, 30 days after facial nerve cut.  
Mutant TDP-43 promotes microglia activation and phagocytosis following facial 
nerve axotomy 
Facial nerve transection results in a glial and inflammatory response in the 
injured facial nucleus. Perineuronal microglia and astrocytes become activated, 
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and there is formation of microglia phagocytic clusters as well as infiltration of T-
lymphocytes (Raivich et al., 1999). Neuroinflammation is also observed around 
degenerating motor neurons in ALS (Alexianu et al., 2001). 
To determine the effect of ALS related mutant TDP-43 overexpression on 
axotomy induced neuroinflammation and astogliosis, TDP-43 mutant mice (n=5) 
and their littermate wild-type controls (n=5) received facial nerve transections. 
Coronal sections through the facial nuclei were taken 14 days after injury and 
underwent immunohistochemistry to visualise microglia in early (αM) and late 
stage (B7.2) activation, activated astrocytes (GFAP), and T-lymphocytes (CD3). 
Facial nerve transection induced microglial activation in the injured facial motor 
nucleus of both control (Fig.3B) and mutant mice (Fig.3D), which was 
characterised by greater αM staining. Quantification of αM 
immunohistochemical staining in the injured or uninjured facial nuclei were 
carried out using the MEAN-SD algorithm (Moller et al., 1996). The level of αM 
immunoreactivity in the uninjured facial motor nuclei of TDP-43 and wild-type 
mice was not significantly different (Fig. 4A-blue bars: p>5% using unpaired 
Student T-test). However, αM immunoreactivity was 18% greater in the injured 
facial motor nucleus of TDP-43 mice compared to control mice, 14 days after 
facial nerve injury (Fig. 4A-red bars: p <5% using unpaired Student T-test). 
αM-positive microglial clusters, defined as 3 or more tightly aggregated 
phagocytes, were counted in the injured or uninjured facial motor nuclei. 
Clusters were almost absent in the uninjured nuclei of both TDP-43 mutants 
and their littermate controls (Fig. 4B-blue bars). However, 14 days following 
facial nerve transection, αM-positive microglial clusters were observed in the 
injured facial nuclei of mutant and control animals. TDP-43 mice had 19 ± 2 αM-
positive microglial clusters in the injured facial nucleus, which was significantly 
more than 12 ± 3 found in controls (Fig. 4B-red bars: p <5% using unpaired 
Student T-test). 
Phagocytic cluster formation was further evaluated by staining for the 
phagocytosis related protein B7.2 that is expressed by microglia in middle and 
late stages of activation (Raivich et al., 1999). There were no B7.2-positive 
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clusters in the uninjured facial motor nucleus of both mutant (Fig.3G) and wild-
type mice (Fig.3E; Fig. 4C-blue bars). However, B7.2-positive clusters were 
found in the injured facial nuclei of both TDP-43 (Fig.3H) and control mice 
(Fig.3F), 14 days after facial nerve transection. In keeping with the αM results 
above, the number of B7.2-positive clusters found in the injured facial nucleus 
of TDP-43 overexpressing mice (10 ± 1) was 2-fold greater than those found in 
their littermate control mice (5 ± 1; Fig. 4C-red bars: p <5% using unpaired 
Student T-test). 
Astrocyte activation, characterised by GFAP-immunoreactivity, was apparent in 
the injured facial nucleus of wild-type (Fig. 3J) and mutant mice (Fig. 3L), 14 
days after facial nerve injury. Quantification of GFAP immunolabelling, using 
optical luminosity values, demonstrated that GFAP immunoreactivity in the 
injured facial nucleus was similar for both control and mutant mice (Fig. 4D-red 
bars; p >5% using unpaired Student T-test). However, there was 11% greater 
GFAP-immunolabelling in the uninjured motor nucleus of TDP-43 mutant mice 
compared to control mice (Fig. 4D-blue bars; p <5% using unpaired Student T-
test). 
Finally, axotomy induced the influx of CD3-positive T-lymphocytes into the 
injured facial motor nucleus of TDP-43 (Fig. 3P) and control mice (Fig. 3N). 
Quantification of CD3-positive T-lymphocytes in the injured facial motor 
nucleus, demonstrated similar numbers of lymphocytes recruited in both groups 
(Fig. 4E-red bars; p>5% using unpaired Student T-test). Interestingly, TDP-43 
mutant mice (Fig. 3O) had more T-lymphocytes in the uninjured facial motor 
nucleus than control mice (Fig. 3M). However, this difference was minimal with 
only 1 ± 1 T-lymphocyte being present in mutant TDP-43 uninjured facial nuclei 
compared no none in wild-type littermate mice (Fig. 4E-blue bars; p <5% using 
unpaired Student T-test). 
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Figure 3. Overexpression of mutant TDP-43 increases microglial response to 
peripheral nerve axotomy and causes minor neuroinflammatory changes 
around uninjured motor neurons. Coronal sections through the uninjured (Co) 
and injured (Ax) facial nuclei of mutant (TDP-43) and wild type littermates (WT), 
14 days after facial nerve cut, immunohistochemically stained for: (A-D) early 
microglial activation marker αM, (E-H) phagocyte marker B7.2, (I-L) activated 
astrocyte marker GFAP, and (M-P) T-lymphocyte maker CD3. Scale bar 
represents 400µm. 
195 
 
 
Figure 4. Quantification of non-neuronal response to axotomy in mutant TDP-
43 and wild-type mice. Histograms representing: immunoreactivity (IR) for αM 
(A) and GFAP (D) quantified using the MEAN-SD algorithm (Moller et al., Glia, 
1996); the number of αM- (B) and B7.2- (C) positive microglial clusters and 
CD3-positve lymphocytes (E). Blue and red bars represent quantifications of 
uninjured and axotomised facial nucleus, respectively. *p<5% using unpaired 
Student’s T-test between mutant (TDP-43) and wild-type littermates (WT) 
groups. n=5 for both groups (A-E). 
Mutant TDP-43 overexpression promotes motor neuronal CD44-expression but 
supresses perineuronal sprouting after facial nerve transection 
Following axonal injury, neurons of the peripheral nervous system upregulate 
regeneration associated molecules such as c-Jun, CD44, Galanin and CGRP 
(Raivich et al., 2004). Axonal injury also induces neurite sprouting in close 
proximity to the injured neuronal cell bodies (Makwana et al., 2010). In addition, 
as demonstrated in Chapter 5, TDP-43 protein clears from the nucleus of 
neurons following peripheral nerve injury and can be observed within 
perineuronal sprouts. To investigate whether over expression TDP-43 affects 
the neuronal response to injury, coronal section through the facial motor 
nucleus of mutant TDP-43 (n=5) and wild-type mice (n=5), with unilateral facial 
nerve injury, were stained for, TDP-43 (Fig.5A-D), c-Jun (Fig.5E-H), CD44 
(Fig.5I-L), Galanin (Fig.5M-P) or CGRP (Fig.5Q-T). 
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Mice overexpressing ALS associated A315T TDP-43 transgene demonstrated 
stronger TDP-43 immunohistochemical labelling in both injured and uninjured 
facial nuclei compared to their wild-type littermate mice (Fig.5A-D). 
Quantification of nuclear TDP-43 immunoreactivity (NIR) in motor neurons, 
using the modified MEAN-SD method described in chapter 5, demonstrated 
25% greater level of TDP-43 immunohistochemical labelling in TDP-43 
transgenic mice compared to wild-type littermate controls (Fig.6A). At the 
cellular level, uninjured neurons demonstrated mainly nuclear TDP-43 
immunoreactivity with some cytoplasmic staining. Fourteen days after facial 
nerve transection there was evidence of some clearing of nuclear TDP-43 
immunoreactivity from axotomised neurons in both TDP-43 mutant and wild-
type littermate mice (Fig.5A-D). Quantification demonstrated a 50% drop in the 
level of nuclear TDP-43 immunoreactivity in the injured (Fig.6A-red bars) 
compared to the uninjured facial nucleus of both mutant and wild-type mice 
(Fig.6A-blue bars). 
Immunohistochemistry for c-Jun showed staining of neuronal nuclei in the facial 
motor pool of both mutant TDP-43 (Fig.5G&H) and wild-type mice (Fig.5E&F). 
Fourteen days following facial nerve transection, there was an increase of c-Jun 
nuclear immunolabelling in injured neurons of both mutant TDP-43 (Fig.5H) and 
wild-type mice (Fig.5F). Quantification showed that TDP-43 mutant mice had a 
trend for 15% greater nuclear c-Jun immunoreactivity in the injured facial 
nucleus compared to wild-type controls (Fig. 6B-red bars; p=6% using unpaired 
Student T-test). However, there was no significant difference in the level of c-
Jun nuclear immunoreactivity in the uninjured facial nuclei of mutant (Fig.5E) 
and wild-type (Fig.5F & 6A-blue bars; p>5% using unpaired Student T-test). 
Immunoreactivity for the adhesion molecule CD44 demonstrated labelling of the 
perinuclear white matter, but no staining in the uninjured facial nuclei of both 
TDP-43 mutant (Fig.5I&J) and wild-type mice (Fig.5K&L) (Fig. 6C&D-blue bars; 
p >5% using unpaired Student T-test). However, CD44 immunolabelling was 
found in the injured facial nucleus of both studied groups at 14 days after 
axotomy (Fig.5J&L). Optical luminosity quantifications showed that there was no 
difference in the levels of CD44 in the injured facial nucleus of mutant and 
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control mice (Fig. 6C-red bars; p>5% using unpaired Student T-test). However, 
following manual counts of CD44-positive motor neurons (MN), TDP-43 mice 
showed significantly more highly CD44-immunoreactive neuronal cell bodies (7 
± 2) in the injured facial nucleus than wild-type mice (3 ± 1) (Fig. 6D-red bars; 
p<5% using unpaired Student T-test).  
Immunohistochemistry for the neuropeptides galanin (Fig.5M&O) and CGRP 
(Fig.5Q&S) showed staining of motor neuronal cell bodies in the uninjured facial 
nucleus of both mutant TDP-43 and control mice. Staining for both 
neuropeptides increased in the injured facial nucleus in both studied groups, 14 
days following axotomy (Fig.5N&P; R&T). There was also evidence of de novo 
appearance of galanin- and CGRP-positive perineuronal sprouts (neurites with 
a large terminal bulb) in and around the injured facial nucleus in both animal 
groups. To evaluate the effect of TDP-43 on axonal sprouting, galanin- or 
CGRP-positive perineuronal sprouts were manually counted. In comparison to 
control mice (Fig. 5N), which had 50 ± 9 galanin-positive sprouts in the injured 
facial nucleus, there were significantly fewer sprouts in the facial nucleus of 
TDP-43 mutant mice (Fig. 5P), with 28 ± 6 sprouts counted in the injured facial 
nucleus (Fig. 6E-red bars; p <5% using unpaired Student T-test). In addition, a 
trend towards fewer numbers of CGRP-positive sprouts were found in the 
injured facial nucleus of TDP-43 mice (Fig.5T) when compared to those counted 
in the facial nucleus of control mice (Fig.5R) (Fig. 6F-red bars; p= 6% using 
unpaired Student T-test). 
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Figure 5. Overexpression of mutant TDP-43 increases the axotomy induced 
upregulation of CD44 by injured motor neurons and decreases normal 
perineuronal sprouting. Coronal sections through the uninjured (Co) and injured 
(Ax) facial nuclei of mutant (TDP-43) and wild type littermates (WT), 14 days 
after facial nerve cut, immunohistochemically stained for: (A-D) TDP-43, (E-H) 
transcription factor c-Jun, (I-L) adhesion molecule CD44, neuropeptides (M-P) 
galanin (Galn) and (Q-T) CGRP. Scale bar represents 400µm. 
 
Figure 6. Quantification of motor neuron response to axotomy in mutant TDP-
43 and wild-type mice. Histograms representing: nuclear immunoreactivity (NIR) 
for TDP-43 (A) and c-Jun (B) quantified using a variation of the MEAN-SD 
algorithm (Moller et al., Glia, 1996), immunoreactivity (IR) for CD44 (C) manual 
counts of highly immunoreactive CD44 motor neurons (D), galanin- (E) and 
CGRP-positive (F) sprouts. Blue and red bars represent quantifications of 
uninjured and axotomised facial nucleus, respectively. *p<5% using unpaired 
Student’s T-test between mutant (TDP-43) and wild-type littermates (WT) 
groups. n=5 for both groups (A-F). 
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Discussion 
TDP-43 is a major component of the protein inclusions characteristic of ALS. 
Mutations in the TDP-43 gene have been found to cause some forms of familial 
ALS. Transgenic mice overexpressing TDP-43 with such mutations develop 
pathology similar to that seen in the disease. The cellular localisation of TDP-43 
protein changes following peripheral nerve injury, suggesting a role in the 
response to axotomy. Here, it was investigated whether the overexpression of 
human TDP-43 carrying the ALS associated mutation A315T affected the 
physiological response to facial nerve axotomy. The current study demonstrates 
that overexpression of mutant TDP-43 results in a reduced functional recovery 
that is associated with increased perineuronal inflammation and reduced 
perineuronal sprouting after facial nerve axotomy. 
Overexpression of mutant A315T TDP-43 reduces functional recovery after 
facial nerve transection 
Peripheral nerve injury in mice is normally associated with nerve regeneration, 
target reinnervation and functional recovery over time (Raivich et al., 2004). 
Overexpression of mutant A315T TDP-43 delays functional recovery after facial 
nerve transection. This effect might be secondary to a delay in reinnervation of 
the whiskerpad, similar to those previously described in α7 integrin knock out 
mice (Werner et al., 2000). In these mice, target reinnervation was poor at day 9 
after facial nerve axotomy but reached normal levels at day 21 (Werner et al., 
2000). In this study, levels of target reinnervation were similar in both mutants 
and controls at day 30 after axotomy. However, retrograde labelling at earlier 
time points might demonstrate poorer target reinnervation in mutant TDP-43 
mice compared to controls. 
Motor function also depends on accurate NMJ innervation (Bendella et al., 
2011, Zhang et al., 2013, Magill et al., 2007) and appropriate synaptic function 
(Brown et al., 1981). TDP-43 appears to play important physiological roles in 
both of these processes (Godena et al., 2011, Wang et al., 2008a, Polymenidou 
et al., 2011, Medina et al., 2014). In addition, there is electromyographic 
(Wegorzewska et al., 2009) and anatomical evidence that mutant A315T TDP-
43 causes NMJ degeneration in mice (Herdewyn et al., 2014). Overexpression 
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of mutant A315T TDP-43 may have delayed motor function recovery after facial 
nerve injury through effects at the NMJ. Future experiments should look at NMJ 
electrophysiology and anatomical reinnervation after facial nerve injury in TDP-
43 mutant and control mice. 
The delay in functional recovery may also represent effects of mutant TDP-43 
on upper motor neurons which regulate the function of the facial nucleus. Intact 
A315T mutant TDP-43 mice demonstrate progressive motor dysfunction which 
appears to be caused more by a disruption of descending motor pathways in 
the spinal cord rather than by the disturbance of peripheral motor nerves 
(Esmaeili et al., 2013, Wegorzewska et al., 2009). In A315T mutant TDP-43 
mice, there is only around 16% axonal loss in the femoral motor nerve 
compared to around 30-50% axonal loss in the dorsal and lateral corticospinal 
tracts (Wegorzewska et al., 2009). After facial nerve transection, there is a 
molecular and cellular response by the neurons that control the injured facial 
nucleus (Hundeshagen et al., 2013, Peeva et al., 2006). This response includes 
the reorganization of synaptic inputs on axotomised facial motor neurons 
(Hundeshagen et al., 2013, Peeva et al., 2006). A315T mutant TDP-43, which 
preferentially affect upper motor neurons in mice, might provoke poor functional 
recovery by affecting this response. 
The interpretation of whisker assessment data following facial nerve axotomy is 
limited in the current study because measures of baseline score of whisker 
activity were formally taken prior to injury or in the uninjured side after injury. 
However, whisker activity on the injured side was compared to the uninjured 
side and a score was given in comparison to that side.  
Overexpression of mutant A315T TDP-43 does not affect motor neuron death 
following facial nerve transection 
Peripheral nerve injury is often associated with some axotomy induced neuronal 
cell death (Sendtner et al., 1996). Overexpression of ALS associated mutant 
A315T TDP-43 in mice did not produce spontaneous loss of uninjured facial 
motor neurons and did not affect axotomy induced motor neuron death after 
facial nerve transection. Animal models of ALS should encompass the features 
of the disease, which include the loss of lower motor neurons (Van den Bosch, 
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2011). Previous studies have disagreed in the level of lower motor neuron death 
in A315T TDP-43 mouse model of ALS (Esmaeili et al., 2013, Wegorzewska et 
al., 2009, Herdewyn et al., 2014). The initial description of these mice claimed a 
20% loss in spinal motor neurons (Wegorzewska et al., 2009). However, later 
studies did not find evidence of motor neuron loss at the spinal cord (Herdewyn 
et al., 2014, Esmaeili et al., 2013). There has been no description of motor 
neuron viability in the intact facial nucleus of these mice. However, as seen in 
Chapter 3 of this thesis and in previous studies (Haenggeli and Kato, 2002), in 
the SOD1 mouse model of ALS there is only minor motor neuron loss at the 
facial nucleus even at the end-stage of the disease, when motor neuron loss in 
the spinal cord is high. Thus, the absence of spontaneous loss of facial motor 
neurons in the A315T TDP-43 mutant mice fits well with previous literature and 
suggests that facial motor neurons have reduced vulnerability to ALS disease in 
mice (Haenggeli and Kato, 2002). 
Overexpression of mutant A315T TDP-43 has been demonstrated to provoke 
loss of cortical and mesenteric neurons  (Esmaeili et al., 2013, Wegorzewska et 
al., 2009, Herdewyn et al., 2014). In the current study, the prodegenerative 
effect of mutant TDP-43 overexpression did not exacerbate axotomy induced 
motor neuron loss. In contrast, previous studies have demonstrated that ALS 
mutant SOD1 mice have greater motor neuron loss than littermate controls 28 
days after facial nerve axotomy (Mariotti et al., 2002, Ikeda et al., 2005, 
Haulcomb et al., 2014, Mesnard et al., 2011b). Interestingly, it has been shown 
that motor neuron loss in control wild type mice reaches levels comparable to 
those in mutant SOD1 mice at day 56 after facial axotomy injury (Haulcomb et 
al., 2014). Suggesting that mutant SOD1 expedites cell death of motor neurons 
that were destined to die as a result of axotomy, but it does not make other 
injured motor neurons more vulnerable to axotomy (Haulcomb et al., 2014). 
Since determining effects on motor neuron loss depends on the time point 
studied, it would be interesting to measure motor neuron number at earlier and 
later time points in mutant TDP-43 mice after facial nerve axotomy. 
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Overexpression of mutant TDP-43 causes gliosis and T-cell recruitment in the 
uninjured facial nucleus and increases axotomy induced microglial activation 
and cluster formation 
Axotomy produces a glial and inflammatory response at the level of the injured 
neuron (Raivich et al., 1999). In this study, mice overexpressing mutant A315T 
TDP-43 demonstrated spontaneous astrogliosis and T-cell recruitment in their 
uninjured facial nucleus and had greater levels of axotomy-induced microglial 
activation and cluster formation than wild-type controls after facial nerve 
transection.  
Astrocyte activation has been previously described in layer 5 of the motor cortex 
and in the ventral horn of the spinal cord in mice overexpressing mutant A315T 
TDP-43 (Wegorzewska et al., 2009, Herdewyn et al., 2014). In the current 
study, the description of spontaneous astrogliosis has been extended to the 
uninjured facial motor nucleus of these mice. Astrocytes may be central in the 
pathogenesis of mutant TDP-43 mediated disease (Tong et al., 2013). Astrocyte 
activation has been described to precede other disease changes in mice 
overexpressing mutant A315T TDP-43 fragments (Swarup et al., 2011). 
Expression of mutant TDP-43 by astrocytes is associated with the production of 
substances that cause neuronal cell death in vitro (Bi et al., 2013, Rojas et al., 
2014, Huang et al., 2014). In addition, rats overexpressing human mutant 
M337V TDP-43 in astrocytes, through an astrocyte specific promoter, develop 
motor neuron degeneration (Tong et al., 2013). 
T-cell recruitment into areas undergoing neurodegeneration has been described 
in human ALS and the SOD1 mouse model of the disease (Alexianu et al., 
2001). However, T-cells recruitment has not been previously studied in mice 
overexpressing mutant A315T TDP-43. The current study demonstrates modest 
but significant T-cell infiltration into the uninjured facial nucleus in these mice. In 
the SOD1 mouse model of ALS, T-cell infiltration is an early event that precedes 
the onset of motor dysfunction (Chiu et al., 2008). Genetic ablation of T-cells in 
mutant SOD1 mice results in a delayed onset of disease (Tada et al., 2011) but 
accelerated disease progression (Chiu et al., 2008). Thus, the presence of T-
cell recruitment in the uninjured facial nucleus of mutant A315T TDP-43 mice 
may be a feature of the early stages of disease in these mice. 
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Microglia activation accompanies motor neuron degeneration in ALS (Alexianu 
et al., 2001) and has been described in the motor cortex of mice overexpressing 
mutant A315T TDP-43 (Wegorzewska et al., 2009). However, it has not yet 
been assessed in the lower motor neuron pools of these mice. Nonetheless, 
microglia activation has been described in the ventral horn of mice 
overexpressing fragments of mutant A315T TDP-43 (Swarup et al., 2011). In 
the current study, there was no evidence of spontaneous microglia activation in 
the uninjured facial nucleus of mutant A315T TDP-43 mice, despite the 
presence of astrogliosis and T-cell recruitment. Microglia activation has been 
described to occur after astrocyte activation in the spinal cord of ALS mutant 
SOD1 mice (Fischer et al., 2004). Similarly, increase in microglia number 
occurs after T-cell recruitment in mutant SOD1 mice (Chiu et al., 2008).The 
results in the current study do not exclude mutant TDP-43 mediated microglia 
activation in the uninjured facial nucleus, as this may occur at a later time point, 
after spontaneous astrogliosis and T-cell recruitment in mutant A315T TDP-43 
mice. 
Facial nerve axotomy results in the activation of astrocytes and microglia as 
well as the infiltration of T-cells in the injured facial nucleus (Raivich et al., 
1999). The effect of overexpression of mutant A315T TDP-43 in axotomy 
induced neuroinfammation has not been previously described. In the current 
study, microglia activation and cluster formation after facial nerve transection 
was found to be greater in mutant A315T TDP-43 mice than wild-type littermate 
controls. However, mutant A315T TDP-43 had no effect on post-axotomy 
astrocyte activation or T-cell recruitment. In contrast, previous studies in ALS 
mutant SOD1 mice have demonstrated that peripheral nerve axotomy causes 
less microglia and astrocyte activation, as well as less T-cell recruitment around 
injured neurons in ALS mutant SOD1 mice than wild type controls (Kawamura 
et al., 2012, Haulcomb et al., 2014). 
TDP-43 has been shown to control the expression of a number of genes 
involved in the inflammatory response by neurons (Polymenidou et al., 2011). 
Thus mutant A315T TDP-43 may enhance axotomy-induced microglia 
activation and cluster formation via affecting the levels of expression of pro-
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inflammatory cytokines. This effect may be secondary to a defect in the gene 
regulatory function of TDP-43 (Polymenidou et al., 2011), or the cellular stress 
caused by the expression of mutant TDP-43 protein (Aggad et al., 2014). 
Mutant A315T TDP-43 protein expressed in C. elegans motor neurons is 
susceptible to misfolding, aggregate formation (Vaccaro et al., 2012a), 
activation of the endoplasmic reticulum unfolded protein response (Vaccaro et 
al., 2012b), and cellular toxicity by the dysregulation of intracellular calcium 
(Aggad et al., 2014). This type of cellular stress has been associated with the 
activation of the immunoproteasome which is involved in the prevention of 
protein aggregates (Bendotti et al., 2012). The immunoproteasome protects the 
cell during viral infection by generating antigenic peptides and presenting them 
to immune cells via cell surface MHCI molecules (Yewdell and Haeryfar, 2005). 
Interestingly, motor neurons increase the expression of MHCI after axotomy, 
suggesting that the immunoproteasome may be also activated in this condition 
(Bendotti et al., 2012). Thus, increased microglia activation and cluster 
formation in A315T TDP-43 mice may be due to the combined effect of 
proteasome activation by mutant TDP-43 protein and the axotomy induced 
stress. 
Overexpression of mutant TDP-43 enhances axotomy-induced CD44 
expression by motor neuron but diminishes perineuronal sprouting 
Axotomy induces a molecular response in the injured cell body which includes 
the upregulation of transcription factors, neuropeptides and adhesion molecules 
(Patodia and Raivich, 2012a). In the current study, it was demonstrated that 
injured and uninjured facial motor neurons in mutant TDP-43 mice have greater 
levels of TDP-43 immunoreactivity in their cellular nucleus compared to their 
littermate controls. The mouse model of ALS used in this study overexpresses 
human A315T mutant TDP-43 under the control of the prion protein promoter 
(Wegorzewska et al., 2009). TDP-43 protein has been described to be present 
at levels approximately 3-fold higher than endogenous protein (Wegorzewska et 
al., 2009). Thus, the greater level of nuclear TDP-43 immunostaining found in 
the mutant mice in this study is consistent with previous observations. 
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After axotomy, both TDP-43 mutant and control littermate mice showed a 
decrease in nuclear TDP-43 immunoreactivity. This is consistent with the data 
presented in Chapter 5 of this thesis and previous studies (Moisse et al., 2009b) 
which show clearing of TDP-43 from the nucleus of motor neurons after axonal 
injury. The level of nuclear TDP-43 clearing was not different between the 
mutant TDP-43 mice and littermate controls. Demonstrating that overexpression 
of A315T TDP-43 does not affect the axotomy-induced nuclear clearing of TDP-
43 immunoreactivity. Spontaneous nuclear clearing has been described in 
neurons of the motor cortex of A315T TDP-43 mutant mice (Wegorzewska et 
al., 2009). However, this observation was uncommon, suggesting that the 
A315T mutation does not particularly affect the nuclear localisation of TDP-43 
as do other mutations in the TDP-43 gene (Cohen et al., 2011). 
In this study the level of nuclear c-Jun immunoreactivity in uninjured facial motor 
neurons was not different between TDP-43 mutant mice and littermate controls. 
After axotomy, nuclear c-Jun immunoreactivity increased in facial motor 
neurons of both TDP-43 mutant mice littermate controls. There was a trend for 
marginally higher levels (15%) of nuclear c-Jun immunoreactivity in TDP-43 
mutant mice than controls. There are no previous studies analysing c-Jun 
expression or phosphorylation in A315T TDP-43 mutant mice. However, a 
previous study, using the mouse motor neuron like NSC34 cell line, has shown 
that TDP-43 overexpression leads to neuronal death via the JNK/c-Jun 
signalling pathway (Suzuki and Matsuoka, 2013). In this model, expression of 
dominant negative c-Jun resulted in reduced cell death (Suzuki and Matsuoka, 
2013). Thus, neurodegeneration caused by mutant A315T TDP-43 
overexpression may depend on c-Jun. The lack of effect of mutant TDP-43 
overexpression on c-Jun immunoreactivity in this study may be explained by a 
low level of neurodegeneration in the facial motor neurons at the time point of 
analysis. Perhaps, as disease progresses and facial motor neurons degenerate 
a change in c-Jun reactivity may ensue. 
In this study, it was found that overexpression of mutant TDP-43 was 
associated with higher levels of axotomy induced CD44 immunoreactivity. This 
finding is in contrast to a previous study, which demonstrates that CD44 mRNA 
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expression increases when TDP-43 is depleted (Polymenidou et al., 2011). In 
that study, endogenous TDP-43 mRNA and protein was reduced in the mouse 
striatum using antisense oligonucleotides (Polymenidou et al., 2011). However, 
here a human mutant form of TDP-43 is overexpressed within injured motor 
neurons. The increased expression of CD44 may be because mutant TDP-43 
was acting in a dominant negative fashion inhibiting the function of endogenous 
TDP-43 and thus reducing its normally inhibitory effect on CD44 expression. A 
previous study on A315T TDP-43 transgenic mice, has indeed shown that 
human mutant TDP-43 overexpression reduces endogenous TDP-43 
expression (Herdewyn et al., 2014). Thus, increased immunoreactivity of CD44 
after axotomy may be due to the reduction in endogenous TDP-43 function 
caused by the overexpression of mutant TDP-43. The increased CD44 
immunoreactivity in the axotomised motor neurons of A315T TDP-43 transgenic 
mice may also be explained by the higher levels of inflammation observed in 
these mice after axotomy. Compared to indirect or mild injury, severe neural 
injury or inflammation causes more CD44 expression by neurons, astrocytes, T-
cells and microglia (Jones et al., 2000, Makwana et al., 2007). Thus, the 
additional cellular stress caused by mutant TDP-43, and the associated 
inflammation may promote the expression of CD44 after axotomy. 
Peripheral nerve axotomy is associated with neurite sprouting at the level of the 
injured motor neuron (Makwana et al., 2010). Overexpression of mutant A315T 
TDP-43 reduced axotomy induced perineuronal sprouting after facial nerve 
axotomy. TDP-43 appears to be involved in the formation and maintenance of 
synapses at the level of the neuromuscular junction (Godena et al., 2011) and 
in the central nervous system (Wang et al., 2008a, Medina et al., 2014). There 
is accumulating evidence that TDP-43 has important roles in the transport of 
mRNA along axons and its translation at the synapse (Liu-Yesucevitz et al., 
2011, Fallini et al., 2012). In vitro, TDP-43 is actively transported in motor 
neuron axons in response to BDNF, it interacts with axonal mRNA binding 
proteins and its overexpression causes less axonal growth and branching 
(Fallini et al., 2012). In vivo, TDP-43 overexpression results in truncation of 
chick embryo motor axon growth to peripheral targets and the perturbation of 
their cytoskeletal components (Tripathi et al., 2014). Similarly, in drosophilia 
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depletion of the TDP-43 homolog TBPH resulted in structural defects at the 
neuromuscular junctions and alterations in the organization of synaptic 
microtubules (Godena et al., 2011). Thus, overexpression of mutant TDP-43 
may affect perineuronal sprouting by interfering with axonal mRNA transport 
and local translation. 
Perineuronal sprouting was analysed using immunohistochemistry for the 
neuropeptides galanin and CGRP. The expression of these peptides are 
upregulated following axotomy and appear to be under the transcriptional 
control of c-Jun (Raivich et al., 2004). Since TDP-43 has an important role in 
gene expression, the reduction in perineuronal sprouting might be secondary to 
an effect of overexpression of mutant TDP-43 on the transcriptional regulation 
or translation of these two peptides. However, previous microarray and  
splicing-sensitive junction array analysis have failed to demonstrate that CGRP 
or galanin expression is under the regulation of TDP-43 (Polymenidou et al., 
2011). In the current study, the overall level of CGRP and galanin 
immunoreactivity in the facial motor nucleus was not measured. Measuring this 
may elucidate a difference in peptide levels between the studied groups, and 
thus may demonstrate that the observed reduction in sprouting is due to sprouts 
not being visible, due to decreased sprout marker expression, rather than an 
actual effect of mutant TDP-43 on the sprouting process. 
Conclusion 
This study has demonstrated that the neuronal overexpression of ALS 
associated mutant TDP-43 reduces functional recovery, increases perineuronal 
inflammation and reduces perineuronal axonal sprouting after peripheral nerve 
injury. It suggests that mutations in TDP-43 associated with ALS may promote 
defects in the normal physiological regenerative response that motor neurons 
mount following injury. Such deficits might be part of the progressive 
degenerative nature of ALS disease. 
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Chapter 6: General discussion 
Summary of Results 
The molecular pathways mediating motor neuron degeneration in Amyotrophic 
lateral sclerosis and axonal regeneration following peripheral nerve injury 
remain elusive.  
The transcription factor c-Jun, an important orchestrator of axonal regeneration, 
has been found upregulated in the spinal cord of ALS cases and the 
SOD1G93A mouse model of the disease. However the functional role of c-Jun 
in ALS degeneration has not been defined. The current thesis demonstrates 
that genetic deletion of c-Jun from neurons and neuroglia prolonged the lifespan 
of SOD1G93A mice. Associated with this effect on survival, motor neuron loss, 
axonal loss and neuroinflammation were attenuated in c-Jun deficient 
SOD1G93A mice. Interestingly, in addition to the neurodegenerative changes, 
motor neuron pools affected by ALS disease in SOD1G93A mice demonstrated 
a disease-mediated axotomy response, which was characterised by the 
expression of regeneration associated proteins and was dependent on the 
expression of c-Jun. 
Since the expression of regeneration-associated proteins changes in ALS, it 
was next investigated whether the expression of ALS-associated proteins 
changes during axonal regeneration. This thesis demonstrates that the pattern 
of expression of ALS associated proteins; TDP-43, FUS and alsin, does indeed 
change within motor neurons following facial nerve axotomy, in wild type mice. 
In addition, it describes for the first time that alsin protein may localise to 
nucleus in uninjured motor neurons. Interestingly, axotomy resulted in a 
transient clearing of the normal nuclear immunoreactivity for all three studied 
proteins. The size of this effect was dependent on the severity of nerve injury for 
TDP-43 and alsin. 
Finally, to begin to investigate the functional role of ALS associated genes in 
axonal regeneration the A315T TDP-43 model of ALS was assessed following 
facial nerve transection. Genetic overexpression of ALS associated A315T 
mutant TDP-43 resulted in delayed motor function recovery following facial 
nerve axotomy in mice. This effect was associated with increased perineuronal 
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inflammation and increased motor neuron expression of the adhesion molecule 
CD44 but reduced perineuronal sprouting. However, overexpression of A315T 
mutant TDP-43 did not affect anatomical target reinnervation, motor neurons 
loss or the pattern of expression of other regeneration associate proteins. 
The role of c-Jun in ALS 
Targeting c-Jun/JNK pathway for the treatment of ALS 
The transcription factor c-Jun has been found upregulated in the astrocytes and 
motor neurons of the spinal cord in ALS cases and mutant SOD1 mice (Vlug et 
al., 2005, Jaarsma et al., 1996). However, the functional role of c-Jun in ALS 
degeneration has not been defined. In this thesis, genetic deletion of c-Jun from 
neurons and glia in SOD1G93A mice produced an increase in lifespan of 10 
days compared to controls. This effect may appear modest but it represents an 
increase of 10% to the lifespan of SOD1G93A mice. The size of this effect on 
survival seems clinically significant as the only approved medical therapy for 
ALS, riluzole, prolongs survival by around 2 months in ALS patients which on 
average have an age of 50 years (increase 0.3% of total lifespan) (Scott et al., 
2008). Thus, pharmacological inhibition of c-Jun activation or expression may 
represent a novel therapeutic avenue to be explored in the treatment of ALS. In 
this vein, a number of JNK inhibitors have been developed and tested in 
neurodegenerative disorders such as Parkinson’s Disease (Chambers et al., 
2011); in fact, an orally active JNK inhibitor (CC-930) has now reached stage II 
clinical trials for the treatment of interstitial pulmonary fibrosis (Krenitsky et al., 
2012). Thus, future experiments may aim to determine whether 
pharmacological inhibition of JNKs modifies disease in SOD1G93A mice. 
Elucidating the mechanism of c-Jun ALS neurodegeneration 
The genetic deletion of c-Jun from neurons and glia attenuated a number of 
neuropathological changes in SOD1G93A mice, demonstrating that c-Jun plays 
a functional role in ALS associated neurodegeneration. However, the 
mechanism through which c-Jun does this was not elucidated in this thesis. The 
transcription factor c-Jun has described roles in cell death, neuroinflammation, 
and axonal regeneration by controlling the expression of a number of gene 
targets (Raivich et al., 2004). Determining what effects neural deletion of c-Jun 
has on gene expression of SOD1G93A mice would help identify the mechanism 
211 
 
through which it promotes neuroprotection in this model. Using laser guided 
dissection, microarrays analysis of gene expression specifically within motor 
neurons and in the surrounding neuropil may indicate whether c-Jun deletion 
affects processes involved in ALS disease, such as proteostasis, mitochondrial 
function, cell death pathways or cytokine gene expression. In addition, it would 
be interesting to find out if the neuroprotective effect of c-Jun deletion is 
secondary to its absence from the degenerating motor neurons or from 
surrounding glia. Following axotomy, mice with neuronal specific deletion of c-
Jun, under the control synapsin promoter, show an identical phenotype as those 
mice with neural specific deletion c-Jun, under the control of the nestin promoter 
(Ruff et al., 2012). This suggests that the effects of c-Jun on motor neuron 
death and neuroinflammation in SOD1G93A mice may be due to the lack of c-
Jun in neurons. However, future experiments may aim to determine whether 
this is in fact the case. 
The role of a disease mediated axotomy response in ALS  
This thesis describes the presence of a disease mediated axotomy response 
mounted in degenerating motor neuron pools in SOD1G93A mice. This 
response was characterised by the expression of regeneration associated 
proteins and was dependent on the expression of c-Jun. The functional role of 
this response and the mechanism that triggers it have not been characterised in 
the current study. Intuitively, a regenerative response mounted by degenerating 
motor neurons can only represent an attempt at maintaining function and 
structure. This view is supported by evidence that regenerative terminal 
sprouting at the NMJ compensates for neurodegenerative muscle denervation 
in ALS (Tsujihata et al., 1984, Atsumi, 1981, Hegedus et al., 2008, Hegedus et 
al., 2007). In addition, enhancing this regenerative effort via pharmacological or 
genetic interventions has been shown to attenuate disease in the SOD1 mouse 
model of ALS (Tonges et al., 2014, Gunther et al., 2014). In contrast, genetic 
inhibition of this regenerative effort exacerbates neurodegeneration in mutant 
SOD1 mice (Williams et al., 2009).  
However, this thesis demonstrates that neuronal and glial c-Jun deletion, which 
in wild-type mice results in a dramatic deficit in axonal regeneration following 
axotomy (Raivich et al., 2004), did not worsen disease in SOD1G93A mice but 
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instead attenuated it. In addition, the disease mediated pro-regenerative 
axotomy response mounted by neurons in SOD1G93A mice was absent if c-Jun 
was genetically deleted from neurons and neuroglia. This suggests that the 
axotomy response mounted by motor neurons in mutant SOD1 mice may not 
necessarily represent a beneficial phenomenon, but may be a part of pro-
degenerative process that is slowed down by the genetic deletion of c-Jun. In 
support of this, it has been reported that sciatic nerve crush, which promotes 
peripheral nerve regeneration, results in an acceleration in disease progression 
and enhanced motor neuron loss in SOD1G93A mice (Sharp et al., 2005). 
However, a different group has demonstrated that sciatic nerve ligation followed 
by transection improves axonal survival in SOD1 G93A mice  (Kong and Xu, 
1999). The difference in the results from these two studies has been explained 
by the fact that the crush injury permits axonal regeneration while nerve ligation 
prevents it (Sharp et al., 2005). It is suggested that axonal regeneration may 
play a pro-degenerative role in ALS by increasing the burden on what is already 
compromised axonal transport. Thus deletion of c-Jun may delay degeneration 
in SOD1G93A mice by inhibiting the axonal regeneration programme initiated in 
these mice by the disease. 
Alternatively, the failure to exacerbated disease despite attenuating a 
regenerative effort at the level of the motor neuron cell body in SOD1G93A 
mice may be interpreted as a disassociation between the regenerative efforts 
that occur at the neuromuscular junction and those that occur at the cell body. 
There is evidence that sprouting at NMJ can be mediated by local protein 
synthesis independent of protein production at the neuronal cell body or axonal 
transport (Alvarez et al., 2000). Thus, c-Jun deletion may not affect sprouting 
and reinnervation at NMJ despite the fact that it affects gene expression at the 
cell body that promotes axonal regeneration following peripheral nerve 
axotomy. However, in this thesis the effect of c-Jun deletion on NMJ innervation 
was only studied at end stage of disease when levels of denervation were 
similar between c-Jun deficient or competent SOD1 mice. NMJ innervation, 
terminal and collateral sprouting should be studied at earlier time points in the 
disease to determine whether c-Jun has any effect on this type of regenerative 
effort. 
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The pattern of expression of ALS associated proteins changes after 
peripheral nerve injury 
The ALS associated proteins TDP-43, FUS and alsin have previously described 
functions in the maintenance of neurite structure and growth (Fallini et al., 2012, 
Liu-Yesucevitz et al., 2011, Tripathi et al., 2014, Fujii et al., 2005, Tudor et al., 
2005). This thesis describes the changes in the pattern of expression of these 
proteins within motor neurons following axonal injury, in vivo. Transient clearing 
of the normal nuclear immunoreactivity for all of the three studied proteins was 
observed following axotomy. This suggests that all these proteins may be 
involved in axonal regeneration following peripheral nerve injury, in vivo. 
Interestingly, nuclear clearing of TDP-43 and FUS immunoreactivity has been 
described in the motor neurons of ALS cases, and has been implicated in the 
pathogenesis of the disease by aberrantly altering gene expression (Lagier-
Tourenne et al., 2012). However, as observed here the transient clearing of 
these proteins from the nucleus represents a physiological response to injury 
and this could also be the case in ALS (Deng et al., 2010). Nonetheless, ALS is 
characterised by the presence of protein inclusions which may sequester TDP-
43 and FUS from the nucleus permanently and thus dysregulate gene 
expression (Lagier-Tourenne et al., 2012). Interestingly, absence of TDP-43 
and FUS from the motor neuron nucleus may promote a regenerative gene 
expression programme, as suggested by this thesis, which as discussed above 
may promote neurodegeneration in ALS. 
In addition, in this thesis, alsin, immunoreactivity, which has been described as 
a cytoplasmic protein associated with endosomes (Tudor et al., 2005, Otomo et 
al., 2003, Devon et al., 2005), is for the first time described as nuclear in 
uninjured motor neurons. Alsin is a large protein with a number of functional 
motifs, some of which may localise it to the nucleus (Yang et al., 2001). This 
suggests that, just like TDP-43 and FUS, alsin may have, up to now 
undescribed, functional roles in the nucleus. The nuclear clearing of alsin 
following axotomy further suggest that it may play a role in axonal regeneration 
in vivo. However, the observations made in this thesis need to be coupled with 
molecular studies which provide evidence that the immunoreactivity observed 
with the anti-alsin antibody used here is indeed specific for alsin. 
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Future work should focus in determining whether the proteins studied in this 
thesis have functional roles in axonal regeneration in vivo. This may be carried 
out using the facial axotomy model on the available TDP-43, FUS and alsin 
transgenic and knock out mice. In addition, other ALS associated proteins 
should be assessed to determine whether they are also involved in the neuronal 
response to axotomy and axonal regeneration. 
ALS associated human mutant TDP-43 disrupts peripheral nerve 
regeneration in vivo 
The change in the pattern of TDP-43 immunoreactivity following axotomy 
suggests that TDP-43 may play a functional role in the response to peripheral 
nerve injury. This thesis demonstrates that the overexpression of ALS 
associated human mutant A315T TDP-43 delayed motor function recovery in 
mice following facial nerve transection. This effect was associated with 
enhanced neuroinflammation around axotomised motor neurons and decreased 
perineuronal sprouting following axotomy. However, the overexpression of 
mutant TDP-43 did not affect axotomy induced motor neuron loss or the 
anatomical reinnervation of target muscle. Because TDP-43 has roles in the 
regulation of gene expression, the effect observed here may be explained by 
mutant TDP-43 mediated dysregulation of gene expression (Polymenidou et al., 
2011, Raivich et al., 2004). In support, the adhesion molecule CD44, a target of 
TDP-43 (Polymenidou et al., 2011), was found aberrantly upregulated in the cell 
body of injured motor neurons. However, the expression of other regeneration 
associated proteins was not dysregulated in injured motor neurons of mutant 
TDP-43 mice. Thus, it is possible that A315T TDP-43 may not mediate its 
effects on regeneration by affecting gene expression at the level of the cell 
body. Since TDP-43 has roles in transport of mRNA along axons and its 
translation at the synapse (Liu-Yesucevitz et al., 2011, Fallini et al., 2012), it is 
possible that mutant TDP-43 may affect axonal regeneration through effects on 
local protein translation. To elucidate the mechanism by which A315T TDP-43 
causes delayed functional recovery, the rate of axonal elongation and effects on 
axonal sprouting at the neuromuscular junction should be assessed. In addition, 
to the determine the molecular mechanisms, analysis of gene and protein 
expression may be carried out at the motor neuron cell body and axon terminal 
of mutant TDP-43 and control mice following facial nerve axotomy. 
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The defect in axonal regeneration observed in the TDP-43 mouse model of ALS 
may suggest that there is an underlying defect in axonal regeneration in ALS. 
However, facial nerve transection in mutant SOD1 mice reveals that the 
molecular response to axotomy is phenotypically regenerative and 
indistinguishable from that of wild type mice (Mesnard et al., 2011a). 
Interestingly, axotomy induced motor neuron death is exacerbated in mutant 
SOD1 mice (Haulcomb et al., 2014). In contrast, such exacerbation was not 
observed here in mutant TDP-43 mice. This may suggests that SOD1 and TDP-
43 associated ALS may represent two different mechanisms of 
neurodegeneration. Indeed, there are many clinical and pathological differences 
between SOD1 and TDP-43 associated ALS in mice (Gurney et al., 1994, 
Wegorzewska et al., 2009) and in humans (Phukan et al., 2012, Wicks et al., 
2009). Further work may aim to characterise the regenerative responses found 
in different forms human ALS. This would help elucidate the common or specific 
mechanism of degeneration involved in the different forms of the disease. 
General Conclusion 
This thesis presents evidence that ALS degeneration involves cellular and 
molecular changes that resemble the regenerative response to acute axonal 
injury. It demonstrates that genetic deletion of c-Jun, an important orchestrator 
of axonal regeneration, attenuates SOD1 associated ALS disease in mice, while 
abolishing a disease-associated regenerative response in degenerating motor 
neurons. In addition, this thesis demonstrates that the expression of ALS 
associated proteins, TDP-43, FUS and alsin, changes in motor neurons after 
axonal injury in mice. Finally, it demonstrates that ALS associated mutant TDP-
43 disrupts axonal regeneration following peripheral nerve injury in mice. Thus, 
the molecular changes in ALS-associated motor neurodegeneration and 
peripheral nerve injury-associated regeneration overlap. This suggests that 
insights obtained from studying one of these processes may be applied to 
further understand the other. 
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